Regeneron Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Regeneron together

Penke I guess you are interested in Regeneron Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Regeneron Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Regeneron Pharmaceuticals Inc

I send you an email if I find something interesting about Regeneron Pharmaceuticals Inc.

Quick analysis of Regeneron (30 sec.)

What can you expect buying and holding a share of Regeneron? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

30.0%

What is your share worth?

Current worth

$228.23

Expected worth in 1 year

$257.66

How sure are you?

97.5%

+ What do you gain per year?

Total Gains per Share

$29.43

Return On Investment

3.3%

For what price can you sell your share?

Current Price per Share

$890.68

Expected price per share

$840.25 - $953.29

How sure are you?

50%

1. Valuation of Regeneron (5 min.)

Live pricePrice per Share (EOD)

$890.68

Book Value per Share

$228.23

Intrinsic Value Per Share

$29.71 - $458.15

Total Value Per Share

$257.95 - $686.39

My calculation of the intrinsic value of Regeneron is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($5.18) 3Y: ($10.85) TTM: ($8.38)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.12) 3Y: ($-0.23) TTM: ($-1.73)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$17.83	$43.83	$17.12 - $45.40
2	$31.36	$88.28	$13.50 - $47.39
3	$41.02	$133.28	$9.89 - $49.38
4	$47.21	$178.75	$6.27 - $51.37
5	$50.29	$224.64	$2.66 - $53.36
6	$50.59	$270.87	$-0.96 - $55.35
7	$48.41	$317.39	$-4.57 - $57.34
8	$44.04	$364.15	$-8.19 - $59.33
9	$37.73	$411.08	$-11.80 - $61.32
10	$29.71	$458.15	$-15.42 - $63.30

2. Growth of Regeneron (5 min.)

Is Regeneron growing?

	Current year	Previous year	Grow	Grow %
How rich?	$25.9b	$21.1b	$3.4b	13.9%

How much money is Regeneron making?

	Current year	Previous year	Grow	Grow %
Making money	$988.4m	$1b	-$96.2m	-9.7%
Net Profit Margin	30.1%	35.6%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Regeneron (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#2 / 1010

Most Revenue
#6 / 1010

Most Profit
#5 / 1010

Most Efficient
#49 / 1010

What can you expect buying and holding a share of Regeneron? (5 min.)

Welcome investor! Regeneron's management wants to use your money to grow the business. In return you get a share of Regeneron.

What can you expect buying and holding a share of Regeneron?

First you should know what it really means to hold a share of Regeneron. And how you can make/lose money.

Speculation

The Price per Share of Regeneron is $890.68. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Regeneron.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Regeneron, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $228.23. Based on the TTM, the Book Value Change Per Share is $7.36 per quarter. Based on the YOY, the Book Value Change Per Share is $8.25 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Regeneron.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	10.19	1.1%	8.69	1.0%	9.56	1.1%	9.71	1.1%	6.05	0.7%
Usd Book Value Change Per Share	8.62	1.0%	7.36	0.8%	8.25	0.9%	7.60	0.9%	5.27	0.6%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.30	0.0%	0.53	0.1%
Usd Total Gains Per Share	8.62	1.0%	7.36	0.8%	8.25	0.9%	7.90	0.9%	5.80	0.7%
Usd Price Per Share	878.29	-	810.37	-	674.98	-	587.05	-	492.79	-
Price to Earnings Ratio	21.55	-	23.62	-	18.00	-	18.66	-	41.88	-
Price-to-Total Gains Ratio	101.90	-	114.83	-	85.07	-	67.64	-	99.80	-
Price to Book Ratio	3.85	-	3.75	-	3.62	-	4.26	-	7.91	-
Price-to-Total Gains Ratio	101.90	-	114.83	-	85.07	-	67.64	-	99.80	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	890.68
Number of shares	1

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.30
Usd Book Value Change Per Share	7.36	7.60
Usd Total Gains Per Share	7.36	7.90
Gains per Quarter (1 shares)	7.36	7.90
Gains per Year (1 shares)	29.43	31.60

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	29	19	1	30	22
2	0	59	48	2	61	54
3	0	88	77	4	91	86
4	0	118	106	5	122	118
5	0	147	135	6	152	150
6	0	177	164	7	182	182
7	0	206	193	8	213	214
8	0	235	222	10	243	246
9	0	265	251	11	274	278
10	0	294	280	12	304	310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	4.0	0.0	0.0	100.0%	12.0	0.0	0.0	100.0%	20.0	0.0	0.0	100.0%	40.0	0.0	0.0	100.0%	52.0	78.0	0.0	40.0%
Book Value Change Per Share	4.0	0.0	0.0	100.0%	12.0	0.0	0.0	100.0%	19.0	1.0	0.0	95.0%	37.0	3.0	0.0	92.5%	68.0	62.0	0.0	52.3%
Dividend per Share	0.0	0.0	4.0	0.0%	0.0	0.0	12.0	0.0%	1.0	0.0	19.0	5.0%	12.0	0.0	28.0	30.0%	13.0	0.0	117.0	10.0%
Total Gains per Share	4.0	0.0	0.0	100.0%	12.0	0.0	0.0	100.0%	19.0	1.0	0.0	95.0%	39.0	1.0	0.0	97.5%	70.0	60.0	0.0	53.8%

Fundamentals of Regeneron

About Regeneron Pharmaceuticals Inc

https://www.regeneron.com
Biotechnology
13450
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Google Maps Bing Maps

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Fundamental data was last updated by Penke on 2024-04-12 16:30:05.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Regeneron Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Regeneron earns for each $1 of revenue.

Above 10% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
A Net Profit Margin of 33.8% means that $0.34 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Regeneron Pharmaceuticals Inc:

The MRQ is 33.8%. The company is making a huge profit. +2
The TTM is 30.1%. The company is making a huge profit. +2

Trends

Current period		Compared to		+/-
MRQ	33.8%	TTM	30.1%	+3.7%
TTM	30.1%	YOY	35.6%	-5.6%
TTM	30.1%	5Y	36.5%	-6.4%
5Y	36.5%	10Y	28.5%	+8.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	33.8%	-207.2%	+241.0%
TTM	30.1%	-216.8%	+246.9%
YOY	35.6%	-282.3%	+317.9%
5Y	36.5%	-436.8%	+473.3%
10Y	28.5%	-597.3%	+625.8%

Measures how much net profit Regeneron earns for each $1 of revenue.

Revenue is the amount of profit Regeneron generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Regeneron earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Regeneron makes more profit. This shows the investor how efficiently Regeneron is operating in general and compared to other companies in the same industry. Regeneron operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Regeneron. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Regeneron is 0.34. This means that Regeneron earned $0.34 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -207.2%.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Regeneron with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Regeneron sells assets (profit will increase while costs remain the same).
It won’t show what part of Regeneron is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Regeneron

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Regeneron = 1,159,600
Total revenue MRQ Regeneron = 3,434,300
$1,159,600 / $3,434,300 = 0.34 or 33.8%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Regeneron is using its assets to generate profit.

Above 5% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
3.5% Return on Assets means that Regeneron generated $0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Regeneron Pharmaceuticals Inc:

The MRQ is 3.5%. Using its assets, the company is less efficient in making profit.
The TTM is 3.1%. Using its assets, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	3.5%	TTM	3.1%	+0.4%
TTM	3.1%	YOY	3.9%	-0.8%
TTM	3.1%	5Y	5.1%	-2.0%
5Y	5.1%	10Y	4.4%	+0.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	3.5%	-13.3%	+16.8%
TTM	3.1%	-12.8%	+15.9%
YOY	3.9%	-11.6%	+15.5%
5Y	5.1%	-13.8%	+18.9%
10Y	4.4%	-15.6%	+20.0%

Shows how efficient Regeneron is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Regeneron is using its resources to generate profit. If the return on assets (3.5%) from Regeneron are higher than the Biotechnology mean (-13.3%) that means Regeneron is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Regeneron is 3.5%. This means the company generated $0.04 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Regeneron

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Regeneron = 1,159,600
Total assets MRQ (balance sheet) from Regeneron = 33,080,200
1,159,600 / 33,080,200 = 0.04 or 3.5%

ROA is an important ratio as it will tell you how effectively Regeneron is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Regeneron is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
4.5% Return on Equity means Regeneron generated $0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Regeneron Pharmaceuticals Inc:

The MRQ is 4.5%. Using its investors money, the company is inefficient in making profit. -1
The TTM is 4.0%. Using its investors money, the company is inefficient in making profit. -1

Trends

Current period		Compared to		+/-
MRQ	4.5%	TTM	4.0%	+0.5%
TTM	4.0%	YOY	5.1%	-1.1%
TTM	4.0%	5Y	7.1%	-3.1%
5Y	7.1%	10Y	6.2%	+0.9%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	4.5%	-16.9%	+21.4%
TTM	4.0%	-16.1%	+20.1%
YOY	5.1%	-14.9%	+20.0%
5Y	7.1%	-19.3%	+26.4%
10Y	6.2%	-20.1%	+26.3%

Shows how efficient Regeneron is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Regeneron is 4.5%. This means Regeneron generated $0.04 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if Regeneron existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Regeneron

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Regeneron = 1,159,600
Shareholders equity (balance sheet) MRQ Regeneron = 25,973,100
1,159,600 / 25,973,100 = 0.04 or 4.5%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Regeneron Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Regeneron is operating .

Measures how much profit Regeneron makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
An Operating Margin of 33.5% means the company generated $0.34 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Regeneron Pharmaceuticals Inc:

The MRQ is 33.5%. The company is operating very efficient. +2
The TTM is 32.1%. The company is operating very efficient. +2

Trends

Current period		Compared to		+/-
MRQ	33.5%	TTM	32.1%	+1.4%
TTM	32.1%	YOY	39.1%	-7.1%
TTM	32.1%	5Y	40.0%	-7.9%
5Y	40.0%	10Y	35.8%	+4.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	33.5%	-298.0%	+331.5%
TTM	32.1%	-238.5%	+270.6%
YOY	39.1%	-288.4%	+327.5%
5Y	40.0%	-486.2%	+526.2%
10Y	35.8%	-628.4%	+664.2%

Measures how efficient Regeneron is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Regeneron to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Regeneron is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Regeneron is 33.5%. This means that Regeneron earned $0.34 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -298.0%.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Regeneron

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Regeneron = 972,900
Total revenue MRQ Regeneron = 3,434,300
$972,900 / $3,434,300 = 0.34 or 33.5%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Regeneron is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.71 means that the operating costs are $0.71 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Regeneron Pharmaceuticals Inc:

The MRQ is 0.708. The company is efficient in keeping operating costs low. +1
The TTM is 0.661. The company is efficient in keeping operating costs low. +1

Trends

Current period		Compared to		+/-
MRQ	0.708	TTM	0.661	+0.047
TTM	0.661	YOY	0.587	+0.074
TTM	0.661	5Y	0.603	+0.058
5Y	0.603	10Y	0.640	-0.038

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.708	3.235	-2.527
TTM	0.661	3.310	-2.649
YOY	0.587	3.838	-3.251
5Y	0.603	5.679	-5.076
10Y	0.640	7.823	-7.183

Measures how efficient Regeneron is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Regeneron to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Regeneron is 70.8%. This means that Regeneron earned $0.71 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.24.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Regeneron

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(517,000 +1,914,400) \ 3,434,300 = 0.71

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Regeneron Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Regeneron is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 5.69 means the company has $5.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Regeneron Pharmaceuticals Inc:

The MRQ is 5.690. The company is very able to pay all its short-term debts. +2
The TTM is 5.444. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	5.690	TTM	5.444	+0.247
TTM	5.444	YOY	5.139	+0.305
TTM	5.444	5Y	4.592	+0.852
5Y	4.592	10Y	4.485	+0.106

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	5.690	3.863	+1.827
TTM	5.444	4.169	+1.275
YOY	5.139	5.337	-0.198
5Y	4.592	6.122	-1.530
10Y	4.485	6.434	-1.949

Measures if Regeneron is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Regeneron if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Regeneron is 5.69. This means Regeneron has $5.69 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.86.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Regeneron

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
19,479,200 \ 3,423,400) = 5.69

The current ratio measures if Regeneron is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Regeneron is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Regeneron does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Regeneron is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Regeneron is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Regeneron to the Biotechnology industry mean.
A Quick Ratio of 7.19 means the company can pay off $7.19 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Regeneron Pharmaceuticals Inc:

The MRQ is 7.194. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 6.651. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	7.194	TTM	6.651	+0.543
TTM	6.651	YOY	5.557	+1.094
TTM	6.651	5Y	4.895	+1.756
5Y	4.895	10Y	4.619	+0.276

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	7.194	3.504	+3.690
TTM	6.651	3.991	+2.660
YOY	5.557	5.371	+0.186
5Y	4.895	6.088	-1.193
10Y	4.619	6.395	-1.776

Measures if Regeneron is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Regeneron to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Regeneron can pay off its short term debts. This shows if Regeneron can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Regeneron is 7.19. This means that Regeneron can pay off $7.19 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.50.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Regeneron

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Regeneron: (10,844,800 + 8,114,800 +5,667,300) / 3,423,400 = 7.19

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Regeneron Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Regeneron assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Regeneron to Biotechnology industry mean.
A Debt to Asset Ratio of 0.21 means that Regeneron assets are financed with 21.5% credit (debt) and the remaining percentage (100% - 21.5%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Regeneron Pharmaceuticals Inc:

The MRQ is 0.215. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.219. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.215	TTM	0.219	-0.004
TTM	0.219	YOY	0.233	-0.014
TTM	0.219	5Y	0.266	-0.047
5Y	0.266	10Y	0.292	-0.027

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.215	0.339	-0.124
TTM	0.219	0.337	-0.118
YOY	0.233	0.271	-0.038
5Y	0.266	0.368	-0.102
10Y	0.292	0.388	-0.096

Measures how much % of Regeneron assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Regeneron than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Regeneron to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Regeneron is 0.21. This means means that Regeneron is financed with 21.5% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 386.3%.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Regeneron has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Regeneron

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
7,107,100 \ 33,080,200 = 21.5% or 0.21.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Regeneron is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Regeneron to the Biotechnology industry mean.
A Debt to Equity ratio of 27.4% means that company has $0.27 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Regeneron Pharmaceuticals Inc:

The MRQ is 0.274. The company is very able to pay all its debts with equity. +2
The TTM is 0.280. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.274	TTM	0.280	-0.007
TTM	0.280	YOY	0.305	-0.024
TTM	0.280	5Y	0.369	-0.089
5Y	0.369	10Y	0.421	-0.051

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.274	0.392	-0.118
TTM	0.280	0.403	-0.123
YOY	0.305	0.335	-0.030
5Y	0.369	0.427	-0.058
10Y	0.421	0.461	-0.040

Measures if Regeneron is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Regeneron is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Regeneron is 0.27. This means that Regeneron can pay off $0.27 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Regeneron

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
7,107,100 \ 25,973,100 = 0.27 or 27.4%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Regeneron Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Regeneron generates.

Above 15 is considered overpriced but always compare Regeneron to the Biotechnology industry mean.
A PE ratio of 21.55 means the investor is paying $21.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Regeneron Pharmaceuticals Inc:

The EOD is 21.852. Based on the earnings, the company is fair priced.
The MRQ is 21.548. Based on the earnings, the company is fair priced.
The TTM is 23.615. Based on the earnings, the company is fair priced.

Trends

Current period		Compared to		+/-
EOD	21.852	MRQ	21.548	+0.304
MRQ	21.548	TTM	23.615	-2.067
TTM	23.615	YOY	18.000	+5.616
TTM	23.615	5Y	18.658	+4.958
5Y	18.658	10Y	41.877	-23.219

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	21.852	-2.300	+24.152
MRQ	21.548	-2.656	+24.204
TTM	23.615	-2.718	+26.333
YOY	18.000	-4.145	+22.145
5Y	18.658	-6.258	+24.916
10Y	41.877	-6.315	+48.192

Measures how much money you pay for each share for every $1 in earnings Regeneron generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Regeneron to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Regeneron is 21.55. This means the investor is paying $21.55 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.66.
What is the trend?
The trend is important because it shows you how Regeneron is performing over time. The most recent quarter might be important if Regeneron released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Regeneron up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Regeneron

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 113,800 = EPS
PE ratio MRQ = 21.55

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Regeneron Pharmaceuticals Inc:

The EOD is 32.646. Based on how much money comes from the company's main activities, the company is fair priced.
The MRQ is 32.192. Based on how much money comes from the company's main activities, the company is fair priced.
The TTM is 24.811. Based on how much money comes from the company's main activities, the company is underpriced. +1

Trends

Current period		Compared to		+/-
EOD	32.646	MRQ	32.192	+0.454
MRQ	32.192	TTM	24.811	+7.381
TTM	24.811	YOY	26.035	-1.224
TTM	24.811	5Y	22.029	+2.782
5Y	22.029	10Y	22.282	-0.253

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	32.646	-2.974	+35.620
MRQ	32.192	-3.306	+35.498
TTM	24.811	-3.508	+28.319
YOY	26.035	-5.613	+31.648
5Y	22.029	-8.378	+30.407
10Y	22.282	-8.873	+31.155

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Regeneron is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 3.85 means the investor is paying $3.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Regeneron Pharmaceuticals Inc:

The EOD is 3.902. Based on the equity, the company is fair priced.
The MRQ is 3.848. Based on the equity, the company is fair priced.
The TTM is 3.747. Based on the equity, the company is fair priced.

Trends

Current period		Compared to		+/-
EOD	3.902	MRQ	3.848	+0.054
MRQ	3.848	TTM	3.747	+0.101
TTM	3.747	YOY	3.619	+0.128
TTM	3.747	5Y	4.265	-0.517
5Y	4.265	10Y	7.905	-3.640

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	3.902	1.914	+1.988
MRQ	3.848	2.116	+1.732
TTM	3.747	2.097	+1.650
YOY	3.619	2.881	+0.738
5Y	4.265	3.550	+0.715
10Y	7.905	3.936	+3.969

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Regeneron Pharmaceuticals Inc.

3.1. Institutions holding Regeneron Pharmaceuticals Inc

Institutions are holding 89.257% of the shares of Regeneron Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	FMR Inc	9.3998	0.6961	10317415	476523	4.8423
2023-12-31	Vanguard Group Inc	8.0522	0.1696	8838285	39780	0.4521
2023-12-31	BlackRock Inc	7.8622	0.1933	8629707	-245602	-2.7673
2023-12-31	JPMorgan Chase & Co	6.584	0.6099	7226769	-162385	-2.1976
2023-12-31	Capital World Investors	4.6742	0.8014	5130485	23146	0.4532
2023-12-31	State Street Corporation	4.4653	0.2094	4901251	72145	1.494
2023-12-31	Capital Research & Mgmt Co - Division 3	2.6566	0.5741	2915972	-58366	-1.9623
2023-12-31	Dodge & Cox	2.1571	1.3199	2367680	-5318	-0.2241
2023-12-31	Geode Capital Management, LLC	2.1448	0.2158	2354217	34231	1.4755
2023-12-31	Loomis, Sayles & Company LP	1.1106	1.6396	1219067	-13812	-1.1203
2023-12-31	Putnam Investments LLC	1.1031	1.4041	1210735	24329	2.0506
2023-12-31	Morgan Stanley - Brokerage Accounts	1.0382	0.0882	1139519	168562	17.3604
2023-12-31	Wellington Management Company LLP	1.0041	0.1805	1102090	-404795	-26.863
2023-12-31	NORGES BANK	0.9674	0.163	1061803	95336	9.8644
2023-12-31	Northern Trust Corp	0.9533	0.1664	1046408	-20802	-1.9492
2023-12-31	Legal & General Group PLC	0.8979	0.2221	985540	165332	20.1573
2023-12-31	Bank of New York Mellon Corp	0.8642	0.1689	948575	-18839	-1.9474
2023-12-31	American Century Companies Inc	0.8485	0.5624	931328	14610	1.5937
2023-12-31	Amundi	0.8328	0.3714	914125	228839	33.3932
2023-12-31	Bank of America Corp	0.8003	0.0777	878413	41554	4.9655
Total		58.4166	9.8338	64119384	+454468	+0.7%

3.2. Funds holding Regeneron Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Capital Group Growth Fnd of Amer Comp	2.9168	1.1292	3201481	-48587	-1.495
2023-12-31	American Funds Growth Fund of Amer A	2.9168	1.1292	3201481	-48587	-1.495
2024-02-29	Vanguard Total Stock Mkt Idx Inv	2.9093	0.199	3193356	-6996	-0.2186
2024-02-29	Vanguard Institutional 500 Index Trust	2.4369	0.2416	2674804	27144	1.0252
2024-02-29	Fidelity Contrafund	2.4225	1.941	2658943	0	0
2024-03-28	Invesco QQQ Trust	1.8434	0.7501	2023348	2422	0.1198
2024-02-29	JPMorgan Large Cap Growth I	1.4965	1.8789	1642548	0	0
2023-12-31	Dodge & Cox Stock I	1.417	1.3532	1555285	0	0
2024-03-28	SPDR® S&P 500 ETF Trust	1.1707	0.2302	1284963	7560	0.5918
2024-02-29	Fidelity 500 Index	1.1706	0.2409	1284846	12929	1.0165
2024-02-29	Fidelity Contrafund Commingled Pl O	1.0208	2.0279	1120471	0	0
2024-03-28	iShares Core S&P 500 ETF	0.9978	0.2302	1095207	8064	0.7418
2023-12-31	American Funds IS® Growth 1	0.9283	2.2772	1018940	-24811	-2.3771
2023-12-31	Capital Group Growth Composite	0.9283	2.2772	1018940	-24811	-2.3771
2023-12-31	American Funds New Perspective A	0.8131	0.6187	892478	12907	1.4674
2023-12-31	Capital Group New Perspective Comp	0.8131	0.6187	892478	12907	1.4674
2024-02-29	Vanguard Value Index Inv	0.7744	0.5061	850017	2860	0.3376
2024-03-28	Health Care Select Sector SPDR® ETF	0.7257	1.8569	796591	-1287	-0.1613
2023-12-31	Vanguard Health Care Inv	0.6615	1.3739	726053	-325631	-30.9628
2024-02-29	Vanguard Institutional Index I	0.643	0.2409	705719	-2821	-0.3981
Total		29.0065	21.121	31837949	-396738	-1.2%

3.3. Insider Transactions

Insiders are holding 2.582% of the shares of Regeneron Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price
2024-03-14	Andrew J Murphy	SELL	5783	956.47
2024-03-01	Arthur F Ryan	SELL	100	982.05
2024-03-01	Marion Mccourt	SELL	358	967.5
2024-02-26	Bonnie L Bassler	SELL	854	979.25
2024-02-22	Joseph J Larosa	SELL	1000	967.65
2024-02-07	Joseph J Larosa	SELL	1000	950
2024-02-05	Marion Mccourt	SELL	1000	934.71
2024-02-01	Arthur F Ryan	SELL	100	954.22
2024-01-30	Bonnie L Bassler	SELL	827	959
2024-01-23	Joseph L Goldstein	SELL	2707	950
2023-12-27	Christopher R Fenimore	SELL	2448	856.71
2023-12-27	Michael S Brown	SELL	2049	898
2023-12-21	Christopher R Fenimore	SELL	1680	844.01
2023-12-01	Arthur F Ryan	SELL	100	817.3
2023-11-07	Arthur F Ryan	SELL	100	827.9
2023-11-01	Marion Mccourt	SELL	1000	783.91
2023-10-13	Huda Y Zoghbi	SELL	1000	850
2023-10-02	Marion Mccourt	SELL	1038	827
2023-08-24	Plew Daniel P Van	SELL	6197	841.71

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Regeneron Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	8.619	7.357	+17%	8.251	+4%	7.598	+13%	5.272	+63%
Book Value Per Share	-	-	228.235	216.204	+6%	186.605	+22%	144.916	+57%	92.540	+147%
Current Ratio	-	-	5.690	5.444	+5%	5.139	+11%	4.592	+24%	4.485	+27%
Debt To Asset Ratio	-	-	0.215	0.219	-2%	0.233	-8%	0.266	-19%	0.292	-27%
Debt To Equity Ratio	-	-	0.274	0.280	-2%	0.305	-10%	0.369	-26%	0.421	-35%
Dividend Per Share	-	-	-	-	0%	-	0%	0.303	-100%	0.526	-100%
Eps	-	-	10.190	8.688	+17%	9.562	+7%	9.710	+5%	6.053	+68%
Free Cash Flow Per Share	-	-	6.821	8.378	-19%	9.749	-30%	8.254	-17%	5.183	+32%
Free Cash Flow To Equity Per Share	-	-	2.901	4.445	-35%	7.521	-61%	5.631	-48%	3.595	-19%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	0.997	+0%	0.999	+0%
Intrinsic Value_10Y_max	-	-	458.151	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	29.712	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	43.830	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	17.829	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	133.277	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	41.022	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	224.636	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	50.289	-	-	-	-	-	-	-	-
Market Cap	96143561920.000	-4%	99949402000.000	92196288000.000	+8%	76583629500.000	+31%	66775281592.766	+50%	56381887102.129	+77%
Net Profit Margin	-	-	0.338	0.301	+12%	0.356	-5%	0.365	-7%	0.285	+19%
Operating Margin	-	-	0.335	0.321	+5%	0.391	-14%	0.400	-16%	0.358	-6%
Operating Ratio	-	-	0.708	0.661	+7%	0.587	+21%	0.603	+17%	0.640	+11%
Pb Ratio	3.902	+1%	3.848	3.747	+3%	3.619	+6%	4.265	-10%	7.905	-51%
Pe Ratio	21.852	+1%	21.548	23.615	-9%	18.000	+20%	18.658	+15%	41.877	-49%
Price Per Share	890.680	+1%	878.290	810.365	+8%	674.978	+30%	587.054	+50%	492.791	+78%
Price To Free Cash Flow Ratio	32.646	+1%	32.192	24.811	+30%	26.035	+24%	22.029	+46%	22.282	+44%
Price To Total Gains Ratio	103.338	+1%	101.900	114.828	-11%	85.072	+20%	67.643	+51%	99.799	+2%
Quick Ratio	-	-	7.194	6.651	+8%	5.557	+29%	4.895	+47%	4.619	+56%
Return On Assets	-	-	0.035	0.031	+12%	0.039	-11%	0.051	-31%	0.044	-20%
Return On Equity	-	-	0.045	0.040	+11%	0.051	-13%	0.071	-37%	0.062	-28%
Total Gains Per Share	-	-	8.619	7.357	+17%	8.251	+4%	7.901	+9%	5.798	+49%
Usd Book Value	-	-	25973100000.000	24597650000.000	+6%	21176325000.000	+23%	16468145000.000	+58%	10551071875.000	+146%
Usd Book Value Change Per Share	-	-	8.619	7.357	+17%	8.251	+4%	7.598	+13%	5.272	+63%
Usd Book Value Per Share	-	-	228.235	216.204	+6%	186.605	+22%	144.916	+57%	92.540	+147%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	0.303	-100%	0.526	-100%
Usd Eps	-	-	10.190	8.688	+17%	9.562	+7%	9.710	+5%	6.053	+68%
Usd Free Cash Flow	-	-	776200000.000	953325000.000	-19%	1106199999.750	-30%	938569999.850	-17%	591290774.825	+31%
Usd Free Cash Flow Per Share	-	-	6.821	8.378	-19%	9.749	-30%	8.254	-17%	5.183	+32%
Usd Free Cash Flow To Equity Per Share	-	-	2.901	4.445	-35%	7.521	-61%	5.631	-48%	3.595	-19%
Usd Market Cap	96143561920.000	-4%	99949402000.000	92196288000.000	+8%	76583629500.000	+31%	66775281592.766	+50%	56381887102.129	+77%
Usd Price Per Share	890.680	+1%	878.290	810.365	+8%	674.978	+30%	587.054	+50%	492.791	+78%
Usd Profit	-	-	1159600000.000	988400000.000	+17%	1084600000.000	+7%	1099815000.000	+5%	687581525.000	+69%
Usd Revenue	-	-	3434300000.000	3279300000.000	+5%	3043225000.000	+13%	2886115000.000	+19%	2052226050.000	+67%
Usd Total Gains Per Share	-	-	8.619	7.357	+17%	8.251	+4%	7.901	+9%	5.798	+49%
	EOD	+2 -6	MRQ	TTM	+23 -10	YOY	+19 -14	5Y	+21 -15	10Y	+26 -10

4.2. Fundamental Score

Let's check the fundamental score of Regeneron Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	21.852
Price to Book Ratio (EOD)	Between	0-1	3.902
Net Profit Margin (MRQ)	Greater than	0	0.338
Operating Margin (MRQ)	Greater than	0	0.335
Quick Ratio (MRQ)	Greater than	1	7.194
Current Ratio (MRQ)	Greater than	1	5.690
Debt to Asset Ratio (MRQ)	Less than	1	0.215
Debt to Equity Ratio (MRQ)	Less than	1	0.274
Return on Equity (MRQ)	Greater than	0.15	0.045
Return on Assets (MRQ)	Greater than	0.05	0.035
Total			6/10 (60.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Regeneron Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	31.268
Ma 20	Greater than	Ma 50	922.507
Ma 50	Greater than	Ma 100	949.141
Ma 100	Greater than	Ma 200	925.127
Open	Greater than	Close	912.680
Total			3/5 (60.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

		2022-12-31		2023-03-31		2023-06-30		2023-09-30		2023-12-31
Tax Provision		127,600	-87,400	40,200	74,300	114,500	-11,500	103,000	-115,000	-12,000
Income Tax Expense		127,600	-87,400	40,200	74,300	114,500	-11,500	103,000	-115,000	-12,000

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	33,080,200
Total Liabilities	7,107,100
Total Stockholder Equity	25,973,100

	As reported
Total Liabilities	7,107,100
Total Stockholder Equity	+ 25,973,100
Total Assets	= 33,080,200

Assets

Total Assets	33,080,200
Total Current Assets	19,479,200
Long-term Assets	13,601,000

Total Current Assets

Total Current Assets (as reported)	19,479,200
Cash And Cash Equivalents	2,730,000
Short-term Investments	8,114,800
Net Receivables	5,667,300
Inventory	2,580,500
Other Current Assets	386,600
Total Current Assets (calculated)	19,479,200
+/-	0

Long-term Assets

Long-term Assets (as reported)	13,601,000
Property Plant Equipment	4,146,400
Long Term Investments	5,396,500
Intangible Assets	1,038,600
Other Assets	830,700
Long-term Assets (calculated)	11,412,200
+/-	2,188,800

Liabilities & Shareholders' Equity

Total Current Liabilities	3,423,400
Long-term Liabilities	3,683,700
Total Stockholder Equity	25,973,100

Total Current Liabilities

Total Current Liabilities (as reported)	3,423,400
Accounts payable	606,600
Other Current Liabilities	2,357,900
Total Current Liabilities (calculated)	2,964,500
+/-	458,900

Long-term Liabilities

Long-term Liabilities (as reported)	3,683,700
Long term Debt	1,982,900
Capital Lease Obligations Min Short Term Debt	720,000
Long-term Liabilities Other	854,100
Long-term Liabilities (calculated)	3,557,000
+/-	126,700

Total Stockholder Equity

Total Stockholder Equity (as reported)	25,973,100
Common Stock	100
Retained Earnings	27,260,300
Accumulated Other Comprehensive Income	-80,900
Other Stockholders Equity	-1,206,400
Total Stockholder Equity (calculated)	25,973,100
+/-	0

Other

Capital Stock	100
Cash and Short Term Investments	10,844,800
Common Stock Shares Outstanding	113,800
Current Deferred Revenue	458,900
Liabilities and Stockholders Equity	33,080,200
Net Debt	-27,100
Net Invested Capital	27,956,000
Net Working Capital	16,055,800
Property Plant and Equipment Gross	6,125,200
Short Long Term Debt Total	2,702,900

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2003-12-31

2003-09-30

2003-06-30

2003-03-31

2002-12-31

2002-09-30

2002-06-30

2002-03-31

2001-12-31

2001-09-30

2001-06-30

2001-03-31

2000-12-31

2000-09-30

2000-06-30

2000-03-31

1999-12-31

1999-09-30

1999-06-30

1999-03-31

1998-12-31

1998-09-30

1998-06-30

1998-03-31

1997-12-31

1997-09-30

1997-06-30

1997-03-31

1996-12-31

1996-09-30

1996-06-30

1996-03-31

1995-12-31

1995-09-30

1995-06-30

1995-03-31

1994-12-31

1994-09-30

1994-06-30

1994-03-31

1993-12-31

1993-09-30

1993-06-30

1993-03-31

1992-12-31

1992-09-30

1992-06-30

1992-03-31

1991-12-31

1991-09-30

1991-06-30

1991-03-31

1990-12-31

1990-09-30

1990-06-30

1990-03-31

> Total Assets

0
0
0
25,400
0
115,200
114,000
114,000
112,200
108,700
104,400
97,900
90,600
82,400
125,900
117,600
106,000
105,700
97,400
94,200
86,100
83,400
74,200
93,800
86,200
139,300
130,600
137,600
129,100
170,000
164,700
168,400
161,400
165,100
162,400
156,900
149,300
139,800
134,400
137,000
132,034
202,117
216,319
208,274
349,185
336,295
318,613
495,397
471,865
440,451
418,592
391,574
430,441
395,547
500,501
479,555
506,178
488,174
472,685
473,108
470,292
446,948
419,275
423,501
402,089
378,332
355,186
585,090
601,431
597,858
573,096
936,258
930,876
851,225
825,891
670,038
681,421
742,345
742,192
741,202
787,156
790,641
942,433
1,089,432
1,074,293
1,046,864
983,031
1,323,583
1,350,159
1,457,500
1,660,615
2,080,490
2,275,998
2,378,259
2,640,415
2,951,013
3,260,396
3,456,078
3,739,419
3,871,827
4,198,573
4,526,970
5,182,915
5,609,132
5,904,460
6,204,906
6,828,019
6,973,466
7,817,365
8,106,373
8,701,215
8,764,286
9,372,696
9,951,980
10,805,613
11,734,500
12,854,800
13,173,600
13,939,300
14,805,200
15,757,500
14,428,700
16,084,000
17,163,300
17,772,200
21,485,900
23,671,500
25,434,800
26,348,700
27,205,800
27,677,800
29,214,500
30,059,900
30,657,500
32,163,300
33,080,200

33,080,200

32,163,300

30,657,500

30,059,900

29,214,500

27,677,800

27,205,800

26,348,700

25,434,800

23,671,500

21,485,900

17,772,200

17,163,300

16,084,000

14,428,700

15,757,500

14,805,200

13,939,300

13,173,600

12,854,800

11,734,500

10,805,613

9,951,980

9,372,696

8,764,286

8,701,215

8,106,373

7,817,365

6,973,466

6,828,019

6,204,906

5,904,460

5,609,132

5,182,915

4,526,970

4,198,573

3,871,827

3,739,419

3,456,078

3,260,396

2,951,013

2,640,415

2,378,259

2,275,998

2,080,490

1,660,615

1,457,500

1,350,159

1,323,583

983,031

1,046,864

1,074,293

1,089,432

942,433

790,641

787,156

741,202

742,192

742,345

681,421

670,038

825,891

851,225

930,876

936,258

573,096

597,858

601,431

585,090

355,186

378,332

402,089

423,501

419,275

446,948

470,292

473,108

472,685

488,174

506,178

479,555

500,501

395,547

430,441

391,574

418,592

440,451

471,865

495,397

318,613

336,295

349,185

208,274

216,319

202,117

132,034

137,000

134,400

139,800

149,300

156,900

162,400

165,100

161,400

168,400

164,700

170,000

129,100

137,600

130,600

139,300

86,200

93,800

74,200

83,400

86,100

94,200

97,400

105,700

106,000

117,600

125,900

82,400

90,600

97,900

104,400

108,700

112,200

114,000

115,200

25,400

> Total Current Assets

0
0
0
22,400
0
111,300
109,600
106,600
102,400
97,400
91,900
84,700
76,800
67,700
109,600
91,800
44,600
55,300
47,000
52,000
37,900
39,500
30,600
49,200
38,500
81,700
73,400
85,000
71,900
110,600
102,100
99,600
90,900
88,400
89,200
92,900
76,200
76,200
74,200
73,000
73,481
137,464
137,002
134,142
286,636
252,782
252,727
394,186
337,118
309,705
313,823
276,948
329,740
295,150
404,378
320,207
392,284
383,330
311,238
343,955
369,854
359,312
324,958
341,392
319,647
291,056
273,749
469,984
489,163
496,981
422,020
797,829
787,505
742,393
715,540
521,442
483,791
526,409
461,594
425,508
395,444
417,750
575,719
720,051
695,738
413,273
339,872
652,875
696,915
769,193
948,603
1,620,787
1,307,122
1,561,362
1,634,160
2,252,208
1,871,049
1,918,695
2,200,512
2,506,894
2,310,714
2,283,341
2,675,640
3,383,756
3,133,379
3,209,225
3,501,689
3,913,920
3,669,263
3,860,051
4,135,742
5,596,552
4,544,732
6,696,021
5,719,583
7,959,300
6,928,600
6,651,000
7,109,100
10,558,800
8,644,100
7,860,200
9,097,600
12,753,900
10,055,100
13,337,600
13,775,400
20,520,500
14,306,000
21,362,200
15,428,600
22,064,700
16,909,200
16,923,000
18,634,800
19,479,200

19,479,200

18,634,800

16,923,000

16,909,200

22,064,700

15,428,600

21,362,200

14,306,000

20,520,500

13,775,400

13,337,600

10,055,100

12,753,900

9,097,600

7,860,200

8,644,100

10,558,800

7,109,100

6,651,000

6,928,600

7,959,300

5,719,583

6,696,021

4,544,732

5,596,552

4,135,742

3,860,051

3,669,263

3,913,920

3,501,689

3,209,225

3,133,379

3,383,756

2,675,640

2,283,341

2,310,714

2,506,894

2,200,512

1,918,695

1,871,049

2,252,208

1,634,160

1,561,362

1,307,122

1,620,787

948,603

769,193

696,915

652,875

339,872

413,273

695,738

720,051

575,719

417,750

395,444

425,508

461,594

526,409

483,791

521,442

715,540

742,393

787,505

797,829

422,020

496,981

489,163

469,984

273,749

291,056

319,647

341,392

324,958

359,312

369,854

343,955

311,238

383,330

392,284

320,207

404,378

295,150

329,740

276,948

313,823

309,705

337,118

394,186

252,727

252,782

286,636

134,142

137,002

137,464

73,481

73,000

74,200

76,200

92,900

89,200

88,400

90,900

99,600

102,100

110,600

71,900

85,000

73,400

81,700

38,500

49,200

30,600

39,500

37,900

52,000

47,000

55,300

44,600

91,800

109,600

67,700

76,800

84,700

91,900

97,400

102,400

106,600

109,600

111,300

22,400

Cash And Cash Equivalents

0
0
0
21,800
0
39,200
35,000
26,200
24,900
22,000
19,200
16,400
10,100
7,900
39,700
12,500
8,000
18,000
15,300
23,600
12,700
16,800
5,900
32,700
11,900
48,900
37,500
34,500
27,900
51,400
40,300
28,900
19,300
22,500
22,600
19,800
21,800
20,600
23,500
23,700
12,294
81,751
49,642
30,978
183,620
142,955
99,974
247,393
135,469
69,374
75,574
80,077
191,586
129,659
298,617
118,285
174,034
122,833
105,047
101,234
147,816
145,201
176,093
184,508
182,332
114,960
167,662
237,876
156,484
109,643
97,416
498,925
520,875
292,129
314,684
247,796
199,097
271,466
250,321
207,075
117,311
112,000
325,286
112,572
135,376
254,312
206,395
483,610
394,585
171,943
118,998
230,276
180,362
381,675
263,211
535,608
461,858
600,135
646,554
648,719
507,907
390,554
654,587
809,102
604,214
646,508
920,359
535,203
811,773
744,313
792,065
812,733
1,019,491
917,876
1,087,843
1,467,700
1,708,500
1,045,500
1,384,800
1,617,800
2,208,200
1,992,200
1,573,000
2,193,700
1,437,900
2,072,200
3,432,400
2,885,600
3,345,700
3,395,100
3,491,300
3,105,900
3,916,300
1,937,200
2,152,300
2,730,000

2,730,000

2,152,300

1,937,200

3,916,300

3,105,900

3,491,300

3,395,100

3,345,700

2,885,600

3,432,400

2,072,200

1,437,900

2,193,700

1,573,000

1,992,200

2,208,200

1,617,800

1,384,800

1,045,500

1,708,500

1,467,700

1,087,843

917,876

1,019,491

812,733

792,065

744,313

811,773

535,203

920,359

646,508

604,214

809,102

654,587

390,554

507,907

648,719

646,554

600,135

461,858

535,608

263,211

381,675

180,362

230,276

118,998

171,943

394,585

483,610

206,395

254,312

135,376

112,572

325,286

112,000

117,311

207,075

250,321

271,466

199,097

247,796

314,684

292,129

520,875

498,925

97,416

109,643

156,484

237,876

167,662

114,960

182,332

184,508

176,093

145,201

147,816

101,234

105,047

122,833

174,034

118,285

298,617

129,659

191,586

80,077

75,574

69,374

135,469

247,393

99,974

142,955

183,620

30,978

49,642

81,751

12,294

23,700

23,500

20,600

21,800

19,800

22,600

22,500

19,300

28,900

40,300

51,400

27,900

34,500

37,500

48,900

11,900

32,700

5,900

16,800

12,700

23,600

15,300

18,000

8,000

12,500

39,700

7,900

10,100

16,400

19,200

22,000

24,900

26,200

35,000

39,200

21,800

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,500
42,500
44,120
36,110
67,386
86,634
90,383
101,852
140,735
137,686
189,601
229,331
224,317
184,194
120,404
144,215
86,056
175,489
146,702
221,217
173,668
194,748
206,090
190,612
131,449
114,037
120,061
158,616
94,227
221,400
295,910
351,054
299,566
267,532
222,373
408,275
348,924
226,954
216,785
120,452
129,475
134,255
186,328
194,337
153,767
136,796
91,065
55,371
39,103
43,332
37,713
129,079
143,554
77,819
127,348
155,831
182,112
158,376
186,275
216,774
395,650
251,761
234,257
213,694
241,055
236,121
244,965
398,656
488,032
503,481
495,311
523,537
586,879
596,847
605,461
765,642
1,104,309
1,342,200
1,523,900
1,624,200
1,493,100
1,596,500
1,795,200
1,152,000
1,452,900
1,393,300
2,065,900
1,838,600
2,355,200
2,809,100
3,704,900
4,171,300
3,530,400
4,636,400
5,043,400
6,990,500
7,761,300
8,114,800

8,114,800

7,761,300

6,990,500

5,043,400

4,636,400

3,530,400

4,171,300

3,704,900

2,809,100

2,355,200

1,838,600

2,065,900

1,393,300

1,452,900

1,152,000

1,795,200

1,596,500

1,493,100

1,624,200

1,523,900

1,342,200

1,104,309

765,642

605,461

596,847

586,879

523,537

495,311

503,481

488,032

398,656

244,965

236,121

241,055

213,694

234,257

251,761

395,650

216,774

186,275

158,376

182,112

155,831

127,348

77,819

143,554

129,079

37,713

43,332

39,103

55,371

91,065

136,796

153,767

194,337

186,328

134,255

129,475

120,452

216,785

226,954

348,924

408,275

222,373

267,532

299,566

351,054

295,910

221,400

94,227

158,616

120,061

114,037

131,449

190,612

206,090

194,748

173,668

221,217

146,702

175,489

86,056

144,215

120,404

184,194

224,317

229,331

189,601

137,686

140,735

101,852

90,383

86,634

67,386

36,110

44,120

42,500

40,500

Net Receivables

0
0
0
200
0
1,100
1,900
1,400
1,600
2,000
1,600
1,100
1,100
200
1,700
1,700
1,500
1,400
1,600
1,700
2,400
2,400
4,500
2,700
4,300
6,500
6,000
4,300
3,300
5,900
4,100
6,600
4,600
12,500
5,400
5,700
7,000
5,000
8,600
600
8,560
9,568
9,851
13,835
8,608
4,380
3,547
2,975
2,739
2,986
4,521
4,017
7,238
7,871
9,197
15,529
59,882
25,397
24,866
43,102
10,371
16,830
10,536
36,521
11,010
12,141
7,940
7,493
33,632
20,478
10,968
18,320
32,960
32,838
42,206
35,212
48,209
60,046
67,766
65,568
71,858
95,196
82,287
93,112
88,156
84,564
78,447
103,035
238,347
435,380
601,271
693,120
802,638
876,016
992,824
891,778
1,047,496
893,924
927,254
1,017,399
1,338,462
1,395,125
1,439,315
1,467,793
1,865,221
1,751,971
1,643,872
1,611,620
1,749,548
1,844,547
1,971,449
1,974,340
1,943,932
2,039,247
2,202,945
2,243,200
2,305,200
2,455,900
2,660,000
2,672,200
2,933,200
2,811,300
4,039,500
4,114,700
4,173,000
6,998,600
5,452,000
6,036,500
4,839,000
5,161,400
5,548,300
5,328,700
5,118,600
5,121,300
5,584,500
5,667,300

5,667,300

5,584,500

5,121,300

5,118,600

5,328,700

5,548,300

5,161,400

4,839,000

6,036,500

5,452,000

6,998,600

4,173,000

4,114,700

4,039,500

2,811,300

2,933,200

2,672,200

2,660,000

2,455,900

2,305,200

2,243,200

2,202,945

2,039,247

1,943,932

1,974,340

1,971,449

1,844,547

1,749,548

1,611,620

1,643,872

1,751,971

1,865,221

1,467,793

1,439,315

1,395,125

1,338,462

1,017,399

927,254

893,924

1,047,496

891,778

992,824

876,016

802,638

693,120

601,271

435,380

238,347

103,035

78,447

84,564

88,156

93,112

82,287

95,196

71,858

65,568

67,766

60,046

48,209

35,212

42,206

32,838

32,960

18,320

10,968

20,478

33,632

7,493

7,940

12,141

11,010

36,521

10,536

16,830

10,371

43,102

24,866

25,397

59,882

15,529

9,197

7,871

7,238

4,017

4,521

2,986

2,739

2,975

3,547

4,380

8,608

13,835

9,851

9,568

8,560

600

8,600

5,000

7,000

5,700

5,400

12,500

4,600

6,600

4,100

5,900

3,300

4,300

6,000

6,500

4,300

2,700

4,500

2,400

1,700

1,600

1,400

1,500

1,700

200

1,100

1,600

2,000

1,600

1,400

1,900

1,100

200

Other Current Assets

0
0
0
400
0
71,000
72,700
79,000
75,900
73,400
71,100
67,200
65,600
59,600
68,200
77,600
35,100
35,900
30,100
26,700
22,800
20,300
20,200
13,800
22,300
26,300
29,900
46,200
40,700
53,300
57,700
64,100
67,000
53,400
61,200
67,400
47,400
50,600
1,600
1,600
2,866
2,104
1,942
780
1,357
1,332
5,415
2,159
4,320
2,649
3,259
1,829
2,075
3,063
2,810
1,898
2,568
3,033
3,391
1,642
2,490
2,923
4,043
3,422
2,990
3,211
3,920
3,215
3,137
15,806
14,070
13,052
11,297
9,151
9,726
11,480
19,700
466,363
14,032
18,610
19,947
16,217
14,379
15,142
607,582
19,026
15,927
9,342
5,653
8,366
55,210
176,159
152,797
90,681
132,721
140,818
88,875
97,965
110,737
120,721
96,225
112,702
150,015
163,501
115,685
96,017
103,806
130,528
146,055
193,334
143,761
224,972
155,451
163,599
284,807
243,300
182,200
208,200
226,900
387,100
226,600
263,800
230,600
160,800
213,600
444,300
482,000
332,400
424,900
583,600
446,400
933,000
406,200
360,800
574,700
386,600

386,600

574,700

360,800

406,200

933,000

446,400

583,600

424,900

332,400

482,000

444,300

213,600

160,800

230,600

263,800

226,600

387,100

226,900

208,200

182,200

243,300

284,807

163,599

155,451

224,972

143,761

193,334

146,055

130,528

103,806

96,017

115,685

163,501

150,015

112,702

96,225

120,721

110,737

97,965

88,875

140,818

132,721

90,681

152,797

176,159

55,210

8,366

5,653

9,342

15,927

19,026

607,582

15,142

14,379

16,217

19,947

18,610

14,032

466,363

19,700

11,480

9,726

9,151

11,297

13,052

14,070

15,806

3,137

3,215

3,920

3,211

2,990

3,422

4,043

2,923

2,490

1,642

3,391

3,033

2,568

1,898

2,810

3,063

2,075

1,829

3,259

2,649

4,320

2,159

5,415

1,332

1,357

780

1,942

2,104

2,866

1,600

50,600

47,400

67,400

61,200

53,400

67,000

64,100

57,700

53,300

40,700

46,200

29,900

26,300

22,300

13,800

20,200

20,300

22,800

26,700

30,100

35,900

35,100

77,600

68,200

59,600

65,600

67,200

71,100

73,400

75,900

79,000

72,700

71,000

400

> Long-term Assets

0
0
0
3,000
0
3,900
4,400
7,400
9,800
11,300
12,500
13,200
13,800
14,700
16,300
25,800
61,400
50,400
50,400
42,200
48,200
43,900
43,600
44,600
47,700
57,600
57,200
52,600
57,200
59,400
62,600
68,800
70,500
76,700
73,200
64,000
73,100
63,600
60,200
64,000
58,553
64,653
79,317
74,132
62,549
83,513
65,886
101,211
134,747
130,746
104,769
114,626
100,701
100,397
96,123
159,348
113,894
104,844
161,447
129,153
100,438
87,636
94,317
82,109
82,442
87,276
81,437
115,106
112,268
100,877
151,076
138,429
143,371
108,832
110,351
148,596
197,630
215,936
280,598
315,694
391,712
372,891
366,714
369,381
378,555
633,591
643,159
670,708
653,244
688,307
712,012
459,703
968,876
816,897
1,006,255
698,805
1,389,347
1,537,383
1,538,907
1,364,933
1,887,859
2,243,629
2,507,275
2,225,376
2,771,081
2,995,681
3,326,330
3,059,546
4,148,102
4,246,322
4,565,473
3,167,734
4,827,964
3,255,959
5,086,030
3,775,200
5,926,200
6,522,600
6,830,200
4,246,400
7,113,400
6,568,500
6,986,400
4,409,400
7,717,100
8,148,300
9,896,100
4,914,300
12,042,700
5,843,600
12,249,200
7,149,800
13,150,700
13,734,500
13,528,500
13,601,000

13,601,000

13,528,500

13,734,500

13,150,700

7,149,800

12,249,200

5,843,600

12,042,700

4,914,300

9,896,100

8,148,300

7,717,100

4,409,400

6,986,400

6,568,500

7,113,400

4,246,400

6,830,200

6,522,600

5,926,200

3,775,200

5,086,030

3,255,959

4,827,964

3,167,734

4,565,473

4,246,322

4,148,102

3,059,546

3,326,330

2,995,681

2,771,081

2,225,376

2,507,275

2,243,629

1,887,859

1,364,933

1,538,907

1,537,383

1,389,347

698,805

1,006,255

816,897

968,876

459,703

712,012

688,307

653,244

670,708

643,159

633,591

378,555

369,381

366,714

372,891

391,712

315,694

280,598

215,936

197,630

148,596

110,351

108,832

143,371

138,429

151,076

100,877

112,268

115,106

81,437

87,276

82,442

82,109

94,317

87,636

100,438

129,153

161,447

104,844

113,894

159,348

96,123

100,397

100,701

114,626

104,769

130,746

134,747

101,211

65,886

83,513

62,549

74,132

79,317

64,653

58,553

64,000

60,200

63,600

73,100

64,000

73,200

76,700

70,500

68,800

62,600

59,400

57,200

52,600

57,200

57,600

47,700

44,600

43,600

43,900

48,200

42,200

50,400

61,400

25,800

16,300

14,700

13,800

13,200

12,500

11,300

9,800

7,400

4,400

3,900

3,000

Property Plant Equipment

0
0
0
2,200
0
2,400
2,700
5,400
7,700
8,900
10,000
10,500
11,000
11,400
12,200
22,400
27,000
27,600
28,100
27,700
26,800
25,700
25,100
27,900
31,200
33,300
33,700
34,300
33,800
34,000
32,900
32,700
32,200
32,200
32,600
33,000
34,200
35,200
35,100
36,300
36,630
37,434
37,659
36,934
37,166
37,619
37,418
39,448
42,043
47,465
56,138
76,825
82,648
84,670
83,715
80,723
77,616
75,986
73,942
71,239
69,055
67,366
64,044
60,535
57,421
53,854
51,035
49,353
47,781
47,647
49,358
58,304
58,419
64,231
72,825
87,853
109,840
195,408
215,169
259,676
274,621
292,329
318,498
347,450
357,423
361,883
363,913
367,955
369,959
372,278
372,917
379,940
392,378
419,651
453,891
526,983
600,864
707,321
818,967
974,309
1,110,597
1,326,112
1,475,123
1,594,120
1,666,391
1,772,923
1,872,167
2,083,421
2,277,029
2,261,702
2,274,529
2,358,605
2,394,727
2,461,614
2,524,446
2,575,800
2,612,800
2,676,600
2,771,400
2,890,400
2,944,600
3,031,400
3,138,300
3,221,600
3,262,600
3,358,500
3,395,700
3,482,200
3,556,400
3,637,700
3,704,200
3,763,000
3,880,900
3,922,600
4,006,100
4,146,400

4,146,400

4,006,100

3,922,600

3,880,900

3,763,000

3,704,200

3,637,700

3,556,400

3,482,200

3,395,700

3,358,500

3,262,600

3,221,600

3,138,300

3,031,400

2,944,600

2,890,400

2,771,400

2,676,600

2,612,800

2,575,800

2,524,446

2,461,614

2,394,727

2,358,605

2,274,529

2,261,702

2,277,029

2,083,421

1,872,167

1,772,923

1,666,391

1,594,120

1,475,123

1,326,112

1,110,597

974,309

818,967

707,321

600,864

526,983

453,891

419,651

392,378

379,940

372,917

372,278

369,959

367,955

363,913

361,883

357,423

347,450

318,498

292,329

274,621

259,676

215,169

195,408

109,840

87,853

72,825

64,231

58,419

58,304

49,358

47,647

47,781

49,353

51,035

53,854

57,421

60,535

64,044

67,366

69,055

71,239

73,942

75,986

77,616

80,723

83,715

84,670

82,648

76,825

56,138

47,465

42,043

39,448

37,418

37,619

37,166

36,934

37,659

37,434

36,630

36,300

35,100

35,200

34,200

33,000

32,600

32,200

32,700

32,900

34,000

33,800

34,300

33,700

33,300

31,200

27,900

25,100

25,700

26,800

27,700

28,100

27,600

27,000

22,400

12,200

11,400

11,000

10,500

10,000

8,900

7,700

5,400

2,700

2,400

2,200

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70,465
37,956
370,053
373,621
0
0
275,887
254,738
288,321
312,600
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,044,703
1,873,569
0
2,339,800
2,884,600
3,112,600
3,256,800
3,236,400
2,587,600
2,875,100
3,135,600
3,543,700
3,900,300
5,631,300
6,838,000
7,084,000
6,415,900
5,968,600
6,591,800
6,066,600
6,327,200
5,778,500
5,396,500

5,396,500

5,778,500

6,327,200

6,066,600

6,591,800

5,968,600

6,415,900

7,084,000

6,838,000

5,631,300

3,900,300

3,543,700

3,135,600

2,875,100

2,587,600

3,236,400

3,256,800

3,112,600

2,884,600

2,339,800

1,873,569

2,044,703

312,600

288,321

254,738

275,887

373,621

370,053

37,956

70,465

Intangible Assets

0
0
0
500
0
0
0
1,600
0
0
2,200
0
0
3,000
3,400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
804,100
915,500
928,700
953,000
1,017,200
1,038,600

1,038,600

1,017,200

953,000

928,700

915,500

804,100

3,400

3,000

2,200

1,600

500

Other Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,923
27,219
41,658
37,198
25,383
45,894
28,468
61,763
92,704
83,281
48,631
37,801
18,053
15,727
12,408
78,625
36,278
28,858
87,505
57,914
31,383
20,270
30,273
21,574
25,021
33,422
30,402
65,753
64,487
53,230
101,718
80,125
84,952
44,601
37,526
60,743
87,790
81,905
65,429
56,018
117,091
80,562
48,216
384,360
391,369
271,708
279,246
302,753
283,285
316,029
339,095
494,538
576,498
397,246
552,364
627,096
788,483
830,062
719,940
730,057
777,262
917,517
1,032,152
1,099,917
1,104,690
1,222,758
1,454,163
1,709,857
1,871,073
1,984,620
2,290,944
2,070,651
2,433,237
2,675,449
2,561,584
910,600
973,600
915,900
903,100
913,300
876,800
878,900
912,400
2,770,000
870,800
4,693,000
630,000
555,200
686,900
10,833,700
766,600
747,600
0
2,453,400
0
830,700

830,700

2,453,400

747,600

766,600

10,833,700

686,900

555,200

630,000

4,693,000

870,800

2,770,000

912,400

878,900

876,800

913,300

903,100

915,900

973,600

910,600

2,561,584

2,675,449

2,433,237

2,070,651

2,290,944

1,984,620

1,871,073

1,709,857

1,454,163

1,222,758

1,104,690

1,099,917

1,032,152

917,517

777,262

730,057

719,940

830,062

788,483

627,096

552,364

397,246

576,498

494,538

339,095

316,029

283,285

302,753

279,246

271,708

391,369

384,360

48,216

80,562

117,091

56,018

65,429

81,905

87,790

60,743

37,526

44,601

84,952

80,125

101,718

53,230

64,487

65,753

30,402

33,422

25,021

21,574

30,273

20,270

31,383

57,914

87,505

28,858

36,278

78,625

12,408

15,727

18,053

37,801

48,631

83,281

92,704

61,763

28,468

45,894

25,383

37,198

41,658

27,219

21,923

> Total Liabilities

0
0
0
13,200
0
5,900
5,600
7,800
9,200
9,400
10,900
10,700
12,800
14,000
15,800
19,200
19,300
29,100
24,600
27,100
22,300
24,000
21,200
25,900
24,100
26,500
26,400
30,700
28,100
30,100
26,500
29,500
26,000
27,300
25,500
25,700
25,900
24,400
23,900
27,500
26,439
26,146
25,347
26,144
24,774
23,001
23,742
229,042
229,381
227,292
237,804
245,593
264,826
257,704
344,299
341,912
302,072
298,044
293,812
290,565
284,508
281,888
282,894
309,499
299,766
294,565
292,713
368,466
404,742
418,522
421,699
475,991
470,273
400,228
388,958
251,186
271,101
331,839
319,749
344,440
400,885
419,425
594,369
561,617
556,202
568,830
554,778
837,851
846,135
862,843
854,591
835,105
869,650
884,922
950,244
998,937
1,049,148
1,087,236
1,187,631
1,329,502
1,227,143
1,188,512
1,886,048
1,954,295
2,139,378
2,128,400
2,336,772
2,524,221
2,951,344
2,585,635
2,649,622
2,620,208
2,805,052
2,765,554
2,937,313
2,977,200
3,410,100
3,417,700
3,434,900
3,715,500
3,624,500
5,371,300
5,958,500
6,138,000
5,795,200
6,358,600
6,413,500
6,666,000
6,434,000
6,518,000
6,239,000
6,550,500
6,564,700
6,639,600
7,258,900
7,107,100

7,107,100

7,258,900

6,639,600

6,564,700

6,550,500

6,239,000

6,518,000

6,434,000

6,666,000

6,413,500

6,358,600

5,795,200

6,138,000

5,958,500

5,371,300

3,624,500

3,715,500

3,434,900

3,417,700

3,410,100

2,977,200

2,937,313

2,765,554

2,805,052

2,620,208

2,649,622

2,585,635

2,951,344

2,524,221

2,336,772

2,128,400

2,139,378

1,954,295

1,886,048

1,188,512

1,227,143

1,329,502

1,187,631

1,087,236

1,049,148

998,937

950,244

884,922

869,650

835,105

854,591

862,843

846,135

837,851

554,778

568,830

556,202

561,617

594,369

419,425

400,885

344,440

319,749

331,839

271,101

251,186

388,958

400,228

470,273

475,991

421,699

418,522

404,742

368,466

292,713

294,565

299,766

309,499

282,894

281,888

284,508

290,565

293,812

298,044

302,072

341,912

344,299

257,704

264,826

245,593

237,804

227,292

229,381

229,042

23,742

23,001

24,774

26,144

25,347

26,146

26,439

27,500

23,900

24,400

25,900

25,700

25,500

27,300

26,000

29,500

26,500

30,100

28,100

30,700

26,400

26,500

24,100

25,900

21,200

24,000

22,300

27,100

24,600

29,100

19,300

19,200

15,800

14,000

12,800

10,700

10,900

9,400

9,200

7,800

5,600

5,900

13,200

> Total Current Liabilities

0
0
0
1,800
0
2,000
2,100
3,300
4,000
4,200
5,300
4,600
6,200
7,400
9,400
13,100
11,000
21,700
16,500
17,900
13,700
16,200
14,100
12,900
10,500
9,600
8,900
12,000
9,700
10,800
7,800
10,700
7,500
8,500
9,600
9,400
9,900
8,700
8,900
13,300
12,450
13,027
12,742
13,786
13,855
12,926
14,415
22,022
22,944
21,477
32,654
40,118
59,366
49,064
54,736
72,923
36,335
37,372
35,900
34,139
29,931
29,949
33,521
40,357
33,667
31,508
32,698
45,014
83,604
104,831
96,686
283,664
285,954
223,918
217,771
83,672
103,113
267,679
114,165
93,575
104,093
119,571
133,833
61,008
396,051
135,868
133,235
148,271
160,386
183,220
178,568
118,604
197,244
203,802
268,727
262,226
305,068
351,578
410,200
620,137
536,134
601,542
734,990
760,619
919,724
951,563
961,185
980,659
1,308,271
1,029,017
1,138,628
967,418
1,265,740
1,032,635
1,417,230
1,352,000
1,511,400
1,713,100
1,765,400
1,790,900
2,055,200
3,702,400
2,337,800
2,806,800
3,217,800
3,732,400
3,714,800
3,451,000
3,007,600
4,537,300
2,879,200
3,849,100
3,100,100
3,104,400
3,598,600
3,423,400

3,423,400

3,598,600

3,104,400

3,100,100

3,849,100

2,879,200

4,537,300

3,007,600

3,451,000

3,714,800

3,732,400

3,217,800

2,806,800

2,337,800

3,702,400

2,055,200

1,790,900

1,765,400

1,713,100

1,511,400

1,352,000

1,417,230

1,032,635

1,265,740

967,418

1,138,628

1,029,017

1,308,271

980,659

961,185

951,563

919,724

760,619

734,990

601,542

536,134

620,137

410,200

351,578

305,068

262,226

268,727

203,802

197,244

118,604

178,568

183,220

160,386

148,271

133,235

135,868

396,051

61,008

133,833

119,571

104,093

93,575

114,165

267,679

103,113

83,672

217,771

223,918

285,954

283,664

96,686

104,831

83,604

45,014

32,698

31,508

33,667

40,357

33,521

29,949

29,931

34,139

35,900

37,372

36,335

72,923

54,736

49,064

59,366

40,118

32,654

21,477

22,944

22,022

14,415

12,926

13,855

13,786

12,742

13,027

12,450

13,300

8,900

8,700

9,900

9,400

9,600

8,500

7,500

10,700

7,800

10,800

9,700

12,000

8,900

9,600

10,500

12,900

14,100

16,200

13,700

17,900

16,500

21,700

11,000

13,100

9,400

7,400

6,200

4,600

5,300

4,200

4,000

3,300

2,100

2,000

1,800

Short-term Debt

0
0
0
0
0
100
100
400
700
900
1,000
1,000
1,400
1,500
1,500
1,600
3,800
2,200
2,300
3,100
100
3,300
3,300
3,500
3,800
3,700
3,800
3,600
3,400
3,100
2,700
1,800
1,300
1,200
1,800
1,100
1,100
1,200
1,200
1,400
1,352
1,106
826
612
537
568
523
426
412
324
237
150
61
-14,043
9,296
13,817
-18,947
-15,743
-20,284
-18,872
-17,468
-17,043
-20,599
-23,337
9,583
11,334
10,355
-21,471
0
14,067
17,500
202,292
200,000
118,653
117,503
200,000
0
0
0
0
435
448
634
675
798
877
920
1,006
1,093
1,183
1,277
1,374
1,473
794
794
939
1,060
1,060
1,252
350,197
372,161
399,489
470,511
452,607
612,681
657,922
590,419
127,274
7,200
564,992
664,480
468,830
0
-298,555
0
-90,800
0
0
0
-305,700
1,143,200
1,500,000
1,303,000
1,631,200
717,800
718,400
719,000
719,700
0
720,000
0
720,000
0
0
0
0

720,000

719,700

719,000

718,400

717,800

1,631,200

1,303,000

1,500,000

1,143,200

-305,700

-90,800

-298,555

468,830

664,480

564,992

7,200

127,274

590,419

657,922

612,681

452,607

470,511

399,489

372,161

350,197

1,252

1,060

939

794

1,473

1,374

1,277

1,183

1,093

1,006

920

877

798

675

634

448

435

200,000

117,503

118,653

200,000

202,292

17,500

14,067

-21,471

10,355

11,334

9,583

-23,337

-20,599

-17,043

-17,468

-18,872

-20,284

-15,743

-18,947

13,817

9,296

-14,043

150

237

324

412

426

523

568

537

612

826

1,106

1,352

1,400

1,200

1,100

1,800

1,200

1,300

1,800

2,700

3,100

3,400

3,600

3,800

3,700

3,800

3,500

3,300

100

3,100

2,300

2,200

3,800

1,600

1,500

1,400

1,000

900

700

400

100

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
127,274
0
0
0
127,274
127,274
127,274
127,274
129,557
7,200
0
0
0
0
0
0
0
0
0
0
0
0
1,500,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1,500,000

7,200

129,557

127,274

Accounts payable

0
0
0
0
0
800
500
1,600
1,900
1,900
0
2,500
3,000
5,200
6,700
10,300
6,000
6,400
4,200
5,000
3,700
4,600
4,300
6,300
4,300
4,200
4,200
4,400
3,400
5,100
4,100
4,700
3,700
5,100
4,400
5,600
6,000
4,900
4,500
6,600
6,921
7,637
8,021
9,446
9,404
8,304
10,120
14,830
17,068
16,933
24,376
30,309
25,201
14,043
20,967
18,933
18,947
15,743
20,284
18,872
17,468
17,043
20,599
23,337
3,758
2,840
3,657
21,471
4,805
18,546
5,330
8,128
9,475
10,436
13,188
6,268
17,779
13,034
13,855
18,638
-136,188
58,256
74,976
-48,048
16,146
25,955
17,309
27,736
25,390
25,672
21,943
38,934
24,729
24,418
31,194
61,936
32,692
47,231
47,342
99,508
90,601
130,016
106,917
140,962
120,595
101,721
124,497
134,984
141,801
151,372
153,946
178,183
207,611
171,906
172,361
218,200
239,600
244,000
335,600
418,100
347,800
380,100
443,100
475,500
542,900
476,000
427,000
564,000
470,300
534,200
535,600
589,200
599,500
547,300
536,600
606,600

606,600

536,600

547,300

599,500

589,200

535,600

534,200

470,300

564,000

427,000

476,000

542,900

475,500

443,100

380,100

347,800

418,100

335,600

244,000

239,600

218,200

172,361

171,906

207,611

178,183

153,946

151,372

141,801

134,984

124,497

101,721

120,595

140,962

106,917

130,016

90,601

99,508

47,342

47,231

32,692

61,936

31,194

24,418

24,729

38,934

21,943

25,672

25,390

27,736

17,309

25,955

16,146

-48,048

74,976

58,256

-136,188

18,638

13,855

13,034

17,779

6,268

13,188

10,436

9,475

8,128

5,330

18,546

4,805

21,471

3,657

2,840

3,758

23,337

20,599

17,043

17,468

18,872

20,284

15,743

18,947

18,933

20,967

14,043

25,201

30,309

24,376

16,933

17,068

14,830

10,120

8,304

9,404

9,446

8,021

7,637

6,921

6,600

4,500

4,900

6,000

5,600

4,400

5,100

3,700

4,700

4,100

5,100

3,400

4,400

4,200

4,300

6,300

4,300

4,600

3,700

5,000

4,200

6,400

6,000

10,300

6,700

5,200

3,000

2,500

1,900

1,600

500

800

Other Current Liabilities

0
0
0
0
0
1,100
1,500
1,300
1,400
1,400
4,300
1,100
1,800
700
1,200
1,200
1,200
13,100
10,000
9,800
9,900
8,300
6,500
3,100
2,400
1,700
900
4,000
2,900
2,600
1,000
4,200
2,500
2,200
3,400
2,700
2,800
2,600
3,200
5,300
4,177
4,284
3,895
3,728
232
9,981
11,381
18,589
19,311
15,638
8,041
26,671
49,790
14,043
41,580
55,228
18,947
15,743
20,284
18,872
17,468
17,043
20,599
23,337
5,042
2,292
5,042
21,471
15,276
2,292
5,042
28,812
20,839
27,853
28,699
-170,100
27,053
38,847
-84,381
30,393
53,905
58,256
74,976
53,658
48,838
55,710
61,581
67,889
81,333
101,096
102,281
27,465
120,684
129,408
187,944
152,351
205,243
236,154
290,634
96,407
2,185
2,291
2,506
13,563
13,508
3,695
3,586
486,737
920,852
397
334
267
666,216
670,709
781,924
772,100
741,100
876,700
821,100
1,086,800
85,000
1,360,800
96,900
122,400
1,492,200
2,018,000
2,061,000
1,725,300
2,046,000
2,658,100
1,796,400
1,992,200
2,074,300
2,176,000
2,644,700
2,357,900

2,357,900

2,644,700

2,176,000

2,074,300

1,992,200

1,796,400

2,658,100

2,046,000

1,725,300

2,061,000

2,018,000

1,492,200

122,400

96,900

1,360,800

85,000

1,086,800

821,100

876,700

741,100

772,100

781,924

670,709

666,216

267

334

397

920,852

486,737

3,586

3,695

13,508

13,563

2,506

2,291

2,185

96,407

290,634

236,154

205,243

152,351

187,944

129,408

120,684

27,465

102,281

101,096

81,333

67,889

61,581

55,710

48,838

53,658

74,976

58,256

53,905

30,393

-84,381

38,847

27,053

-170,100

28,699

27,853

20,839

28,812

5,042

2,292

15,276

21,471

5,042

2,292

5,042

23,337

20,599

17,043

17,468

18,872

20,284

15,743

18,947

55,228

41,580

14,043

49,790

26,671

8,041

15,638

19,311

18,589

11,381

9,981

232

3,728

3,895

4,284

4,177

5,300

3,200

2,600

2,800

2,700

3,400

2,200

2,500

4,200

1,000

2,600

2,900

4,000

900

1,700

2,400

3,100

6,500

8,300

9,900

9,800

10,000

13,100

1,200

700

1,800

1,100

4,300

1,400

1,300

1,500

1,100

> Long-term Liabilities

0
0
0
11,400
0
3,900
3,500
4,500
5,200
5,200
5,600
6,100
6,600
6,600
6,400
6,100
8,300
7,400
8,100
9,200
8,600
7,800
7,100
13,000
13,600
16,900
17,500
18,700
18,400
19,300
18,700
18,800
18,500
18,800
15,900
16,300
16,000
15,700
15,000
14,200
13,989
13,119
12,605
12,358
10,919
10,075
9,327
207,020
206,437
205,815
205,150
205,475
205,460
208,640
289,563
268,989
265,737
260,672
257,912
256,426
254,577
251,939
249,373
269,142
266,099
263,057
260,015
323,452
321,138
313,691
325,013
192,327
184,319
176,310
171,187
167,514
167,988
64,160
205,584
250,865
296,792
299,854
460,536
500,609
160,151
432,962
421,543
689,580
685,749
679,623
676,023
716,501
672,406
681,120
681,517
736,711
744,080
735,658
777,431
709,365
691,009
586,970
1,151,058
1,193,676
1,219,654
1,176,837
1,375,587
1,543,562
1,643,073
1,556,618
1,510,994
1,652,790
1,539,312
1,732,919
1,520,083
1,625,200
1,898,700
1,704,600
1,669,500
1,924,600
1,569,300
1,668,900
3,620,700
3,331,200
2,577,400
2,626,200
2,698,700
3,215,000
3,426,400
1,980,700
3,359,800
2,701,400
3,464,600
3,535,200
3,660,300
3,683,700

3,683,700

3,660,300

3,535,200

3,464,600

2,701,400

3,359,800

1,980,700

3,426,400

3,215,000

2,698,700

2,626,200

2,577,400

3,331,200

3,620,700

1,668,900

1,569,300

1,924,600

1,669,500

1,704,600

1,898,700

1,625,200

1,520,083

1,732,919

1,539,312

1,652,790

1,510,994

1,556,618

1,643,073

1,543,562

1,375,587

1,176,837

1,219,654

1,193,676

1,151,058

586,970

691,009

709,365

777,431

735,658

744,080

736,711

681,517

681,120

672,406

716,501

676,023

679,623

685,749

689,580

421,543

432,962

160,151

500,609

460,536

299,854

296,792

250,865

205,584

64,160

167,988

167,514

171,187

176,310

184,319

192,327

325,013

313,691

321,138

323,452

260,015

263,057

266,099

269,142

249,373

251,939

254,577

256,426

257,912

260,672

265,737

268,989

289,563

208,640

205,460

205,475

205,150

205,815

206,437

207,020

9,327

10,075

10,919

12,358

12,605

13,119

13,989

14,200

15,000

15,700

16,000

16,300

15,900

18,800

18,500

18,800

18,700

19,300

18,400

18,700

17,500

16,900

13,600

13,000

7,100

7,800

8,600

9,200

8,100

7,400

8,300

6,100

6,400

6,600

6,100

5,600

5,200

4,500

3,500

3,900

11,400

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
157,359
158,382
159,355
159,353
0
0
275,019
280,206
285,491
290,959
296,518
302,268
308,116
314,162
320,315
326,673
282,261
287,950
146,773
144,082
30,360
30,723
0
0
0
0
0
0
0
0
0
0
0
0
708,500
709,900
711,300
712,700
713,900
715,200
0
1,978,300
1,978,500
1,978,900
1,979,200
1,979,600
1,980,000
1,980,400
1,980,700
1,981,100
1,981,400
1,981,800
1,982,200
0
0

1,982,200

1,981,800

1,981,400

1,981,100

1,980,700

1,980,400

1,980,000

1,979,600

1,979,200

1,978,900

1,978,500

1,978,300

715,200

713,900

712,700

711,300

709,900

708,500

30,723

30,360

144,082

146,773

287,950

282,261

326,673

320,315

314,162

308,116

302,268

296,518

290,959

285,491

280,206

275,019

159,353

159,355

158,382

157,359

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,469
10,783
10,428
10,289
9,005
8,326
7,681
6,870
6,384
5,815
5,150
5,475
5,460
3,493
89,563
68,989
65,737
60,672
57,912
56,426
54,577
51,939
49,373
69,142
66,099
63,057
60,015
123,452
121,138
113,691
125,013
192,327
184,319
176,310
171,187
167,514
167,988
148,490
143,013
141,843
140,328
142,495
302,154
293,206
284,597
273,505
262,061
253,747
246,009
234,574
225,565
215,492
211,131
208,612
200,136
195,529
214,027
218,872
213,369
217,131
218,533
198,923
756,191
780,214
857,424
815,314
993,359
931,157
942,666
855,445
808,677
781,272
834,667
728,461
812,880
0
0
969,600
933,400
889,000
854,100
953,000
925,900
635,500
598,500
647,000
719,100
515,300
726,000
625,000
607,300
707,800
0
833,000
0
0

833,000

707,800

607,300

625,000

726,000

515,300

719,100

647,000

598,500

635,500

925,900

953,000

854,100

889,000

933,400

969,600

812,880

728,461

834,667

781,272

808,677

855,445

942,666

931,157

993,359

815,314

857,424

780,214

756,191

198,923

218,533

217,131

213,369

218,872

214,027

195,529

200,136

208,612

211,131

215,492

225,565

234,574

246,009

253,747

262,061

273,505

284,597

293,206

302,154

142,495

140,328

141,843

143,013

148,490

167,988

167,514

171,187

176,310

184,319

192,327

125,013

113,691

121,138

123,452

60,015

63,057

66,099

69,142

49,373

51,939

54,577

56,426

57,912

60,672

65,737

68,989

89,563

3,493

5,460

5,475

5,150

5,815

6,384

6,870

7,681

8,326

9,005

10,289

10,428

10,783

11,469

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
138,177
296,865
285,856
277,417
0
0
0
0
0
0
0
0
0
0
76,522
73,694
75,862
75,283
72,367
48,656
46,095
599,339
664,679
565,773
549,342
529,791
830,772
520,191
443,904
408,786
629,199
406,778
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

406,778

629,199

408,786

443,904

520,191

830,772

529,791

549,342

565,773

664,679

599,339

46,095

48,656

72,367

75,283

75,862

73,694

76,522

277,417

285,856

296,865

138,177

> Total Stockholder Equity

0
0
0
12,200
0
109,300
108,400
106,200
103,000
99,300
93,500
87,200
77,800
68,400
110,100
98,400
86,700
76,600
72,800
67,100
63,800
59,400
53,000
67,900
62,100
112,800
104,200
106,900
101,000
139,900
138,200
138,900
135,400
137,800
136,900
131,200
123,400
115,400
110,500
109,500
105,595
175,971
190,972
182,130
324,411
313,294
294,871
266,355
242,484
213,159
180,788
145,981
165,615
137,843
156,202
137,643
204,106
190,130
178,873
182,543
185,784
165,060
136,381
114,002
102,323
83,767
62,473
216,624
196,689
179,336
151,397
460,267
460,603
450,997
436,933
418,852
410,320
410,506
422,443
396,762
386,271
371,216
348,064
527,815
518,091
478,034
428,253
485,732
504,024
594,657
806,024
1,245,385
1,406,348
1,493,337
1,690,171
1,952,076
2,211,248
2,368,842
2,551,788
2,542,325
2,971,430
3,338,458
3,296,867
3,654,837
3,765,082
4,076,506
4,491,247
4,449,245
4,866,021
5,520,738
6,051,593
6,144,078
6,567,644
7,186,426
7,868,300
8,757,300
9,444,700
9,755,900
10,504,400
11,089,700
12,133,000
9,057,400
10,125,500
11,025,300
11,977,000
15,127,300
17,258,000
18,768,800
19,914,700
20,687,800
21,438,800
22,664,000
23,495,200
24,017,900
24,904,400
25,973,100

25,973,100

24,904,400

24,017,900

23,495,200

22,664,000

21,438,800

20,687,800

19,914,700

18,768,800

17,258,000

15,127,300

11,977,000

11,025,300

10,125,500

9,057,400

12,133,000

11,089,700

10,504,400

9,755,900

9,444,700

8,757,300

7,868,300

7,186,426

6,567,644

6,144,078

6,051,593

5,520,738

4,866,021

4,449,245

4,491,247

4,076,506

3,765,082

3,654,837

3,296,867

3,338,458

2,971,430

2,542,325

2,551,788

2,368,842

2,211,248

1,952,076

1,690,171

1,493,337

1,406,348

1,245,385

806,024

594,657

504,024

485,732

428,253

478,034

518,091

527,815

348,064

371,216

386,271

396,762

422,443

410,506

410,320

418,852

436,933

450,997

460,603

460,267

151,397

179,336

196,689

216,624

62,473

83,767

102,323

114,002

136,381

165,060

185,784

182,543

178,873

190,130

204,106

137,643

156,202

137,843

165,615

145,981

180,788

213,159

242,484

266,355

294,871

313,294

324,411

182,130

190,972

175,971

105,595

109,500

110,500

115,400

123,400

131,200

136,900

137,800

135,400

138,900

138,200

139,900

101,000

106,900

104,200

112,800

62,100

67,900

53,000

59,400

63,800

67,100

72,800

76,600

86,700

98,400

110,100

68,400

77,800

87,200

93,500

99,300

103,000

106,200

108,400

109,300

12,200

Common Stock

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33
35
37
37
44
44
44
44
44
44
45
44
46
52
55
55
55
55
55
56
56
56
56
56
57
57
57
65
65
66
66
79
79
79
79
80
80
80
78
81
82
82
82
89
91
91
92
93
95
96
96
97
97
99
99
99
101
102
102
104
105
107
108
108
109
109
109
110
110
111
111
112
112
112
112
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100

100

112

111

110

109

108

107

105

104

102

101

Retained Earnings Total Equity

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-997,091
-1,030,966
-1,045,563
-1,089,010
-1,151,515
-1,213,880
-1,267,323
-1,255,672
-1,178,929
-987,461
-517,054
-418,180
-330,804
-189,498
-92,692
-27,249
65,486
145,206
255,382
292,665
487,308
697,706
852,700
1,018,436
1,230,303
1,495,107
1,748,222
1,997,153
2,384,897
2,773,214
2,946,733
3,287,767
3,839,179
4,433,904
5,254,300
5,725,100
5,918,200
6,587,800
7,379,800
8,004,400
8,901,700
9,743,800
10,893,000
12,008,200
15,107,100
16,739,300
18,968,300
19,941,800
20,793,900
22,109,600
23,306,700
24,124,500
25,092,900
0
0

25,092,900

24,124,500

23,306,700

22,109,600

20,793,900

19,941,800

18,968,300

16,739,300

15,107,100

12,008,200

10,893,000

9,743,800

8,901,700

8,004,400

7,379,800

6,587,800

5,918,200

5,725,100

5,254,300

4,433,904

3,839,179

3,287,767

2,946,733

2,773,214

2,384,897

1,997,153

1,748,222

1,495,107

1,230,303

1,018,436

852,700

697,706

487,308

292,665

255,382

145,206

65,486

-27,249

-92,692

-189,498

-330,804

-418,180

-517,054

-987,461

-1,178,929

-1,255,672

-1,267,323

-1,213,880

-1,151,515

-1,089,010

-1,045,563

-1,030,966

-997,091

Accumulated Other Comprehensive Income

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-13,300
-5,900
-15,600
-16,800
-18,000
-5,900
-20,400
-21,600
-21,600
-23,600
-23,600
-23,600
-25,900
-26,600
-27,300
-28,200
-400
-500
-516
-421
-202
-780
-63
-156
712
-1,615
-2,030
-1,203
-792
-3,172
-2,756
-2,219
-1,817
-3,997
-3,190
-2,880
-2,191
-3,068
-2,893
-2,005
-1,493
-785
-371
-473
-95
-231
-159
-516
-5
170
828
-315
-3,960
-114
-1,248
1,014
3,537
1,044
717
-306
-175
-2,491
-2,175
-904
-1,731
-1,862
-1,337
-2,371
-1,904
-1,166
-1,644
-3,429
-2,851
-1,188
1,465
4,263
26,895
52,251
47,904
19,153
7,721
8,572
4,364
5,204
-2,899
-12,840
-5,884
2,348
23,835
640
-15,594
-11,612
-10,519
-12,300
2,800
15,800
16,500
21,100
-9,100
35,500
30,800
29,300
16,200
15,700
9,500
-26,200
-170,100
-223,800
-275,100
-238,800
-181,600
-197,700
-176,800
-80,900

-80,900

-176,800

-197,700

-181,600

-238,800

-275,100

-223,800

-170,100

-26,200

9,500

15,700

16,200

29,300

30,800

35,500

-9,100

21,100

16,500

15,800

2,800

-12,300

-10,519

-11,612

-15,594

640

23,835

2,348

-5,884

-12,840

-2,899

5,204

4,364

8,572

7,721

19,153

47,904

52,251

26,895

4,263

1,465

-1,188

-2,851

-3,429

-1,644

-1,166

-1,904

-2,371

-1,337

-1,862

-1,731

-904

-2,175

-2,491

-175

-306

717

1,044

3,537

1,014

-1,248

-114

-3,960

-315

828

170

-5

-516

-159

-231

-95

-473

-371

-785

-1,493

-2,005

-2,893

-3,068

-2,191

-2,880

-3,190

-3,997

-1,817

-2,219

-2,756

-3,172

-792

-1,203

-2,030

-1,615

712

-156

-63

-780

-202

-421

-516

-500

-400

-28,200

-27,300

-26,600

-25,900

-23,600

-21,600

-20,400

-5,900

-18,000

-16,800

-15,600

-5,900

-13,300

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,368,531
1,379,123
1,575,780
1,609,185
1,630,362
1,643,772
1,754,824
1,760,938
1,775,861
1,795,293
1,763,508
1,826,075
1,827,471
1,882,421
2,045,857
2,236,931
2,342,839
2,423,434
2,404,118
2,812,573
3,118,969
2,880,109
3,099,526
3,049,651
3,156,942
3,314,982
3,029,993
3,190,882
3,449,622
3,570,673
3,512,833
3,611,599
3,712,599
3,841,174
3,911,600
4,160,900
4,263,600
4,388,400
4,428,600
5,211,400
6,263,000
6,592,800
6,716,200
6,887,800
7,225,800
7,919,300
8,087,500
8,754,100
9,120,200
9,518,200
9,949,300
10,597,700
10,888,500
0
0

10,888,500

10,597,700

9,949,300

9,518,200

9,120,200

8,754,100

8,087,500

7,919,300

7,225,800

6,887,800

6,716,200

6,592,800

6,263,000

5,211,400

4,428,600

4,388,400

4,263,600

4,160,900

3,911,600

3,841,174

3,712,599

3,611,599

3,512,833

3,570,673

3,449,622

3,190,882

3,029,993

3,314,982

3,156,942

3,049,651

3,099,526

2,880,109

3,118,969

2,812,573

2,404,118

2,423,434

2,342,839

2,236,931

2,045,857

1,882,421

1,827,471

1,826,075

1,763,508

1,795,293

1,775,861

1,760,938

1,754,824

1,643,772

1,630,362

1,609,185

1,575,780

1,379,123

1,368,531

Treasury Stock

-9,914,000

-9,002,600

-8,611,200

-8,260,900

-7,410,200

-7,221,400

-6,935,300

-6,613,300

-6,242,000

-6,142,900

-1,073,800

-739,900

-488,400

-441,800

-444,200

-396,400

-396,371

-353,852

-316,240

-316,052

-307,478

-306,069

-288,777

-287,079

-181,817

-169,530

-43,849

-43,848

Other Stockholders Equity

0
0
0
19,200
0
117,800
117,700
117,600
117,700
117,700
117,700
117,800
117,700
117,700
169,000
168,800
167,900
168,000
168,200
168,200
169,100
169,000
183,100
198,400
210,100
269,600
271,100
269,800
284,400
328,700
328,900
331,100
331,400
331,700
334,500
335,000
336,900
337,600
309,800
310,300
313,699
386,925
404,916
406,391
560,985
564,795
565,435
567,624
569,613
569,884
569,917
573,184
622,510
622,931
670,120
673,118
674,242
674,505
673,635
675,389
682,578
687,965
693,426
700,011
708,297
713,419
719,157
904,407
914,317
924,094
931,482
1,253,235
1,264,531
1,274,527
1,285,223
1,294,813
1,304,896
1,313,003
1,323,432
1,336,732
1,357,089
1,368,531
1,379,123
1,575,780
1,609,185
1,630,362
1,643,772
1,754,824
1,760,938
1,775,861
1,795,293
1,763,508
1,826,075
1,827,471
1,882,421
2,045,857
2,236,931
2,298,991
2,379,585
2,234,588
2,630,756
2,831,890
2,591,332
2,793,457
2,742,173
2,840,890
2,998,930
2,713,753
2,874,642
3,133,382
3,254,433
3,196,593
3,295,359
3,358,747
3,444,803
3,515,200
3,716,700
3,821,800
3,900,000
3,688,700
4,137,600
120,100
350,800
102,900
-47,500
4,400
509,100
-173,400
142,900
117,600
-395,800
-404,000
-447,800
-877,400
-1,019,600
-1,206,400

-1,206,400

-1,019,600

-877,400

-447,800

-404,000

-395,800

117,600

142,900

-173,400

509,100

4,400

-47,500

102,900

350,800

120,100

4,137,600

3,688,700

3,900,000

3,821,800

3,716,700

3,515,200

3,444,803

3,358,747

3,295,359

3,196,593

3,254,433

3,133,382

2,874,642

2,713,753

2,998,930

2,840,890

2,742,173

2,793,457

2,591,332

2,831,890

2,630,756

2,234,588

2,379,585

2,298,991

2,236,931

2,045,857

1,882,421

1,827,471

1,826,075

1,763,508

1,795,293

1,775,861

1,760,938

1,754,824

1,643,772

1,630,362

1,609,185

1,575,780

1,379,123

1,368,531

1,357,089

1,336,732

1,323,432

1,313,003

1,304,896

1,294,813

1,285,223

1,274,527

1,264,531

1,253,235

931,482

924,094

914,317

904,407

719,157

713,419

708,297

700,011

693,426

687,965

682,578

675,389

673,635

674,505

674,242

673,118

670,120

622,931

622,510

573,184

569,917

569,884

569,613

567,624

565,435

564,795

560,985

406,391

404,916

386,925

313,699

310,300

309,800

337,600

336,900

335,000

334,500

331,700

331,400

331,100

328,900

328,700

284,400

269,800

271,100

269,600

210,100

198,400

183,100

169,000

169,100

168,200

168,000

167,900

168,800

169,000

117,700

117,800

117,700

117,600

117,700

117,800

19,200

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31	1993-12-31	1992-12-31	1991-12-31	1990-12-31
Accounts Payable	606,600	589,200	564,000	475,500	418,100	218,200	178,183	134,984	140,962	99,508	61,936	38,934	27,736	-48,048	18,638	6,268	8,128	21,471	23,337	18,872	18,933	30,309	14,830	9,446	6,600	5,600	4,700	4,400	6,300	5,000	10,300	2,500	1,600	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Other Comprehensive Income	-80,900	-238,800	-26,200	29,300	21,100	-12,300	640	-12,840	8,572	52,251	-1,188	-1,166	-1,862	-2,491	1,044	-114	170	-231	-785	-3,068	-3,997	-3,172	-1,615	-780	-500	-26,600	-23,600	-5,900	-5,900	0	0	0	0	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Lease Obligations	720,000	720,000	719,700	717,200	713,900	708,500	703,453	478,843	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Stock	100	100	100	100	100	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Surpluse	0	9,949,300	8,087,500	6,716,200	4,428,600	3,911,600	3,512,833	3,029,993	3,099,526	2,404,118	2,045,857	1,763,508	1,754,824	1,575,780	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Cash	2,730,000	3,105,900	2,885,600	2,193,700	1,617,800	1,467,700	812,733	535,203	809,102	648,719	535,608	230,276	483,610	112,572	207,075	247,796	498,925	237,876	184,508	101,234	118,285	80,077	247,393	30,978	23,700	19,800	28,900	34,500	32,700	23,600	12,500	16,400	26,200	21,800
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Cash And Short Term Investments	10,844,800	14,334,100	12,532,700	6,722,600	6,471,100	4,564,900	2,896,074	1,902,944	1,677,385	1,360,634	1,083,875	587,511	526,942	626,939	341,330	474,750	766,457	459,276	298,545	295,982	293,774	264,271	385,079	117,612	66,200	19,800	28,900	34,500	32,700	23,600	12,500	16,400	26,200	21,800
Common Stock	100	100	100	100	100	100	112	110	108	104	99	97	93	89	81	80	79	65	56	56	55	44	44	37	0	0	0	0	0	0	0	0	0	-
Common Stock Shares Outstanding	113,700	113,500	112,200	115,100	114,600	114,800	115,909	116,300	115,230	113,465	111,290	115,382	90,610	82,926	79,782	78,827	66,334	57,970	55,950	56,172	50,450	43,949	42,088	35,174	31,449	31,000	29,000	24,464	19,748	18,951	16,556	15,403	15,517	15,364
Common Stock Total Equity	0	100	100	100	100	100	112	110	108	104	99	97	93	89	81	80	79	65	56	56	55	44	44	37	0	0	0	0	0	0	0	0	0	-
Current Deferred Revenue	458,900	547,700	442,000	577,700	591,700	452,500	320,138	231,664	153,487	74,025	47,000	50,831	300,250	54,723	44,544	209,925	44,432	23,543	17,020	15,267	40,173	9,659	6,766	0	0	0	0	0	0	0	0	0	0	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Deferred Long Term Liab	0	0	0	0	0	0	629,199	830,772	664,679	72,367	76,522	0	0	285,856	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Good Will	0	0	-6,844,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Intangible Assets	1,038,600	915,500	6,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,600	500
Inventory	2,580,500	2,401,900	1,951,300	1,916,600	1,415,500	1,151,200	726,138	399,356	238,578	128,861	70,354	28,638	13,556	-15,142	0	0	0	0	2,904	3,229	9,006	6,831	3,973	1,915	4,600	0	0	0	0	0	0	0	0	-
Liabilities And Stockholders Equity	33,080,200	29,214,500	25,434,800	17,163,300	14,805,200	11,734,500	8,764,286	6,973,466	5,609,132	3,871,827	2,951,013	2,080,490	1,323,583	1,089,432	741,202	670,038	936,258	585,090	423,501	473,108	479,555	391,574	495,397	208,274	137,000	156,900	168,400	137,600	93,800	94,200	117,600	97,900	114,000	25,400
Long Term Debt	1,982,900	1,981,400	1,980,000	1,978,500	0	0	703,453	351,569	362,919	146,773	320,315	296,518	275,019	159,355	109,022	0	0	200,000	200,000	200,000	200,000	200,000	200,150	2,069	0	0	0	0	0	0	0	0	0	-
Long Term Debt Total	0	1,981,400	1,980,000	1,978,500	713,900	708,500	703,453	351,569	362,919	146,773	320,315	296,518	275,019	159,355	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Long Term Investments	5,396,500	6,591,800	6,838,000	3,135,600	3,256,800	1,755,000	1,486,494	864,260	0	0	0	0	275,887	370,053	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Debt	-27,100	-404,500	-185,900	502,000	-903,900	-759,200	-109,280	-54,077	-433,592	-189,655	-30,096	227,052	-48,077	47,458	-98,075	-242,703	-296,633	-37,876	15,492	98,766	95,532	120,073	-46,817	-28,297	-19,600	-15,600	-23,300	-25,800	-23,200	-11,300	-5,000	-9,600	-23,400	-21,800
Net Invested Capital	27,956,000	1,981,400	1,980,000	13,003,800	11,089,700	8,757,300	6,144,078	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Receivables	5,667,300	5,328,700	6,036,500	4,114,700	2,672,200	2,243,200	1,974,340	1,611,620	1,467,793	1,017,399	891,778	693,120	103,035	93,112	65,568	35,212	18,320	7,493	36,521	43,102	15,529	4,017	2,975	13,835	600	5,700	6,600	4,300	2,700	1,700	1,700	1,100	1,400	200
Net Tangible Assets	0	21,748,500	18,768,800	11,025,300	11,089,700	8,757,300	6,144,078	4,449,245	3,654,837	2,550,251	1,952,076	1,245,385	485,732	527,813	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Working Capital	16,055,800	17,495,600	17,069,500	7,081,700	5,592,500	5,004,800	3,199,547	2,933,261	2,623,137	1,886,757	1,989,982	1,502,183	511,267	659,043	331,933	437,770	514,165	424,970	301,035	309,816	247,284	236,830	372,164	120,356	59,700	83,500	88,900	73,000	36,300	34,100	78,700	80,100	103,300	-
Non Current Assets Total	13,601,000	7,149,800	4,914,300	4,409,400	4,246,400	3,775,200	3,167,734	3,059,546	2,225,376	1,364,933	698,805	459,703	409,998	369,381	315,694	148,596	138,429	115,106	82,109	129,153	159,348	114,626	101,211	74,132	64,000	64,000	68,800	52,600	44,600	42,200	25,800	13,200	7,400	3,000
Non Current Liabilities Other	854,100	1,427,800	753,500	1,462,100	1,618,900	825,900	152,073	100,385	115,535	40,855	11,330	0	0	7,350	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Current Liabilities Total	3,683,700	2,701,400	3,215,000	3,331,200	1,924,600	1,625,200	1,652,790	1,543,562	1,193,676	709,365	736,711	716,501	435,533	500,609	250,865	167,514	192,327	323,452	269,142	256,426	268,989	205,475	207,020	12,358	14,200	16,300	18,800	18,700	13,000	9,200	6,100	6,100	4,500	11,400
Non Currrent Assets Other	444,100	-4,658,800	555,200	328,900	531,800	370,700	302,838	150,822	169,311	74,520	171,822	79,763	-233,844	-348,122	8,938	9,682	80,125	65,753	21,574	57,914	78,625	37,801	61,763	37,198	27,700	31,000	36,100	18,300	16,700	14,500	3,400	2,700	400	300
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Assets	0	747,600	555,200	2,770,000	913,300	910,600	546,700	845,597	467,755	269,903	237,205	223,308	26,866	14,307	8,938	9,682	1,903	3,770	3,465	4,984	5,833	17,005	28,422	173	0	0	0	0	0	0	0	0	0	-
Other Current Assets	386,600	933,000	332,400	1,164,000	959,300	243,300	224,972	130,528	163,501	120,721	140,818	176,159	810,550	15,142	18,610	11,480	13,052	3,215	3,422	1,642	1,898	1,829	2,159	780	1,600	67,400	64,100	46,200	13,800	26,700	77,600	67,200	79,000	400
Other Current Liab	2,357,900	1,992,200	1,725,300	122,400	781,100	772,100	267	486,737	13,563	96,407	152,351	27,465	73,326	53,658	30,393	29,900	28,812	21,471	23,337	18,872	55,228	26,671	18,589	3,728	5,300	2,700	4,200	4,000	3,100	9,800	1,200	1,100	1,300	-
Other Liab	0	707,800	515,300	635,500	889,000	825,900	781,200	931,157	780,214	217,131	195,529	215,492	253,747	293,206	141,843	167,514	192,327	123,452	69,142	56,426	68,989	5,475	6,870	10,289	0	0	0	0	0	0	0	0	0	-
Other Stockholder Equity	-1,206,400	-404,000	-173,400	102,900	3,688,700	3,515,200	3,196,593	2,713,753	2,793,457	2,234,588	2,045,857	1,763,508	1,754,824	1,575,780	1,336,732	1,294,813	1,253,235	904,407	700,011	675,389	673,118	573,184	567,624	406,391	310,300	335,000	331,100	269,800	198,400	168,200	168,800	117,800	117,600	19,200
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Property Plant And Equipment Gross	6,125,200	5,432,200	4,880,300	3,221,600	2,890,400	2,575,800	2,358,605	2,083,421	1,594,120	974,309	526,983	379,940	367,955	347,450	259,676	87,853	58,304	49,353	60,535	71,239	80,723	76,825	39,448	36,934	36,300	33,000	32,700	34,300	27,900	0	0	0	0	-
Property Plant And Equipment Net	4,146,400	3,763,000	3,482,200	3,221,600	2,890,400	2,575,800	2,358,605	2,083,421	1,594,120	974,309	526,983	379,940	367,955	347,450	259,676	87,853	58,304	49,353	60,535	71,239	80,723	76,825	39,448	36,934	36,300	33,000	32,700	34,300	27,900	27,700	22,400	10,500	5,400	2,200
Property Plant Equipment	0	3,763,000	3,482,200	3,221,600	2,890,400	2,575,800	2,358,605	2,083,421	1,594,120	974,309	526,983	379,940	367,955	347,450	259,676	87,853	58,304	49,353	60,535	71,239	80,723	76,825	39,448	36,934	0	0	0	0	0	0	0	0	0	-
Retained Earnings	27,260,300	23,306,700	18,968,300	10,893,000	7,379,800	5,254,300	2,946,733	1,748,222	852,700	255,382	-92,692	-517,054	-1,267,323	-1,045,563	-941,095	-875,927	-793,217	-687,617	-585,280	-489,834	-531,533	-424,075	-299,698	-223,518	-200,300	-177,200	-168,600	-157,000	-124,600	-101,100	-70,400	-30,600	-11,400	-7,000
Retained Earnings Total Equity	0	23,306,700	18,968,300	10,893,000	7,379,800	5,254,300	2,946,733	1,748,222	852,700	255,382	-92,692	-517,054	-1,267,323	-1,045,563	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Short Long Term Debt	0	0	0	0	0	0	0	129,557	127,274	127,274	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Short Long Term Debt Total	2,702,900	2,701,400	2,699,700	2,695,700	713,900	708,500	703,453	481,126	375,510	459,064	505,512	457,328	435,533	160,030	109,000	5,093	202,292	200,000	200,000	200,000	213,817	200,150	200,576	2,681	4,100	4,200	5,600	8,700	9,500	12,300	7,500	6,800	2,800	-
Short Term Debt	0	720,000	719,700	1,631,200	0	-90,800	468,830	127,274	452,607	350,197	939	1,374	1,006	675	0	-162,421	202,292	-21,471	-23,337	-18,872	13,817	150	426	612	1,400	1,100	1,800	3,600	3,500	3,100	1,600	1,000	400	-
Short Term Investments	8,114,800	4,636,400	2,809,100	1,393,300	1,596,500	1,342,200	596,847	503,481	236,121	251,761	158,376	77,819	43,332	136,796	134,255	226,954	267,532	221,400	114,037	194,748	175,489	184,194	137,686	86,634	42,500	0	0	0	0	0	0	0	0	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Assets	33,080,200	29,214,500	25,434,800	17,163,300	14,805,200	11,734,500	8,764,286	6,973,466	5,609,132	3,871,827	2,951,013	2,080,490	1,323,583	1,089,432	741,202	670,038	936,258	585,090	423,501	473,108	479,555	391,574	495,397	208,274	137,000	156,900	168,400	137,600	93,800	94,200	117,600	97,900	114,000	25,400
Total Current Assets	19,479,200	22,064,700	20,520,500	12,753,900	10,558,800	7,959,300	5,596,552	3,913,920	3,383,756	2,506,894	2,252,208	1,620,787	913,585	720,051	425,508	521,442	797,829	469,984	341,392	343,955	320,207	276,948	394,186	134,142	73,000	92,900	99,600	85,000	49,200	52,000	91,800	84,700	106,600	22,400
Total Current Liabilities	3,423,400	3,849,100	3,451,000	2,806,800	1,790,900	1,352,000	967,418	980,659	760,619	620,137	262,226	118,604	402,318	61,008	93,575	83,672	283,664	45,014	40,357	34,139	72,923	40,118	22,022	13,786	13,300	9,400	10,700	12,000	12,900	17,900	13,100	4,600	3,300	1,800
Total Liab	7,107,100	6,550,500	6,666,000	6,138,000	3,715,500	2,977,200	2,620,208	2,524,221	1,954,295	1,329,502	998,937	835,105	837,851	561,617	344,440	251,186	475,991	368,466	309,499	290,565	341,912	245,593	229,042	26,144	27,500	25,700	29,500	30,700	25,900	27,100	19,200	10,700	7,800	13,200
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Stockholder Equity	25,973,100	22,664,000	18,768,800	11,025,300	11,089,700	8,757,300	6,144,078	4,449,245	3,654,837	2,542,325	1,952,076	1,245,385	485,732	527,815	396,762	418,852	460,267	216,624	114,002	182,543	137,643	145,981	266,355	182,130	109,500	131,200	138,900	106,900	67,900	67,100	98,400	87,200	106,200	12,200
Treasury Stock	0	0	-8,260,900	-6,613,300	-739,900	-396,400	-316,240	-316,240	-306,069	-169,530	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31	1993-12-31	1993-09-30	1993-06-30	1993-03-31	1992-12-31	1992-09-30	1992-06-30	1992-03-31	1991-12-31	1991-09-30	1991-06-30	1991-03-31	1990-12-31	1990-09-30	1990-06-30	1990-03-31
Accounts Payable	606,600	536,600	547,300	599,500	589,200	535,600	534,200	470,300	564,000	427,000	476,000	542,900	475,500	443,100	380,100	347,800	418,100	335,600	244,000	239,600	218,200	172,361	171,906	207,611	178,183	153,946	151,372	141,801	134,984	124,497	101,721	120,595	140,962	106,917	130,016	90,601	99,508	47,342	47,231	32,692	61,936	31,194	24,418	24,729	38,934	21,943	25,672	25,390	27,736	17,309	25,955	16,146	-48,048	74,976	58,256	-136,188	18,638	13,855	13,034	17,779	6,268	13,188	10,436	9,475	8,128	5,330	18,546	4,805	21,471	3,657	2,840	3,758	23,337	20,599	17,043	17,468	18,872	20,284	15,743	18,947	18,933	20,967	14,043	25,201	30,309	24,376	16,933	17,068	14,830	10,120	8,304	9,404	9,446	8,021	7,637	6,921	6,600	4,500	4,900	6,000	5,600	4,400	5,100	3,700	4,700	4,100	5,100	3,400	4,400	4,200	4,200	4,300	6,300	4,300	4,600	3,700	5,000	4,200	6,400	6,000	10,300	6,700	5,200	3,000	2,500	0	1,900	1,900	1,600	500	800	-	-	-	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Accumulated Other Comprehensive Income	-80,900	-176,800	-197,700	-181,600	-238,800	-275,100	-223,800	-170,100	-26,200	9,500	15,700	16,200	29,300	30,800	35,500	-9,100	21,100	16,500	15,800	2,800	-12,300	-10,519	-11,612	-15,594	640	23,835	2,348	-5,884	-12,840	-2,899	5,204	4,364	8,572	7,721	19,153	47,904	52,251	26,895	4,263	1,465	-1,188	-2,851	-3,429	-1,644	-1,166	-1,904	-2,371	-1,337	-1,862	-1,731	-904	-2,175	-2,491	-175	-306	717	1,044	3,537	1,014	-1,248	-114	-3,960	-315	828	170	-5	-516	-159	-231	-95	-473	-371	-785	-1,493	-2,005	-2,893	-3,068	-2,191	-2,880	-3,190	-3,997	-1,817	-2,219	-2,756	-3,172	-792	-1,203	-2,030	-1,615	712	-156	-63	-780	-202	-421	-516	-500	-400	-28,200	-27,300	-26,600	-25,900	-23,600	-23,600	-23,600	-21,600	-21,600	-20,400	-5,900	-18,000	-16,800	-15,600	-5,900	-13,300	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Lease Obligations	720,000	720,000	720,000	720,000	720,000	720,000	720,000	720,000	719,700	719,000	718,400	717,800	717,200	716,500	715,900	715,200	713,900	712,700	711,300	709,900	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Stock	100	100	100	100	100	100	100	100	100	100	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Surpluse	0	0	10,888,500	10,597,700	9,949,300	9,518,200	9,120,200	8,754,100	8,087,500	7,919,300	7,225,800	6,887,800	6,716,200	6,592,800	6,263,000	5,211,400	4,428,600	4,388,400	4,263,600	4,160,900	3,911,600	3,841,174	3,712,599	3,611,599	3,512,833	3,570,673	3,449,622	3,190,882	3,029,993	3,314,982	3,156,942	3,049,651	3,099,526	2,880,109	3,118,969	2,812,573	2,404,118	2,423,434	2,342,839	2,236,931	2,045,857	1,882,421	1,827,471	1,826,075	1,763,508	1,795,293	1,775,861	1,760,938	1,754,824	1,643,772	1,630,362	1,609,185	1,575,780	1,379,123	1,368,531	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Cash	2,730,000	2,152,300	1,937,200	3,916,300	3,105,900	3,491,300	3,395,100	3,345,700	2,885,600	3,432,400	2,072,200	1,437,900	2,193,700	1,573,000	1,992,200	2,208,200	1,617,800	1,384,800	1,045,500	1,708,500	1,467,700	1,087,843	917,876	1,019,491	812,733	792,065	744,313	811,773	535,203	920,359	646,508	604,214	809,102	654,587	390,554	507,907	648,719	646,554	600,135	461,858	535,608	263,211	381,675	180,362	230,276	118,998	171,943	394,585	483,610	206,395	254,312	135,376	112,572	325,286	112,000	117,311	207,075	250,321	271,466	199,097	247,796	314,684	292,129	520,875	498,925	97,416	109,643	156,484	237,876	167,662	114,960	182,332	184,508	176,093	145,201	147,816	101,234	105,047	122,833	174,034	118,285	298,617	129,659	191,586	80,077	75,574	69,374	135,469	247,393	99,974	142,955	183,620	30,978	49,642	81,751	12,294	23,700	23,500	20,600	21,800	19,800	22,600	22,500	19,300	28,900	40,300	51,400	27,900	34,500	37,500	48,900	11,900	32,700	5,900	16,800	12,700	23,600	15,300	18,000	8,000	12,500	39,700	7,900	10,100	16,400	19,200	22,000	24,900	26,200	35,000	39,200	-	21,800	-	-	-
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Cash And Short Term Investments	10,844,800	9,913,600	8,927,700	8,959,700	14,334,100	7,021,700	13,982,300	7,050,600	12,532,700	5,787,600	3,910,800	3,503,800	6,722,600	3,025,900	3,144,200	4,003,400	6,471,100	2,877,900	2,669,700	3,232,400	4,564,900	2,192,152	3,728,221	1,624,952	2,896,074	1,378,944	1,267,850	1,307,084	1,902,944	1,408,391	1,045,164	849,179	1,677,385	895,642	604,248	742,164	1,360,634	1,042,204	816,909	648,133	1,083,875	445,323	537,506	307,710	587,511	262,552	301,022	432,298	526,942	245,498	309,683	226,441	626,939	479,053	306,337	303,639	341,330	379,796	391,918	415,882	474,750	663,608	700,404	743,248	766,457	396,982	460,697	452,394	459,276	261,889	273,576	302,393	298,545	307,542	335,813	353,906	295,982	278,715	344,050	320,736	293,774	384,673	273,874	311,990	264,271	299,891	298,705	325,070	385,079	240,709	244,807	274,003	117,612	117,028	117,861	56,414	66,200	64,000	20,600	21,800	19,800	22,600	22,500	19,300	28,900	40,300	51,400	27,900	34,500	37,500	48,900	11,900	32,700	5,900	16,800	12,700	23,600	15,300	18,000	8,000	12,500	39,700	7,900	10,100	16,400	19,200	22,000	24,900	26,200	35,000	39,200	-	21,800	-	-	-
Common Stock	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	112	112	112	112	111	111	110	110	109	109	109	108	108	107	105	104	102	102	101	99	99	99	97	97	96	96	95	93	92	91	91	89	82	82	82	81	78	80	80	80	79	79	79	79	66	66	65	65	57	57	57	56	56	56	56	56	55	55	55	55	55	52	46	44	45	44	44	44	44	44	44	37	37	35	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Common Stock Shares Outstanding	113,800	113,400	113,900	114,000	114,000	112,800	114,000	113,100	113,200	113,901	110,800	110,525	112,214	113,951	117,911	115,100	114,318	114,266	114,940	115,564	114,800	115,100	114,500	114,904	116,204	117,028	116,137	115,246	115,788	116,654	116,231	114,228	115,665	115,944	115,259	115,183	114,295	117,423	113,354	112,151	112,557	116,713	111,060	109,860	117,237	115,830	110,167	107,734	93,446	91,046	90,436	89,162	87,405	81,638	81,492	81,169	81,169	79,866	79,626	79,498	79,498	78,937	78,689	78,493	78,493	66,069	65,950	65,563	65,563	57,011	56,915	56,727	56,727	55,978	55,917	55,815	55,815	55,468	55,383	63,625	55,283	52,692	49,566	44,279	44,279	43,950	44,091	43,871	43,871	43,328	43,629	37,434	37,249	36,134	36,619	31,817	31,817	30,625	31,200	30,690	30,690	35,000	30,000	31,667	31,667	31,667	26,875	25,652	25,652	25,429	24,516	22,286	22,286	19,189	20,000	19,091	19,048	19,048	18,889	18,772	16,552	16,552	15,410	15,246	15,263	15,263	15,417	15,714	15,000	15,000	15,000	15,364	15,364	15,364	15,364	15,364
Common Stock Total Equity	0	0	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	112	112	112	112	111	111	110	110	109	109	109	108	108	107	105	104	102	102	101	99	99	99	97	97	96	96	95	93	92	91	91	89	82	82	82	81	78	80	80	80	79	79	79	79	66	66	65	65	57	57	57	56	56	56	56	56	55	55	55	55	55	52	46	44	45	44	44	44	44	44	44	37	37	35	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Current Deferred Revenue	458,900	417,300	381,100	426,300	547,700	547,200	625,000	491,300	442,000	507,800	520,000	464,900	577,700	494,800	461,500	479,200	591,700	608,700	592,400	530,700	452,500	462,945	488,575	391,913	320,138	319,868	312,256	238,418	231,664	242,683	188,225	172,940	153,487	155,056	69,746	71,187	74,025	70,972	67,133	66,073	47,000	48,795	49,182	50,358	50,831	53,067	55,269	52,570	51,640	53,425	53,326	330,269	54,723	58,223	60,867	185,941	44,544	198,546	215,798	58,281	47,504	58,381	66,976	55,640	44,432	68,814	69,926	63,523	23,543	13,644	15,042	15,284	17,020	12,922	12,906	12,463	15,267	15,616	21,629	17,388	40,173	24,473	35,021	34,104	9,659	8,041	4,220	5,464	6,766	3,772	4,054	3,682	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	406,778	629,199	408,786	443,904	520,191	830,772	529,791	549,342	565,773	664,679	599,339	46,095	48,656	72,367	75,283	75,862	73,694	76,522	0	0	0	0	0	0	0	0	0	0	277,417	285,856	296,865	138,177	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Intangible Assets	1,038,600	1,017,200	953,000	928,700	915,500	804,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,400	3,000	0	0	2,200	0	0	1,600	0	-	-	500	-	-	-
Inventory	2,580,500	2,562,000	2,008,200	1,869,600	2,401,900	2,412,200	2,218,500	1,991,500	1,951,300	2,053,800	1,983,900	2,164,700	1,916,600	1,801,600	1,640,900	1,480,900	1,415,500	1,344,300	1,317,200	1,208,800	1,151,200	1,039,679	928,553	820,397	726,138	641,588	554,320	466,576	399,356	345,620	316,073	303,294	238,578	190,668	171,266	133,863	128,861	120,317	109,897	86,545	70,354	63,292	57,159	43,977	28,638	29,570	24,425	20,617	13,556	1,000	600	-226,441	-15,142	0	0	0	0	0	-391,918	0	0	0	0	0	0	0	0	0	0	0	2,128	3,254	2,904	2,837	3,746	3,087	3,229	4,266	10,850	9,098	9,006	7,698	10,342	8,437	6,831	6,152	5,365	4,989	3,973	3,056	2,263	2,668	1,915	8,181	7,931	5,641	4,600	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Liabilities And Stockholders Equity	33,080,200	32,163,300	30,657,500	30,059,900	29,214,500	27,677,800	27,205,800	26,348,700	25,434,800	23,671,500	21,485,900	17,772,200	17,163,300	16,084,000	14,428,700	15,757,500	14,805,200	13,939,300	13,173,600	12,854,800	11,734,500	10,805,613	9,951,980	9,372,696	8,764,286	8,701,215	8,106,373	7,817,365	6,973,466	6,828,019	6,204,906	5,904,460	5,609,132	5,182,915	4,526,970	4,198,573	3,871,827	3,739,419	3,456,078	3,260,396	2,951,013	2,640,415	2,378,259	2,275,998	2,080,490	1,660,615	1,457,500	1,350,159	1,323,583	983,031	1,046,864	1,074,293	1,089,432	942,433	790,641	787,156	741,202	742,192	742,345	681,421	670,038	825,891	851,225	930,876	936,258	573,096	597,858	601,431	585,090	355,186	378,332	402,089	423,501	419,275	446,948	470,292	473,108	472,685	488,174	506,178	479,555	500,501	395,547	430,441	391,574	418,592	440,451	471,865	495,397	318,613	336,295	349,185	208,274	216,319	202,117	132,034	137,000	134,400	139,800	149,300	156,900	162,400	165,100	161,400	168,400	164,700	170,000	129,100	137,600	130,600	139,300	86,200	93,800	74,200	83,400	86,100	94,200	97,400	105,700	106,000	117,600	125,900	82,400	90,600	97,900	104,400	108,700	112,200	114,000	114,000	115,200	-	25,400	-	-	-
Long Term Debt	1,982,900	1,982,600	1,982,200	1,981,800	1,981,400	1,981,100	1,980,700	1,980,400	1,980,000	1,979,600	1,979,200	1,978,900	1,978,500	1,978,300	0	0	0	0	0	0	0	707,203	705,903	704,645	703,453	702,317	701,173	700,407	351,569	382,228	361,523	362,230	362,919	30,723	30,360	144,082	146,773	287,950	282,261	326,673	320,315	314,162	308,116	302,268	296,518	290,959	285,491	280,206	275,019	159,482	159,457	159,353	159,355	158,382	157,359	156,464	109,022	62,571	62,925	0	0	0	0	0	0	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	205,147	200,000	200,000	200,000	200,000	200,053	200,150	1,646	1,749	1,914	2,069	2,177	2,336	2,520	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Long Term Debt Total	0	0	1,982,200	1,981,800	1,981,400	1,981,100	1,980,700	1,980,400	1,980,000	1,979,600	1,979,200	1,978,900	1,978,500	1,978,300	0	715,200	713,900	712,700	711,300	709,900	708,500	0	0	0	0	0	0	0	0	0	0	0	0	30,723	30,360	144,082	146,773	287,950	282,261	326,673	320,315	314,162	308,116	302,268	296,518	290,959	285,491	280,206	275,019	0	0	159,353	159,355	158,382	157,359	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Long Term Investments	5,396,500	5,778,500	6,327,200	6,066,600	6,591,800	5,968,600	6,415,900	7,084,000	6,838,000	5,631,300	3,900,300	3,543,700	3,135,600	2,875,100	2,587,600	3,236,400	3,256,800	3,112,600	2,884,600	2,339,800	0	1,873,569	2,044,703	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	312,600	288,321	254,738	275,887	0	0	373,621	370,053	37,956	70,465	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Debt	-27,100	550,300	765,000	-1,214,500	-404,500	-790,200	-694,400	-645,300	-185,900	-733,800	625,400	1,258,800	502,000	1,121,800	223,700	-1,493,000	-903,900	-672,100	-334,200	-998,600	-759,200	-380,640	-211,973	-314,846	-109,280	-89,748	-43,140	-104,166	-54,077	-538,131	-284,985	-241,984	-433,592	-259,720	-2,507	-35,431	-189,655	-81,240	-82,289	69,255	-30,096	218,964	91,627	282,386	227,052	332,737	274,289	46,248	-48,077	-45,993	-93,978	24,775	47,458	-166,270	45,807	39,588	-98,075	-187,750	-208,541	-199,097	-242,703	-197,181	-173,476	-320,875	-296,633	102,584	90,357	43,516	-37,876	32,338	85,040	17,668	15,492	23,907	54,799	52,184	98,766	94,953	77,167	25,966	95,532	-89,321	75,488	8,475	120,073	124,663	130,950	64,996	-46,817	-97,805	-140,638	-181,169	-28,297	-46,639	-78,309	-8,422	-19,600	-20,200	-16,900	-17,900	-15,600	-18,100	-17,700	-14,500	-23,300	-33,500	-44,100	-20,100	-25,800	-28,500	-40,300	-3,200	-23,200	4,400	-5,800	-4,000	-11,300	-5,000	-8,600	3,900	-5,000	-32,000	-100	-2,400	-9,600	-13,000	-16,300	-20,100	-23,400	-34,200	-38,800	-	-21,800	-	-	-
Net Invested Capital	27,956,000	26,887,000	26,000,100	25,477,000	1,981,400	23,419,900	22,668,500	21,895,100	1,980,000	19,237,600	17,106,500	13,955,900	13,003,800	12,103,800	10,557,400	12,133,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Receivables	5,667,300	5,584,500	5,121,300	5,118,600	5,328,700	5,548,300	5,161,400	4,839,000	6,036,500	5,452,000	6,998,600	4,173,000	4,114,700	4,039,500	2,811,300	2,933,200	2,672,200	2,660,000	2,455,900	2,305,200	2,243,200	2,202,945	2,039,247	1,943,932	1,974,340	1,971,449	1,844,547	1,749,548	1,611,620	1,643,872	1,751,971	1,865,221	1,467,793	1,439,315	1,395,125	1,338,462	1,017,399	927,254	893,924	1,047,496	891,778	992,824	876,016	802,638	693,120	601,271	435,380	238,347	103,035	78,447	84,564	88,156	93,112	82,287	95,196	71,858	65,568	67,766	60,046	48,209	35,212	42,206	32,838	32,960	18,320	10,968	20,478	33,632	7,493	7,940	12,141	11,010	36,521	10,536	16,830	10,371	43,102	24,866	25,397	59,882	15,529	9,197	7,871	7,238	4,017	4,521	2,986	2,739	2,975	3,547	4,380	8,608	13,835	9,851	9,568	8,560	600	8,600	5,000	7,000	5,700	5,400	12,500	4,600	6,600	4,100	5,900	3,300	4,300	6,000	6,500	4,300	2,700	4,500	2,400	2,400	1,700	1,600	1,400	1,500	1,700	1,700	200	1,100	1,100	1,600	2,000	1,600	1,400	1,900	1,100	-	200	-	-	-
Net Tangible Assets	0	0	24,017,900	23,495,200	21,748,500	20,634,700	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000	11,089,700	10,504,400	9,755,900	9,444,700	8,757,300	7,868,300	7,186,426	6,567,644	6,144,078	6,051,593	5,520,738	4,866,021	4,449,245	4,491,247	4,076,506	3,765,082	3,654,837	3,296,867	3,338,458	2,971,430	2,550,251	2,551,788	2,368,842	2,211,248	1,952,076	1,690,171	1,493,337	1,406,348	1,245,385	806,024	594,657	504,024	485,732	428,253	478,034	518,091	527,813	348,064	371,216	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Working Capital	16,055,800	15,036,200	13,818,600	13,809,100	17,495,600	12,549,400	12,496,000	11,298,400	17,069,500	10,060,600	9,605,200	6,837,300	7,081,700	6,759,800	4,157,800	6,588,900	8,767,900	5,343,700	4,937,900	5,417,200	6,607,300	4,302,353	5,663,386	3,278,992	4,629,134	2,997,114	2,831,034	2,360,992	2,933,261	2,540,504	2,257,662	2,213,655	2,623,137	1,940,650	1,681,799	1,774,580	1,886,757	1,790,312	1,567,117	1,565,981	1,989,982	1,365,433	1,357,560	1,109,878	1,502,183	770,035	585,973	536,529	504,604	206,637	277,405	299,687	659,043	441,886	298,179	291,351	331,933	347,429	258,730	380,678	437,770	497,769	518,475	501,551	514,165	325,334	392,150	405,559	424,970	241,051	259,548	285,980	301,035	291,437	329,363	339,923	309,816	275,338	345,958	355,949	247,284	349,642	246,086	270,374	236,830	281,169	288,228	314,174	372,164	238,312	239,856	272,781	120,356	124,260	124,437	61,031	59,700	65,300	67,500	66,300	83,500	79,600	79,900	83,400	88,900	94,300	99,800	62,200	73,000	64,500	72,100	28,000	36,300	16,500	23,300	24,200	34,100	30,500	33,600	33,600	78,700	100,200	60,300	70,600	80,100	86,600	93,200	98,400	103,300	107,500	-	-	-	-	-	-
Non Current Assets Total	13,601,000	13,528,500	13,734,500	13,150,700	7,149,800	12,249,200	5,843,600	12,042,700	4,914,300	9,896,100	8,148,300	7,717,100	4,409,400	6,986,400	6,568,500	7,113,400	4,246,400	6,830,200	6,522,600	5,926,200	3,775,200	5,086,030	3,255,959	4,827,964	3,167,734	4,565,473	4,246,322	4,148,102	3,059,546	3,326,330	2,995,681	2,771,081	2,225,376	2,507,275	2,243,629	1,887,859	1,364,933	1,538,907	1,537,383	1,389,347	698,805	1,006,255	816,897	968,876	459,703	712,012	688,307	653,244	670,708	643,159	633,591	378,555	369,381	366,714	372,891	391,712	315,694	280,598	215,936	197,630	148,596	110,351	108,832	143,371	138,429	151,076	100,877	112,268	115,106	81,437	87,276	82,442	82,109	94,317	87,636	100,438	129,153	161,447	104,844	113,894	159,348	96,123	100,397	100,701	114,626	104,769	130,746	134,747	101,211	65,886	83,513	62,549	74,132	79,317	64,653	58,553	64,000	60,200	63,600	73,100	64,000	73,200	76,700	70,500	68,800	62,600	59,400	57,200	52,600	57,200	57,600	47,700	44,600	43,600	43,900	48,200	42,200	50,400	50,400	61,400	25,800	16,300	14,700	13,800	13,200	12,500	11,300	9,800	7,400	4,400	3,900	-	3,000	-	-	-
Non Current Liabilities Other	854,100	832,400	1,553,000	1,482,800	1,427,800	1,378,700	1,503,400	1,446,000	753,500	719,100	596,300	598,500	1,462,100	1,275,400	1,278,600	1,118,800	1,618,900	1,669,500	1,704,600	1,898,700	825,900	194,033	190,020	169,922	152,073	125,225	115,920	106,248	100,385	135,700	119,523	120,993	115,535	77,910	76,080	55,559	40,855	23,747	14,968	11,794	11,330	0	0	0	0	0	0	0	0	0	0	7,180	7,350	5,289	4,318	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Non Current Liabilities Total	3,683,700	3,660,300	3,535,200	3,464,600	2,701,400	3,359,800	1,980,700	3,426,400	3,215,000	2,698,700	2,626,200	2,577,400	3,331,200	3,620,700	1,668,900	1,569,300	1,924,600	1,669,500	1,704,600	1,898,700	1,625,200	1,520,083	1,732,919	1,539,312	1,652,790	1,510,994	1,556,618	1,643,073	1,543,562	1,375,587	1,176,837	1,219,654	1,193,676	1,151,058	586,970	691,009	709,365	777,431	735,658	744,080	736,711	681,517	681,120	672,406	716,501	676,023	679,623	685,749	689,580	421,543	432,962	160,151	500,609	460,536	299,854	296,792	250,865	205,584	64,160	167,988	167,514	171,187	176,310	184,319	192,327	325,013	313,691	321,138	323,452	260,015	263,057	266,099	269,142	249,373	251,939	254,577	256,426	257,912	260,672	265,737	268,989	289,563	208,640	205,460	205,475	205,150	205,815	206,437	207,020	9,327	10,075	10,919	12,358	12,605	13,119	13,989	14,200	15,000	15,700	16,000	16,300	15,900	18,800	18,500	18,800	18,700	19,300	18,400	18,700	17,500	16,900	13,600	13,000	7,100	7,800	8,600	9,200	8,100	7,400	8,300	6,100	6,400	6,600	6,600	6,100	5,600	5,200	5,200	4,500	3,500	3,900	-	11,400	-	-	-
Non Currrent Assets Other	444,100	409,900	393,200	349,600	-4,658,800	320,200	-5,562,400	262,000	555,200	145,900	142,900	145,700	328,900	168,800	175,500	161,200	531,800	137,900	139,800	144,300	370,700	125,197	249,268	78,984	302,838	36,618	36,963	37,087	150,822	20,705	6,715	5,791	169,311	4,583	4,138	4,473	74,520	3,416	8,877	5,340	171,822	4,409	15,211	28,572	79,763	26,495	27,708	28,547	26,866	21,173	20,452	-352,489	-348,122	10,260	10,097	8,813	8,938	8,229	-52,317	9,330	9,682	37,526	44,601	84,952	80,125	101,718	53,230	64,487	65,753	30,402	33,422	25,021	21,574	30,273	20,270	31,383	57,914	87,505	28,858	36,278	78,625	12,408	15,727	18,053	37,801	48,631	83,281	92,704	61,763	28,468	45,894	25,383	37,198	41,658	27,219	21,923	27,700	25,100	28,400	38,900	31,000	40,600	44,500	38,300	36,100	29,700	25,400	23,400	18,300	23,500	24,300	16,500	16,700	18,500	18,200	21,400	14,500	22,300	22,800	34,400	3,400	700	300	2,800	2,700	300	2,400	2,100	400	1,700	1,500	-	300	-	-	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Assets	830,700	0	2,453,400	0	747,600	766,600	10,833,700	686,900	555,200	630,000	4,693,000	870,800	2,770,000	912,400	878,900	876,800	913,300	903,100	915,900	973,600	910,600	2,561,584	2,675,449	2,433,237	2,070,651	2,290,944	1,984,620	1,871,073	1,709,857	1,454,163	1,222,758	1,104,690	1,099,917	1,032,152	917,517	777,262	730,057	719,940	830,062	788,483	627,096	552,364	397,246	576,498	494,538	339,095	316,029	283,285	302,753	279,246	271,708	391,369	384,360	48,216	80,562	117,091	56,018	65,429	81,905	87,790	60,743	37,526	44,601	84,952	80,125	101,718	53,230	64,487	65,753	30,402	33,422	25,021	21,574	30,273	20,270	31,383	57,914	87,505	28,858	36,278	78,625	12,408	15,727	18,053	37,801	48,631	83,281	92,704	61,763	28,468	45,894	25,383	37,198	41,658	27,219	21,923	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Current Assets	386,600	574,700	360,800	406,200	933,000	446,400	583,600	424,900	332,400	482,000	444,300	213,600	160,800	230,600	263,800	226,600	387,100	226,900	208,200	182,200	243,300	284,807	163,599	155,451	224,972	143,761	193,334	146,055	130,528	103,806	96,017	115,685	163,501	150,015	112,702	96,225	120,721	110,737	97,965	88,875	140,818	132,721	90,681	152,797	176,159	55,210	8,366	5,653	9,342	15,927	19,026	607,582	15,142	14,379	16,217	19,947	18,610	14,032	466,363	19,700	11,480	9,726	9,151	11,297	13,052	14,070	15,806	3,137	3,215	3,920	3,211	2,990	3,422	4,043	2,923	2,490	1,642	3,391	3,033	2,568	1,898	2,810	3,063	2,075	1,829	3,259	2,649	4,320	2,159	5,415	1,332	1,357	780	1,942	2,104	2,866	1,600	1,600	50,600	47,400	67,400	61,200	53,400	67,000	64,100	57,700	53,300	40,700	46,200	29,900	26,300	22,300	13,800	20,200	20,300	22,800	26,700	30,100	35,900	35,100	77,600	68,200	59,600	65,600	67,200	71,100	73,400	75,900	79,000	72,700	71,000	-	400	-	-	-
Other Current Liab	2,357,900	2,644,700	2,176,000	2,074,300	1,992,200	1,796,400	2,658,100	2,046,000	1,725,300	2,061,000	2,018,000	1,492,200	122,400	96,900	1,360,800	85,000	1,086,800	821,100	876,700	741,100	772,100	781,924	670,709	666,216	267	334	397	920,852	486,737	3,586	3,695	13,508	13,563	2,506	2,291	2,185	96,407	290,634	236,154	205,243	152,351	187,944	129,408	120,684	27,465	102,281	101,096	81,333	67,889	61,581	55,710	48,838	53,658	74,976	58,256	53,905	30,393	-84,381	38,847	27,053	-170,100	28,699	27,853	20,839	28,812	5,042	2,292	15,276	21,471	5,042	2,292	5,042	23,337	20,599	17,043	17,468	18,872	20,284	15,743	18,947	55,228	41,580	14,043	49,790	26,671	8,041	15,638	19,311	18,589	11,381	9,981	232	3,728	3,895	4,284	4,177	5,300	3,200	2,600	2,800	2,700	3,400	2,200	2,500	4,200	1,000	2,600	2,900	4,000	900	1,700	2,400	3,100	6,500	8,300	9,900	9,800	10,000	13,100	1,200	1,200	1,200	700	1,800	1,100	4,300	1,400	1,400	1,300	1,500	1,100	-	-	-	-	-
Other Liab	0	0	833,000	0	707,800	607,300	625,000	726,000	515,300	719,100	647,000	598,500	635,500	925,900	953,000	854,100	889,000	933,400	969,600	0	0	812,880	728,461	834,667	781,272	808,677	855,445	942,666	931,157	993,359	815,314	857,424	780,214	756,191	198,923	218,533	217,131	213,369	218,872	214,027	195,529	200,136	208,612	211,131	215,492	225,565	234,574	246,009	253,747	262,061	273,505	284,597	293,206	302,154	142,495	140,328	141,843	143,013	148,490	167,988	167,514	171,187	176,310	184,319	192,327	125,013	113,691	121,138	123,452	60,015	63,057	66,099	69,142	49,373	51,939	54,577	56,426	57,912	60,672	65,737	68,989	89,563	3,493	5,460	5,475	5,150	5,815	6,384	6,870	7,681	8,326	9,005	10,289	10,428	10,783	11,469	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Stockholder Equity	-1,206,400	-1,019,600	-877,400	-447,800	-404,000	-395,800	117,600	142,900	-173,400	509,100	4,400	-47,500	102,900	350,800	120,100	4,137,600	3,688,700	3,900,000	3,821,800	3,716,700	3,515,200	3,444,803	3,358,747	3,295,359	3,196,593	3,254,433	3,133,382	2,874,642	2,713,753	2,998,930	2,840,890	2,742,173	2,793,457	2,591,332	2,831,890	2,630,756	2,234,588	2,379,585	2,298,991	2,236,931	2,045,857	1,882,421	1,827,471	1,826,075	1,763,508	1,795,293	1,775,861	1,760,938	1,754,824	1,643,772	1,630,362	1,609,185	1,575,780	1,379,123	1,368,531	1,357,089	1,336,732	1,323,432	1,313,003	1,304,896	1,294,813	1,285,223	1,274,527	1,264,531	1,253,235	931,482	924,094	914,317	904,407	719,157	713,419	708,297	700,011	693,426	687,965	682,578	675,389	673,635	674,505	674,242	673,118	670,120	622,931	622,510	573,184	569,917	569,884	569,613	567,624	565,435	564,795	560,985	406,391	404,916	386,925	313,699	310,300	309,800	337,600	336,900	335,000	334,500	331,700	331,400	331,100	328,900	328,700	284,400	269,800	271,100	269,600	210,100	198,400	183,100	169,000	169,100	168,200	168,200	168,000	167,900	168,800	169,000	117,700	117,700	117,800	117,700	117,700	117,700	117,600	117,700	117,800	-	19,200	-	-	-
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Property Plant And Equipment Gross	6,125,200	0	0	0	5,432,200	0	0	0	0	0	3,358,500	3,262,600	3,221,600	3,138,300	3,031,400	2,944,600	2,890,400	2,771,400	2,676,600	2,612,800	2,575,800	2,524,446	2,461,614	2,394,727	2,358,605	2,274,529	2,261,702	2,277,029	2,083,421	1,872,167	1,772,923	1,666,391	1,594,120	1,475,123	1,326,112	1,110,597	974,309	818,967	707,321	600,864	526,983	453,891	419,651	392,378	379,940	372,917	372,278	369,959	367,955	363,913	361,883	357,423	347,450	318,498	292,329	274,621	259,676	215,169	195,408	109,840	87,853	72,825	64,231	58,419	58,304	49,358	47,647	47,781	49,353	51,035	53,854	57,421	60,535	64,044	67,366	69,055	71,239	73,942	75,986	77,616	80,723	83,715	84,670	82,648	76,825	56,138	47,465	42,043	39,448	37,418	37,619	37,166	36,934	37,659	37,434	36,630	36,300	35,100	35,200	34,200	33,000	32,600	32,200	32,200	32,700	32,900	34,000	33,800	34,300	33,700	33,300	31,200	27,900	25,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Property Plant And Equipment Net	4,146,400	4,006,100	3,922,600	3,880,900	3,763,000	3,704,200	3,637,700	3,556,400	3,482,200	3,395,700	3,358,500	3,262,600	3,221,600	3,138,300	3,031,400	2,944,600	2,890,400	2,771,400	2,676,600	2,612,800	2,575,800	2,524,446	2,461,614	2,394,727	2,358,605	2,274,529	2,261,702	2,277,029	2,083,421	1,872,167	1,772,923	1,666,391	1,594,120	1,475,123	1,326,112	1,110,597	974,309	818,967	707,321	600,864	526,983	453,891	419,651	392,378	379,940	372,917	372,278	369,959	367,955	363,913	361,883	357,423	347,450	318,498	292,329	274,621	259,676	215,169	195,408	109,840	87,853	72,825	64,231	58,419	58,304	49,358	47,647	47,781	49,353	51,035	53,854	57,421	60,535	64,044	67,366	69,055	71,239	73,942	75,986	77,616	80,723	83,715	84,670	82,648	76,825	56,138	47,465	42,043	39,448	37,418	37,619	37,166	36,934	37,659	37,434	36,630	36,300	35,100	35,200	34,200	33,000	32,600	32,200	32,200	32,700	32,900	34,000	33,800	34,300	33,700	33,300	31,200	27,900	25,100	25,700	26,800	27,700	28,100	27,600	27,000	22,400	12,200	11,400	11,000	10,500	10,000	8,900	7,700	5,400	2,700	2,400	-	2,200	-	-	-
Property Plant Equipment	0	0	3,922,600	0	3,763,000	3,704,200	3,637,700	3,556,400	3,482,200	3,395,700	3,358,500	3,262,600	3,221,600	3,138,300	3,031,400	2,944,600	2,890,400	2,771,400	2,676,600	2,612,800	2,575,800	2,524,446	2,461,614	2,394,727	2,358,605	2,274,529	2,261,702	2,277,029	2,083,421	1,872,167	1,772,923	1,666,391	1,594,120	1,475,123	1,326,112	1,110,597	974,309	818,967	707,321	600,864	526,983	453,891	419,651	392,378	379,940	372,917	372,278	369,959	367,955	363,913	361,883	357,423	347,450	318,498	292,329	274,621	259,676	215,169	195,408	109,840	87,853	72,825	64,231	58,419	58,304	49,358	47,647	47,781	49,353	51,035	53,854	57,421	60,535	64,044	67,366	69,055	71,239	73,942	75,986	77,616	80,723	83,715	84,670	82,648	76,825	56,138	47,465	42,043	39,448	37,418	37,619	37,166	36,934	37,659	37,434	36,630	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Retained Earnings	27,260,300	26,100,700	25,092,900	24,124,500	23,306,700	22,109,600	20,793,900	19,941,800	18,968,300	16,739,300	15,107,100	12,008,200	10,893,000	9,743,800	8,901,700	8,004,400	7,379,800	6,587,800	5,918,200	5,725,100	5,254,300	4,433,904	3,839,179	3,287,767	2,946,733	2,773,214	2,384,897	1,997,153	1,748,222	1,495,107	1,230,303	1,018,436	852,700	697,706	487,308	292,665	255,382	145,206	65,486	-27,249	-92,692	-189,498	-330,804	-418,180	-517,054	-987,461	-1,178,929	-1,255,672	-1,267,323	-1,213,880	-1,151,515	-1,089,010	-1,045,563	-1,030,966	-997,091	-971,617	-941,095	-904,606	-903,591	-893,408	-875,927	-844,409	-823,294	-804,835	-793,217	-780,146	-744,308	-717,534	-687,617	-656,646	-629,236	-605,660	-585,280	-555,608	-520,956	-493,957	-489,834	-492,626	-481,550	-467,001	-531,533	-512,156	-482,921	-454,185	-424,075	-388,382	-355,566	-325,143	-299,698	-271,320	-251,389	-236,555	-223,518	-213,779	-210,568	-207,621	-200,300	-198,900	-194,000	-186,200	-177,200	-171,700	-170,300	-172,400	-168,600	-169,100	-167,200	-163,000	-157,000	-148,900	-140,000	-132,400	-124,600	-116,800	-109,600	-105,300	-101,100	-95,400	-91,400	-81,200	-70,400	-58,900	-49,300	-39,900	-30,600	-24,200	-18,400	-14,700	-11,400	-9,300	-8,500	-	-7,000	-	-	-
Retained Earnings Total Equity	0	0	25,092,900	24,124,500	23,306,700	22,109,600	20,793,900	19,941,800	18,968,300	16,739,300	15,107,100	12,008,200	10,893,000	9,743,800	8,901,700	8,004,400	7,379,800	6,587,800	5,918,200	5,725,100	5,254,300	4,433,904	3,839,179	3,287,767	2,946,733	2,773,214	2,384,897	1,997,153	1,748,222	1,495,107	1,230,303	1,018,436	852,700	697,706	487,308	292,665	255,382	145,206	65,486	-27,249	-92,692	-189,498	-330,804	-418,180	-517,054	-987,461	-1,178,929	-1,255,672	-1,267,323	-1,213,880	-1,151,515	-1,089,010	-1,045,563	-1,030,966	-997,091	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,500,000	0	0	0	0	0	0	0	0	0	0	0	0	7,200	129,557	127,274	127,274	127,274	127,274	0	0	0	127,274	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Short Long Term Debt Total	2,702,900	2,702,600	2,702,200	2,701,800	2,701,400	2,701,100	2,700,700	2,700,400	2,699,700	2,698,600	2,697,600	2,696,700	2,695,700	2,694,800	2,215,900	715,200	713,900	712,700	711,300	709,900	708,500	707,203	705,903	704,645	703,453	702,317	701,173	707,607	481,126	382,228	361,523	362,230	375,510	394,867	388,047	472,476	459,064	565,314	517,846	531,113	505,512	482,175	473,302	462,748	457,328	451,735	446,232	440,833	435,533	160,402	160,334	160,151	160,030	159,016	157,807	156,899	109,000	62,571	62,925	0	5,093	117,503	118,653	200,000	202,292	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	213,817	209,296	205,147	200,061	200,150	200,237	200,324	200,465	200,576	2,169	2,317	2,451	2,681	3,003	3,442	3,872	4,100	3,300	3,700	3,900	4,200	4,500	4,800	4,800	5,600	6,800	7,300	7,800	8,700	9,000	8,600	8,700	9,500	10,300	11,000	8,700	12,300	10,300	9,400	11,900	7,500	7,700	7,800	7,700	6,800	6,200	5,700	4,800	2,800	800	400	-	-	-	-	-
Short Term Debt	0	0	0	0	720,000	0	720,000	0	719,700	719,000	718,400	717,800	1,631,200	1,303,000	1,500,000	1,143,200	-305,700	0	0	0	-90,800	0	-298,555	0	468,830	664,480	564,992	7,200	127,274	590,419	657,922	612,681	452,607	470,511	399,489	372,161	350,197	1,252	1,060	1,060	939	794	794	1,473	1,374	1,277	1,183	1,093	1,006	920	877	798	675	634	448	435	0	0	0	0	200,000	117,503	118,653	200,000	202,292	17,500	14,067	0	-21,471	10,355	11,334	9,583	-23,337	-20,599	-17,043	-17,468	-18,872	-20,284	-15,743	-18,947	13,817	9,296	-14,043	61	150	237	324	412	426	523	568	537	612	826	1,106	1,352	1,400	1,200	1,200	1,100	1,100	1,800	1,200	1,300	1,800	2,700	3,100	3,400	3,600	3,800	3,700	3,800	3,500	3,300	3,300	100	3,100	2,300	2,200	3,800	1,600	1,500	1,500	1,400	1,000	1,000	900	700	400	100	100	-	-	-	-	-
Short Term Investments	8,114,800	7,761,300	6,990,500	5,043,400	4,636,400	3,530,400	4,171,300	3,704,900	2,809,100	2,355,200	1,838,600	2,065,900	1,393,300	1,452,900	1,152,000	1,795,200	1,596,500	1,493,100	1,624,200	1,523,900	1,342,200	1,104,309	765,642	605,461	596,847	586,879	523,537	495,311	503,481	488,032	398,656	244,965	236,121	241,055	213,694	234,257	251,761	395,650	216,774	186,275	158,376	182,112	155,831	127,348	77,819	143,554	129,079	37,713	43,332	39,103	55,371	91,065	136,796	153,767	194,337	186,328	134,255	129,475	120,452	216,785	226,954	348,924	408,275	222,373	267,532	299,566	351,054	295,910	221,400	94,227	158,616	120,061	114,037	131,449	190,612	206,090	194,748	173,668	221,217	146,702	175,489	86,056	144,215	120,404	184,194	224,317	229,331	189,601	137,686	140,735	101,852	90,383	86,634	67,386	36,110	44,120	42,500	40,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Assets	33,080,200	32,163,300	30,657,500	30,059,900	29,214,500	27,677,800	27,205,800	26,348,700	25,434,800	23,671,500	21,485,900	17,772,200	17,163,300	16,084,000	14,428,700	15,757,500	14,805,200	13,939,300	13,173,600	12,854,800	11,734,500	10,805,613	9,951,980	9,372,696	8,764,286	8,701,215	8,106,373	7,817,365	6,973,466	6,828,019	6,204,906	5,904,460	5,609,132	5,182,915	4,526,970	4,198,573	3,871,827	3,739,419	3,456,078	3,260,396	2,951,013	2,640,415	2,378,259	2,275,998	2,080,490	1,660,615	1,457,500	1,350,159	1,323,583	983,031	1,046,864	1,074,293	1,089,432	942,433	790,641	787,156	741,202	742,192	742,345	681,421	670,038	825,891	851,225	930,876	936,258	573,096	597,858	601,431	585,090	355,186	378,332	402,089	423,501	419,275	446,948	470,292	473,108	472,685	488,174	506,178	479,555	500,501	395,547	430,441	391,574	418,592	440,451	471,865	495,397	318,613	336,295	349,185	208,274	216,319	202,117	132,034	137,000	134,400	139,800	149,300	156,900	162,400	165,100	161,400	168,400	164,700	170,000	129,100	137,600	130,600	139,300	86,200	93,800	74,200	83,400	86,100	94,200	97,400	105,700	106,000	117,600	125,900	82,400	90,600	97,900	104,400	108,700	112,200	114,000	114,000	115,200	-	25,400	-	-	-
Total Current Assets	19,479,200	18,634,800	16,923,000	16,909,200	22,064,700	15,428,600	21,362,200	14,306,000	20,520,500	13,775,400	13,337,600	10,055,100	12,753,900	9,097,600	7,860,200	8,644,100	10,558,800	7,109,100	6,651,000	6,928,600	7,959,300	5,719,583	6,696,021	4,544,732	5,596,552	4,135,742	3,860,051	3,669,263	3,913,920	3,501,689	3,209,225	3,133,379	3,383,756	2,675,640	2,283,341	2,310,714	2,506,894	2,200,512	1,918,695	1,871,049	2,252,208	1,634,160	1,561,362	1,307,122	1,620,787	948,603	769,193	696,915	652,875	339,872	413,273	695,738	720,051	575,719	417,750	395,444	425,508	461,594	526,409	483,791	521,442	715,540	742,393	787,505	797,829	422,020	496,981	489,163	469,984	273,749	291,056	319,647	341,392	324,958	359,312	369,854	343,955	311,238	383,330	392,284	320,207	404,378	295,150	329,740	276,948	313,823	309,705	337,118	394,186	252,727	252,782	286,636	134,142	137,002	137,464	73,481	73,000	74,200	76,200	76,200	92,900	89,200	88,400	90,900	99,600	102,100	110,600	71,900	85,000	73,400	81,700	38,500	49,200	30,600	39,500	37,900	52,000	47,000	55,300	44,600	91,800	109,600	67,700	76,800	84,700	91,900	97,400	102,400	106,600	109,600	111,300	-	22,400	-	-	-
Total Current Liabilities	3,423,400	3,598,600	3,104,400	3,100,100	3,849,100	2,879,200	4,537,300	3,007,600	3,451,000	3,714,800	3,732,400	3,217,800	2,806,800	2,337,800	3,702,400	2,055,200	1,790,900	1,765,400	1,713,100	1,511,400	1,352,000	1,417,230	1,032,635	1,265,740	967,418	1,138,628	1,029,017	1,308,271	980,659	961,185	951,563	919,724	760,619	734,990	601,542	536,134	620,137	410,200	351,578	305,068	262,226	268,727	203,802	197,244	118,604	178,568	183,220	160,386	148,271	133,235	135,868	396,051	61,008	133,833	119,571	104,093	93,575	114,165	267,679	103,113	83,672	217,771	223,918	285,954	283,664	96,686	104,831	83,604	45,014	32,698	31,508	33,667	40,357	33,521	29,949	29,931	34,139	35,900	37,372	36,335	72,923	54,736	49,064	59,366	40,118	32,654	21,477	22,944	22,022	14,415	12,926	13,855	13,786	12,742	13,027	12,450	13,300	8,900	8,700	9,900	9,400	9,600	8,500	7,500	10,700	7,800	10,800	9,700	12,000	8,900	9,600	10,500	12,900	14,100	16,200	13,700	17,900	16,500	21,700	11,000	13,100	9,400	7,400	6,200	4,600	5,300	4,200	4,000	3,300	2,100	2,000	-	1,800	-	-	-
Total Liab	7,107,100	7,258,900	6,639,600	6,564,700	6,550,500	6,239,000	6,518,000	6,434,000	6,666,000	6,413,500	6,358,600	5,795,200	6,138,000	5,958,500	5,371,300	3,624,500	3,715,500	3,434,900	3,417,700	3,410,100	2,977,200	2,937,313	2,765,554	2,805,052	2,620,208	2,649,622	2,585,635	2,951,344	2,524,221	2,336,772	2,128,400	2,139,378	1,954,295	1,886,048	1,188,512	1,227,143	1,329,502	1,187,631	1,087,236	1,049,148	998,937	950,244	884,922	869,650	835,105	854,591	862,843	846,135	837,851	554,778	568,830	556,202	561,617	594,369	419,425	400,885	344,440	319,749	331,839	271,101	251,186	388,958	400,228	470,273	475,991	421,699	418,522	404,742	368,466	292,713	294,565	299,766	309,499	282,894	281,888	284,508	290,565	293,812	298,044	302,072	341,912	344,299	257,704	264,826	245,593	237,804	227,292	229,381	229,042	23,742	23,001	24,774	26,144	25,347	26,146	26,439	27,500	23,900	24,400	25,900	25,700	25,500	27,300	26,000	29,500	26,500	30,100	28,100	30,700	26,400	26,500	24,100	25,900	21,200	24,000	22,300	27,100	24,600	29,100	19,300	19,200	15,800	14,000	12,800	10,700	10,900	9,400	9,200	7,800	5,600	5,900	-	13,200	-	-	-
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Stockholder Equity	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000	11,089,700	10,504,400	9,755,900	9,444,700	8,757,300	7,868,300	7,186,426	6,567,644	6,144,078	6,051,593	5,520,738	4,866,021	4,449,245	4,491,247	4,076,506	3,765,082	3,654,837	3,296,867	3,338,458	2,971,430	2,542,325	2,551,788	2,368,842	2,211,248	1,952,076	1,690,171	1,493,337	1,406,348	1,245,385	806,024	594,657	504,024	485,732	428,253	478,034	518,091	527,815	348,064	371,216	386,271	396,762	422,443	410,506	410,320	418,852	436,933	450,997	460,603	460,267	151,397	179,336	196,689	216,624	62,473	83,767	102,323	114,002	136,381	165,060	185,784	182,543	178,873	190,130	204,106	137,643	156,202	137,843	165,615	145,981	180,788	213,159	242,484	266,355	294,871	313,294	324,411	182,130	190,972	175,971	105,595	109,500	110,500	115,400	123,400	131,200	136,900	137,800	135,400	138,900	138,200	139,900	101,000	106,900	104,200	112,800	62,100	67,900	53,000	59,400	63,800	67,100	72,800	76,600	86,700	98,400	110,100	68,400	77,800	87,200	93,500	99,300	103,000	106,200	108,400	109,300	-	12,200	-	-	-
Treasury Stock	0	0	0	0	0	-9,914,000	-9,002,600	-8,611,200	-8,260,900	-7,410,200	-7,221,400	-6,935,300	-6,613,300	-6,242,000	-6,142,900	-1,073,800	-739,900	-488,400	-441,800	-444,200	-396,400	-396,371	-353,852	-316,240	-316,240	-316,240	-316,240	-316,240	-316,240	-316,052	-316,052	-307,478	-306,069	-288,777	-287,079	-181,817	-169,530	-43,849	-43,848	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31	1993-12-31	1992-12-31	1991-12-31
Begin Period Cash Flow	3,119,400	2,898,100	2,207,300	1,630,300	1,480,200	825,200	535,203	809,102	648,719	535,608	230,276	483,610	112,572	207,075	247,796	498,925	237,876	184,508	95,229	118,285	80,077	247,393	30,978	23,697	19,800	28,900	34,500	32,700	23,600	12,500	16,400	26,200	19,200
Capital Expenditures	926,400	590,100	551,900	614,600	429,600	383,100	272,600	511,900	677,933	333,006	156,323	49,337	57,217	99,689	97,318	34,857	18,446	2,811	4,964	6,174	29,656	34,370	8,223	6,495	5,700	3,000	2,100	8,600	3,300	6,900	10,200	2,100	1,000
Cash And Cash Equivalents Changes	0	221,300	690,800	577,000	150,100	655,000	277,530	-273,899	160,383	113,111	305,332	-253,334	371,038	-94,503	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-381,600	221,300	690,800	577,000	150,100	655,000	277,530	-273,899	160,383	113,111	305,332	-253,334	371,038	-94,503	-40,721	-251,129	261,049	53,368	89,279	-17,051	38,208	-167,316	216,415	7,281	3,900	-9,200	-5,600	1,700	9,100	11,200	-3,900	-9,800	7,100
Change In Working Capital	-94,100	-243,300	-1,916,500	-1,503,600	-200,500	-697,000	-926,533	228,190	229,827	20,239	-190,669	-672,799	-17,464	140,935	-49,468	-52,434	87,467	92,958	27,787	-58,743	84,326	3,580	11,015	-15,254	1,200	-7,400	-2,600	-8,500	-14,800	-3,000	3,100	1,500	-600
Change Receivables	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-338,800	707,800	-1,927,400	-1,356,100	-473,100	-268,900	-362,720	-143,827	-491,421	-62,432	-198,658	-590,085	-21,118	-27,544	-30,356	-16,892	0	29,028	6,581	0	0	0	10,860	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-271,700	-696,500	-494,300	-529,400	-335,500	-387,900	-314,195	-149,776	-111,825	-60,900	-47,956	-52,616	0	0	-4,574	0	0	3,594	1,250	6,914	-1,049	-1,732	-941	4,050	-4,000	0	0	0	0	0	0	0	0
Change To Liabilities	0	-106,000	745,900	267,000	738,500	15,500	-136,300	498,300	912,549	152,779	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Netincome	0	676,500	-994,000	-895,100	314,200	-249,300	108,601	577,874	694,724	395,083	159,286	-824,884	80,078	200,812	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	-148,600	-240,700	114,900	-130,400	-55,700	-113,300	36,100	-79,476	-45,327	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	421,000	341,400	286,200	235,900	210,300	148,200	145,467	104,745	74,909	52,686	41,204	36,940	31,082	19,687	14,247	11,287	11,487	14,592	15,504	15,362	12,937	8,454	6,077	4,421	3,400	3,000	4,400	6,100	5,900	4,200	3,100	2,000	800
Dividends Paid	0	0	0	0	0	0	358,688	500,183	547,467	294,552	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	2,737,800	3,119,400	2,898,100	2,207,300	1,630,300	1,480,200	812,733	535,203	809,102	648,719	535,608	230,276	483,610	112,572	207,075	247,796	498,925	237,876	184,508	101,234	118,285	80,077	247,393	30,978	23,700	19,700	28,900	34,400	32,700	23,700	12,500	16,400	26,300
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	3,667,600	4,424,800	6,529,400	2,003,500	2,000,400	1,812,000	1,034,500	974,000	652,847	419,429	432,273	-123,952	-198,899	-3,345	-169,548	-123,943	8,926	20,264	-35,260	-23,083	-35,789	-144,893	-65,543	-34,405	-19,500	-13,200	-8,200	-28,900	-21,500	-27,400	-40,300	-19,300	-7,800
Investments	-4,976,600	-1,937,400	-4,832,800	544,000	-1,598,200	-1,069,900	-732,556	-534,963	-229,668	-87,771	-199,132	-31,184	185,965	-328,523	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	1,217,100	1,519,500	1,672,300	2,575,200	211,800	114,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	1,981,900	1,981,900	1,981,900	37,075	-40,589	-140,447	-221,734	-2,024	-2,203	-118,493	-104	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	3,953,600	4,338,400	8,075,300	3,513,200	2,115,800	2,444,400	1,198,511	895,522	636,056	348,074	424,362	750,269	-221,760	-104,468	-67,830	-82,710	-105,600	-102,337	-95,446	41,699	-107,458	-124,377	-76,180	-23,215	-23,100	-8,600	-11,600	-32,400	-23,500	-30,700	-39,900	-19,100	-4,500
Other Cashflows From Financing Activities	-700,600	-445,700	-1,032,700	3,481,900	-188,000	-1,463,000	415,688	-143,182	405,317	448,556	216,857	4,308	367,407	47,544	22,765	30,815	-85,723	390	115,494	3,827	13,506	-426	190,598	-1,498	-1,100	-1,900	-4,000	-3,700	-3,300	-200	-1,300	-800	-100
Other Cashflows From Investing Activities	0	-1,257,100	0	0	-1,598,200	-10,000	-10,000	-10,000	-229,668	0	0	-552	-277	-5,941	50	0	0	0	0	11,051	10,999	11,000	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	266,300	599,800	181,700	-135,000	-29,300	12,100	-36,900	485,700	619,815	361,623	133,654	-861,824	10,366	293	-382	2,248	34,018	17,862	21,859	-15,227	4,062	1,820	1,768	6,138	4,700	2,800	3,700	14,500	14,200	9,000	3,600	-1,600	-2,500
Sale Purchase Of Stock	-2,935,600	-2,528,500	-2,678,100	-6,527,600	-463,900	-191,600	-301,688	-143,182	-160,537	-267,584	-195,087	-163,300	112,309	196,790	0	0	0	0	0	-888	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	885,000	725,000	601,700	432,000	464,300	427,400	507,277	559,878	459,049	307,238	198,399	94,157	56,094	39,897	31,259	32,523	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-1,790,100	-1,009,000	-1,005,800	-1,970,500	-252,100	-77,100	-24,400	-700,391	-262,796	-209,269	77,139	-97,646	384,249	243,306	31,363	-192,858	319,400	185,398	4,081	4,441	108,184	1,723	349,120	92,867	300	-1,400	39,400	66,300	19,900	-200	49,800	-800	91,500
Total Cash From Operating Activities	4,594,000	5,014,900	7,081,300	2,618,100	2,430,000	2,195,100	1,307,100	1,485,900	1,330,780	752,435	588,596	-74,615	-141,682	96,344	-72,230	-89,086	27,372	23,075	-30,296	-16,909	-6,133	-110,523	-57,320	-27,910	-13,800	-10,200	-6,100	-20,300	-18,200	-20,500	-30,100	-17,200	-6,800
Total Cashflows From Investing Activities	0	-3,784,600	-5,384,700	-70,600	-2,027,800	-1,463,000	-1,005,182	-1,046,904	-907,601	-420,777	-355,455	-81,073	128,471	-434,153	146	30,815	0	0	115,494	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31	1993-12-31	1993-09-30	1993-06-30	1993-03-31	1992-12-31	1992-09-30	1992-06-30	1992-03-31	1991-12-31	1991-09-30
Begin Period Cash Flow	2,160,200	1,949,700	3,928,800	3,119,400	3,504,800	3,408,600	3,359,200	2,898,100	3,444,900	2,084,700	1,450,400	2,207,300	1,586,600	2,004,700	2,220,700	1,630,300	1,397,300	1,058,000	1,721,000	1,480,200	1,100,343	930,376	1,031,991	825,233	792,065	744,313	811,773	535,203	920,359	646,508	604,214	809,102	654,587	390,554	507,907	648,719	646,554	600,135	461,858	535,608	263,211	381,675	180,362	230,276	118,998	171,943	394,585	483,610	206,395	254,312	135,376	112,572	325,286	112,000	117,311	207,075	250,321	271,466	199,097	247,796	314,684	292,129	520,875	498,925	97,416	109,643	156,484	237,876	167,662	114,960	182,332	184,508	176,093	145,201	147,816	95,229	105,047	122,833	174,034	118,285	298,617	129,659	191,586	80,077	75,574	69,374	135,469	247,393	99,974	142,955	183,620	30,978	49,641	81,751	12,294	23,697	23,500	20,700	21,800	19,800	100	3,300	19,300	29,000	0	23,600	27,900	34,500	0	36,900	11,900	32,700	0	4,200	12,600	23,600	0	10,400	7,700	12,500	31,900	0	10,100	16,400	0	0	24,900	26,200	0	0
Capital Expenditures	313,500	176,000	113,000	178,200	152,200	142,500	153,600	141,800	154,900	133,200	148,500	115,300	161,400	153,200	129,900	170,100	139,000	121,700	94,600	74,300	85,500	106,200	112,000	79,400	107,637	59,653	54,849	50,461	150,455	118,556	138,836	104,094	177,779	146,099	239,893	114,162	117,542	79,769	70,873	64,822	68,976	31,691	34,453	21,203	15,162	10,248	12,872	11,055	11,289	8,898	14,864	22,166	32,262	22,103	22,581	22,743	22,316	22,331	30,754	21,917	15,740	9,328	6,742	3,047	10,730	4,692	1,827	1,197	1,208	617	340	646	351	1,716	1,538	1,359	1,327	2,314	1,548	985	1,285	3,386	4,981	20,004	15,171	8,318	6,881	4,000	2,600	1,767	2,213	1,643	1,165	1,041	2,518	1,771	800	1,200	2,700	1,000	600	1,300	200	900	600	400	100	1,200	600	500	2,700	4,800	2,700	400	100	100	500	700	1,200	5,500	8,100	1,200	700	200	49,900	50,800	700	500	800	100
Cash And Cash Equivalents Changes	0	0	-1,978,700	809,400	-385,400	96,200	49,400	461,100	-546,800	1,360,200	634,300	-756,900	620,700	-418,100	-216,000	590,400	233,000	339,300	-663,000	240,800	379,890	169,967	-101,615	206,758	20,668	47,752	-67,460	276,570	-385,156	273,851	42,294	-204,888	154,515	264,033	-117,353	-140,812	2,165	46,419	138,277	-73,750	272,397	-118,464	201,313	-49,914	111,278	-52,945	-222,642	-89,025	277,215	-47,917	118,936	22,804	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	577,600	210,500	-1,979,100	809,400	-385,400	96,200	49,400	461,100	-546,800	1,360,200	634,300	-756,900	620,700	-418,100	-216,000	590,400	233,000	339,300	-663,000	240,800	379,857	169,967	-101,615	206,758	20,668	47,752	-67,460	276,570	-385,156	273,851	42,294	-204,888	154,515	264,033	-117,353	-140,812	2,165	46,419	138,277	-73,750	272,397	-118,464	201,313	-49,914	111,278	-52,945	-222,642	-89,025	277,215	-47,917	118,936	22,804	-212,714	213,286	-5,311	-89,764	-43,246	-21,145	72,369	-48,699	-66,888	22,555	-228,746	21,950	401,509	-12,227	-46,841	-81,392	70,214	52,702	-67,372	-2,176	8,415	30,892	-2,615	52,587	-3,813	-17,786	-51,201	55,749	-180,332	168,958	-61,927	111,509	4,503	6,200	-66,095	-111,924	147,419	-42,981	-40,665	152,642	-18,663	-32,110	69,457	-11,403	200	2,800	-1,100	2,000	-2,900	100	3,300	-9,700	-11,400	-11,200	23,600	-6,600	-3,000	-11,400	36,900	-20,800	26,900	-11,000	4,200	-11,000	8,500	-2,900	10,400	-4,800	-27,200	31,900	-2,300	-6,300	-2,800	-2,900	-2,800	-1,300	-8,700	-4,200
Change In Working Capital	-61,400	-192,300	-81,300	240,900	382,000	-667,200	-781,300	823,200	-355,400	1,463,200	-2,484,900	-539,400	-35,400	-1,321,300	34,100	-181,000	-29,300	-300,100	-182,600	311,500	-249,344	-242,822	-237,376	32,542	-214,826	-92,181	-591,624	-27,902	79,504	248,891	125,590	-225,795	-1,263	553,200	-40,383	-281,727	-33,608	2,887	156,969	-106,009	119,065	-99,154	-83,037	-127,543	-113,297	-231,634	-191,653	-136,215	-28,578	-7,299	7,907	10,506	-46,805	181,043	-337	7,034	-23,125	-19,849	-3,398	-3,096	-14,899	-32,064	12,040	-17,511	48,312	14,435	13,481	11,239	75,745	4,108	-5,489	18,594	1,710	9,798	-11,237	27,516	-19,533	3,343	27,248	-69,801	-14,258	85,351	-15,195	28,428	2,135	6,336	-1,833	-3,058	8,739	-3,406	3,603	2,079	1,985	-3,246	-2,527	-11,466	5,500	-4,600	1,600	-1,300	-1,800	4,100	-7,700	-2,000	1,000	-1,400	-1,700	-500	2,600	-3,900	-3,400	-3,800	3,400	-9,200	-2,400	-6,600	-8,500	-5,300	12,300	-1,500	-400	1,300	900	1,300	-200	1,300	-200	600	1,300	-1,400
Change Receivables	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-82,700	-463,500	-2,700	210,100	219,600	-386,900	-322,400	1,197,500	-584,500	1,541,000	-2,825,600	-58,300	-80,800	-1,228,200	121,900	-169,000	-12,200	-204,100	-150,700	-106,100	-40,295	-163,698	-95,315	30,408	-2,891	-126,902	-94,999	-137,928	32,252	108,099	113,250	-397,428	-28,478	-44,190	-97,690	-321,063	-90,145	-33,330	153,572	-92,529	101,046	-116,808	-73,378	-109,518	-91,849	-165,891	-197,033	-135,312	-35,783	6,117	3,592	4,956	-10,825	12,909	-23,338	-6,290	2,198	-7,720	-11,837	-12,997	0	0	0	0	0	0	0	-26,139	29,028	28,581	24,380	25,511	6,581	32,566	26,272	32,731	0	0	0	-44,353	0	0	0	0	0	0	0	236	10,860	10,288	9,455	5,227	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-47,300	-77,200	-100,400	-46,800	-144,300	-223,500	-240,100	-88,600	-163,700	-109,100	31,300	-252,800	-127,000	-169,000	-162,600	-70,800	-108,300	-59,000	-109,600	-58,600	-106,276	-99,524	-93,340	-88,760	-78,550	-84,101	-81,800	-69,744	-50,070	-26,818	-10,625	-62,263	-30,366	-31,607	-43,920	-5,932	-9,983	-13,622	-21,745	-15,550	-47,956	-32,412	-8,037	-43,660	-19,955	0	0	-4,487	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-440	70	2,245	1,371	-92	42	1,067	-386	527	1,313	6,861	-1,448	188	-1,027	2,925	-1,623	-1,324	-397	-505	-95	-735	-637	-513	683	-474	6,544	104	-1,898	-700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	25,200	0	288,000	-178,000	24,900	-240,900	316,700	70,300	537,200	-178,300	73,900	93,300	111,100	-11,300	242,800	-15,700	104,500	0	0	0	0	22,058	-136,287	69,863	-357,982	200,095	498,250	189,839	5,139	194,636	912,549	0	0	0	152,779	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,301	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Netincome	0	0	54,000	549,800	522,800	-686,800	-287,700	1,128,200	143,500	1,781,400	-58,400	-446,700	81,800	-1,096,400	46,100	73,400	-4,600	-112,300	-4,800	435,900	-91,522	-141,694	-156,847	140,763	393,430	26,515	-418,314	106,970	124,764	386,225	203,281	-136,396	126,829	682,455	48,963	-163,523	88,107	83,837	235,055	-11,916	179,975	-48,851	40,788	-12,626	-377,222	-193,850	-155,120	-98,692	3,126	15,630	28,455	32,867	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	-3,400	-3,400	18,700	121,200	-243,700	-44,800	76,100	-39,000	-227,800	-50,000	98,500	-17,400	-36,300	70,100	-151,600	-21,300	-26,800	0	0	0	0	68,836	-113,331	48,959	-56,843	-20,325	23,543	-22,229	17,826	39,260	-79,476	0	0	0	-45,327	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	113,000	105,400	103,100	99,500	100,100	92,600	74,400	74,300	74,500	73,200	71,100	67,400	61,700	59,300	58,800	56,100	54,300	52,900	52,100	51,000	42,759	35,441	33,642	36,358	34,507	37,719	35,126	38,115	28,900	27,839	25,029	22,977	22,910	20,674	15,298	16,027	14,135	14,005	13,016	11,530	11,292	10,803	9,702	9,407	9,778	9,329	9,417	8,416	7,926	8,276	7,902	6,978	6,086	4,894	4,524	4,183	4,935	3,590	2,998	2,724	2,626	2,774	2,941	2,946	2,899	2,859	2,874	2,855	3,396	3,708	3,690	3,798	3,880	3,935	3,831	3,858	3,916	3,876	3,797	3,773	4,314	3,656	2,679	2,288	2,049	2,169	2,228	2,008	1,810	1,519	1,419	1,329	1,296	1,154	1,045	926	900	900	900	700	700	700	700	900	1,100	900	1,200	1,200	1,600	1,500	1,500	1,500	1,300	1,600	1,400	1,600	1,200	1,100	1,000	900	900	800	700	700	600	500	500	400	300	200
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	680,800	0	0	0	0	0	0	0	0	0	0	0	243,781	0	0	0	308,252	5,173	43,971	242,117	50,385	399,331	20,042	117,793	151,511	0	143,041	0	0	0	0	0	0	0	0	49,578	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	2,737,800	2,160,200	1,949,700	3,928,800	3,119,400	3,504,800	3,408,600	3,359,200	2,898,100	3,444,900	2,084,700	1,450,400	2,207,300	1,586,600	2,004,700	2,220,700	1,630,300	1,397,300	1,058,000	1,721,000	1,480,200	1,100,343	930,376	1,031,991	812,733	792,065	744,313	811,773	535,203	920,359	646,508	604,214	809,102	654,587	390,554	507,907	648,719	646,554	600,135	461,858	535,608	263,211	381,675	180,362	230,276	118,998	171,943	394,585	483,610	206,395	254,312	135,376	112,572	325,286	112,000	117,311	207,075	250,321	271,466	199,097	247,796	314,684	292,129	520,875	498,925	97,416	109,643	156,484	237,876	167,662	114,960	182,332	184,508	176,093	145,201	147,816	101,234	105,047	122,833	174,034	118,285	298,617	129,659	191,586	80,077	75,574	69,374	135,469	247,393	99,974	142,955	183,620	30,978	49,641	81,751	12,294	23,700	23,500	-1,100	21,800	-2,900	100	3,300	19,300	-11,400	-11,200	23,600	27,900	-3,000	-11,400	36,900	11,900	26,900	-11,000	4,200	12,600	8,500	-2,900	10,400	7,700	-27,200	31,900	-2,300	10,100	-2,800	-2,900	-2,800	24,900	-8,700	-4,200
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	776,200	938,300	909,400	1,189,400	1,567,700	486,400	410,800	1,959,900	2,217,600	3,280,400	478,200	553,200	1,069,600	-407,500	813,500	527,900	648,400	435,600	93,700	822,700	643,300	346,700	282,600	539,400	459,300	355,179	-85,419	305,440	227,424	532,473	260,663	-59,105	104,044	746,754	17,938	-215,889	80,633	84,552	265,539	-11,295	207,805	60,764	93,711	65,045	78,023	-12,630	-91,249	-98,096	-61,606	-55,633	-48,914	-32,746	-73,961	138,566	-35,206	-32,744	-68,720	-32,153	-36,559	-32,116	-51,580	-50,874	-545	-20,944	40,087	-15,392	-5,334	-10,435	52,095	-15,448	-21,015	4,632	-20,198	-16,714	-30,121	31,773	-13,526	-5,900	15,910	-19,567	-29,714	58,424	-45,688	-18,811	-46,197	-32,172	-36,470	-30,054	-20,254	-23,658	-11,591	-10,040	-4,935	-5,245	-5,867	-18,358	6,200	-8,900	-7,400	-9,400	-6,300	2,900	-4,700	-5,100	2,500	-2,100	-4,000	-4,600	-700	-7,500	-8,600	-12,100	-600	-11,700	-2,500	-6,700	-10,900	-6,600	4,600	-14,500	-17,100	-7,200	-8,500	-7,500	43,900	-54,600	-4,900	-3,700	-2,200	-2,800
Investments	-66,200	-496,300	-2,253,000	43,400	-1,605,500	1,261,600	-30,000	-1,563,500	-1,857,800	-2,305,600	125,800	-943,700	-143,600	-622,600	1,583,300	-273,100	-69,700	-85,300	-741,400	-701,800	-180,445	-170,462	-372,956	-346,037	-228,083	-299,231	-115,560	-89,682	-120,901	-287,297	-187,174	60,409	54,479	-137,072	-131,756	-15,319	174,187	-43,299	-47,250	-171,409	-40,972	-182,761	150,769	-126,168	106,299	-38,457	-126,310	27,284	-23,027	7,999	158,480	42,513	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	301,000	268,600	90,700	485,200	372,600	318,500	306,800	521,600	542,700	821,400	213,200	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	0	0	0	0	0	0	0	0	0	0	481,900	1,500,000	1,500,000	1,500,000	1,500,000	0	0	0	0	0	0	37,075	0	-7,064	44,139	-31,171	4,445	-11,526	-2,337	-20,845	-2,381	-107,273	-9,948	-159,799	-276	-61,397	-262	-399	-628	-348	-649	-602	-587	-514	-500	-117,781	-275	-220	-217	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	1,159,600	1,007,800	968,400	817,800	1,197,100	1,315,700	852,100	973,500	2,229,000	1,632,200	3,098,900	1,115,200	1,149,200	842,100	897,300	624,600	792,000	669,600	193,100	461,100	820,353	594,655	551,412	477,980	173,519	388,317	387,744	248,931	253,115	264,804	211,867	165,736	154,994	210,398	194,643	76,021	110,176	79,720	92,735	65,443	96,806	141,306	87,376	98,874	470,407	191,468	76,743	11,651	-53,443	-62,365	-62,505	-43,447	-14,597	-33,875	-25,474	-30,522	-36,489	-1,015	-12,845	-17,481	-31,518	-21,115	-18,459	-11,618	-13,071	-35,838	-26,774	-29,917	-30,971	-27,410	-23,576	-20,380	-29,672	-34,652	-26,999	-4,123	2,792	-11,076	-14,549	64,532	-19,377	-29,235	-28,736	-30,110	-35,693	-32,816	-30,423	-25,445	-28,378	-19,931	-14,834	-13,037	-9,739	-3,211	-2,947	-7,318	-1,400	-4,900	-7,900	-8,900	-5,500	-1,400	2,100	-3,800	500	-1,900	-4,300	-5,900	-8,100	-8,900	-7,600	-7,800	-7,800	-7,100	-4,400	-4,200	-5,800	-3,900	-10,300	-10,700	-11,500	-9,700	-9,400	-9,300	-6,400	-5,700	-3,700	-3,300	-2,100	-900
Other Cashflows From Financing Activities	-458,100	-129,400	-16,100	-97,000	-189,100	-108,900	-48,900	-1,705,300	-2,012,700	-2,438,800	125,800	-1,059,000	2,180,800	481,900	1,500,000	-443,200	-208,700	-207,000	-836,000	-776,100	-265,907	-286,708	-31,853	-425,412	263,706	-358,884	-170,409	57,000	-96,228	10,831	28,322	15,649	99,766	56,833	133,233	155,569	105,024	99,335	126,937	117,260	119,017	89,964	5,583	2,293	4,308	-48,754	-139,188	49,578	368,119	-320	142,935	20,347	-271	-83	-119	46,989	18,356	-773	5,182	-39,538	-117,503	-1,156	-82,148	37,944	36,463	-1,874	-46,200	-74,112	-163,214	66,463	390	-10,870	25,303	45,800	25,966	18,425	7,567	-888	-68,988	3,827	4,426	4,083	5,086	-89	-87	-87	-141	-111	191,110	-148	-134	-230	-322	-438	-430	-308	-200	-400	-200	-300	-400	-300	-400	-800	-1,200	-800	42,200	-1,000	-1,100	-900	-900	-800	-900	-800	-800	-800	1,500	-700	-800	-200	-400	51,000	-300	-300	-200	-300	-200	-100	-100	-1,500
Other Cashflows From Investing Activities	0	0	-20,900	-100,900	-100,000	-926,800	-230,300	0	0	0	0	0	0	0	0	-273,100	-1,598,200	-1,528,500	-1,443,200	-701,800	-1,079,900	-10,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-314	-34	-49	-6	-463	408	-4	-681	0	0	0	0	0	50	50	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11,051	0	0	0	10,999	0	0	0	11,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-75,600	115,200	39,500	187,200	88,400	-192,800	415,400	288,800	69,000	1,708,200	-2,543,300	-514,100	20,100	-1,155,700	-12,700	17,300	-58,900	-165,200	-56,900	384,900	-134,400	-177,200	-190,400	104,400	358,889	-11,204	-453,440	68,855	95,864	358,386	178,252	-159,373	103,919	661,781	47,890	-193,775	93,945	66,941	227,045	-26,308	168,683	-59,654	31,086	-22,033	-387,000	-203,179	7,510	5,863	176,562	-61,076	-105,702	582	51	-183	-245	470	-382	-56	2,093	0	7,951	8,859	9,675	8,286	12,677	7,844	6,912	6,585	5,133	4,763	4,700	4,079	4,235	5,921	5,822	5,881	626	271	962	-17,086	892	2,038	545	587	483	457	439	441	175	-73	434	1,232	2,688	1,099	1,080	1,271	2,000	900	700	1,100	900	800	400	700	500	700	700	1,800	3,800	4,300	3,600	2,800	5,200	3,400	3,000	2,600	1,700	2,200	2,800	2,300	2,000	1,600	0	0	0	100	-800	-900	-900	-600
Sale Purchase Of Stock	-747,100	-675,900	-704,900	-807,700	-620,200	-1,043,500	-407,900	-456,900	-1,449,300	-436,000	-331,400	-461,400	-409,400	-173,000	-5,469,400	-475,800	-394,000	-19,400	-29,800	-20,700	-110,126	-49,621	20,646	13,427	-223,856	-46,395	-31,437	16,673	-96,228	-1,941	-43,971	-1,042	-88,864	-35,743	-14,738	-21,192	-91,718	-110,876	-1,904	-63,086	-28,729	-93,221	-70,052	-3,085	-91,825	-10,031	-12,366	-49,078	88,320	237	10,409	13,343	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	240,400	203,900	202,000	238,700	232,000	166,300	159,800	166,900	188,400	136,900	145,500	130,900	121,500	101,200	103,500	105,800	133,500	117,100	105,800	107,900	126,748	111,435	106,795	82,422	127,133	125,097	121,258	133,789	154,558	131,379	131,691	142,250	158,392	102,641	94,257	103,759	81,454	73,864	70,512	81,408	55,182	45,744	44,443	53,030	51,307	0	19,606	23,244	15,533	13,364	12,396	14,801	13,566	8,790	8,707	8,834	8,657	7,508	7,440	7,654	0	0	0	0	0	0	0	6,585	0	4,632	4,700	4,079	0	0	0	5,881	0	0	0	671	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-446,100	-407,300	-614,200	-322,500	-247,600	-725,000	-101,100	64,700	-906,600	385,400	-118,200	-366,400	-305,300	612,000	-2,612,800	335,600	-345,700	-11,000	-15,300	119,900	-83,034	3,714	-11,207	13,427	-210,535	-8,196	133,519	60,812	-491,679	28,675	-46,844	-190,543	-4,008	-345,649	10,690	76,171	-252,763	5,930	-71,390	108,954	105,564	3,533	-43,481	11,523	-73,010	-1,809	-5,077	-17,750	361,440	-279	10,051	13,037	182,759	1,613	2,719	56,215	22,328	2,148	5,849	1,038	-115,719	1,324	-80,366	1,903	314,229	347	2,866	1,958	180,125	1,070	787	3,416	2,959	90	2	1,030	819	-808	329	4,101	4,588	49,523	5,576	48,497	594	-48	120	1,057	191,280	398	3,290	154,152	-161	17,555	72,798	2,675	200	-300	-200	600	-300	-300	-300	-500	-1,100	-700	42,200	-1,000	9,500	-900	57,500	200	21,800	-700	-700	-500	1,500	-700	-800	-200	-600	51,000	-300	-300	-200	-300	-200	-100	-100	0
Total Cash From Operating Activities	1,089,700	1,114,300	1,022,400	1,367,600	1,719,900	628,900	564,400	2,101,700	2,372,500	3,413,600	626,700	668,500	1,231,000	-254,300	943,400	698,000	787,400	557,300	188,300	897,000	728,800	452,900	394,600	618,800	566,937	414,832	-30,570	355,901	377,879	651,029	399,499	44,989	281,823	892,853	257,831	-101,727	198,175	164,321	336,412	53,527	276,781	92,455	128,164	86,248	93,185	-2,382	-78,377	-87,041	-50,317	-46,735	-34,050	-10,580	-41,699	160,669	-12,625	-10,001	-46,404	-9,822	-5,805	-10,199	-35,840	-41,546	6,197	-17,897	50,817	-10,700	-3,507	-9,238	53,303	-14,831	-20,675	5,278	-19,847	-14,998	-28,583	33,132	-12,199	-3,586	17,458	-18,582	-28,429	61,810	-40,707	1,193	-31,026	-23,854	-29,589	-26,054	-17,654	-21,891	-9,378	-8,397	-3,770	-4,204	-3,349	-16,587	7,000	-7,700	-4,700	-8,400	-5,700	4,200	-4,500	-4,200	3,100	-1,700	-4,100	-3,400	-100	-7,000	-5,900	-7,300	2,100	-11,300	-2,400	-6,600	-11,400	-5,900	5,800	-9,000	-9,000	-6,000	-7,800	-7,300	-6,000	-3,800	-4,200	-3,200	-1,400	-2,700
Total Cashflows From Investing Activities	0	0	-2,386,900	-235,700	-1,857,700	192,300	-413,900	-1,705,300	-2,012,700	-2,438,800	125,800	-1,059,000	-305,000	-775,800	1,453,400	-443,200	-208,700	-207,000	-836,000	-776,100	-265,907	-286,708	-484,973	-425,412	-335,746	-358,884	-170,409	-140,143	-271,356	-405,853	-326,010	-43,685	-123,300	-283,171	-371,649	-129,481	56,645	-123,068	-118,123	-236,231	-109,948	-214,452	116,630	-147,685	91,103	-48,754	-139,188	15,766	-33,908	-903	142,935	20,347	0	0	0	0	146	19,316	32,787	0	30,815	0	0	37,944	0	0	0	0	0	8,109	0	0	115,494	90,191	44,391	18,425	0	0	1,242	70,230	0	92,648	35,023	61,819	0	0	0	0	0	0	0	6,887	0	0	2,517	2,509	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31	1993-12-31	1992-12-31	1991-12-31	1990-12-31
Cost Of Revenue	883,700	1,560,400	2,437,500	1,119,900	782,200	434,100	397,061	299,694	392,709	205,018	155,355	84,455	4,216	2,093	1,686	923	227,991	8,146	9,557	15,214	6,676	6,483	6,509	15,566	3,600	5,000	2,600	1,100	0	0	0	0	12,800	6,300
Depreciation And Amortization	421,000	434,400	436,300	290,700	210,300	148,200	145,467	104,745	74,909	52,686	41,204	36,940	31,082	19,687	14,247	11,287	11,487	14,592	15,504	15,362	12,937	8,454	6,077	4,421	3,400	3,000	4,400	6,100	5,900	4,200	3,100	2,000	800	300
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Ebit	4,047,100	4,738,900	8,946,800	3,576,600	2,209,800	2,534,400	2,079,591	1,330,741	1,251,916	838,431	760,028	457,713	-205,159	-97,472	-74,103	-89,830	-135,351	-124,203	83,400	-42,582	-104,450	-131,388	-97,843	-20,701	-24,800	-17,000	-4,100	-3,000	7,100	-29,200	-38,800	-18,300	-14,800	-3,300
Ebitda	4,047,100	5,173,300	9,383,100	3,867,300	2,420,100	2,682,600	2,225,058	1,435,486	1,326,825	891,117	801,232	494,653	-174,077	-77,785	-59,856	-78,543	-123,864	-109,611	98,904	-27,220	-91,513	-122,934	-91,766	-16,280	-21,400	-14,000	300	3,100	13,000	-25,000	-35,700	-16,300	-14,000	-3,000
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Extraordinary Items	0	0	0	0	0	68,000	-326,200	0	0	0	0	0	0	0	0	0	0	813	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Gross Profit	12,233,500	10,612,500	13,634,200	7,377,200	7,081,200	6,276,700	5,475,166	4,560,733	3,711,019	2,614,539	1,949,390	1,294,022	441,608	456,981	377,582	237,534	125,024	55,301	56,636	158,803	50,821	15,505	15,464	43,710	30,900	33,200	30,500	23,000	27,400	23,200	10,600	11,500	-5,500	-1,300
Income Before Tax	4,199,300	4,858,800	9,325,800	3,810,400	2,429,100	2,553,500	2,078,511	1,329,815	1,225,097	775,747	713,360	414,421	-222,892	-104,468	-71,952	-80,359	-93,557	-91,107	124,421	53,874	-95,526	-112,518	-73,523	-29,851	-22,800	-8,200	-7,500	-17,300	-7,600	0	0	0	-4,400	-
Income Tax Expense	245,700	520,400	1,250,500	297,200	313,300	109,100	880,000	434,293	589,041	427,673	288,998	-335,848	-1,132	-2,122	-4,122	2,351	-29,751	-21,866	178,846	-84,281	3,008	-7,011	-21,663	2,514	-1,700	-8,400	7,500	29,400	30,600	1,500	1,100	800	-10,300	-
Interest Expense	73,000	59,400	57,300	56,900	30,200	28,200	25,119	7,195	14,241	37,372	46,437	45,304	21,282	9,118	2,337	7,752	20,897	16,548	41,021	48,228	4,462	9,435	12,160	4,575	1,000	4,400	3,400	14,300	14,700	0	0	0	5,200	0
Interest Income	417,700	160,100	45,800	0	88,100	13,700	25,119	7,195	14,241	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income	3,953,600	4,338,400	8,075,300	3,513,200	2,115,800	2,444,400	1,198,511	895,522	636,056	348,074	424,362	750,269	-221,760	-104,468	-67,830	-82,710	-105,600	-102,337	-95,446	41,699	-107,458	-124,377	-76,180	-23,215	-23,100	-8,600	-11,600	-32,400	-23,500	-30,700	-39,900	-19,100	-4,500	-3,300
Net Income Applicable To Common Shares	0	4,338,400	8,075,300	3,513,200	2,115,800	2,444,400	1,198,511	895,522	636,056	348,074	424,362	750,269	-221,760	-104,468	0	0	0	0	0	41,699	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income From Continuing Ops	3,991,100	4,338,400	8,075,300	3,513,200	2,115,800	2,444,400	1,198,511	895,522	636,056	338,126	424,362	750,269	-221,760	-104,468	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Interest Income	345,600	100,700	-57,300	-56,900	-30,200	-28,200	-25,119	-7,195	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Operating Income Net Other	0	179,300	436,300	290,700	249,500	47,300	24,039	6,269	-12,578	-25,312	-231	2,012	3,549	2,122	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Recurring	0	255,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Operating Income	4,047,100	4,738,900	8,946,800	3,576,600	2,209,800	2,534,400	2,079,591	1,330,741	1,251,916	838,431	760,028	457,713	-205,159	-97,472	-74,103	-89,830	-114,454	-107,655	124,421	5,646	-99,988	-121,953	-85,683	-25,276	-23,800	-12,600	-7,500	-17,300	-7,600	-29,200	-38,800	-18,300	-9,600	-3,300
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Operating Expenses	7,954,000	7,178,900	7,124,900	4,920,500	5,653,600	4,176,400	3,792,636	3,529,686	2,851,812	1,981,126	1,344,717	920,764	650,983	556,546	453,371	328,287	239,478	171,102	58,228	168,371	157,485	143,941	107,656	84,552	58,300	50,800	40,600	41,400	35,000	52,400	49,400	29,800	16,900	8,300
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Reconciled Depreciation	408,100	341,400	286,200	235,900	210,300	148,200	145,467	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Research Development	4,439,000	3,592,500	2,908,100	2,735,000	3,036,600	2,186,100	2,075,142	2,052,295	1,620,577	1,271,353	859,947	625,554	529,506	489,252	398,762	278,016	201,613	137,064	155,581	136,095	136,024	124,926	91,540	56,256	44,900	37,000	27,800	28,300	23,300	39,700	0	0	0	-
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Selling General Administrative	2,554,100	2,115,900	1,824,900	1,346,000	1,834,800	1,556,200	1,320,433	1,177,697	838,526	504,755	329,415	210,755	117,261	65,201	52,923	49,348	37,865	25,892	25,476	17,062	14,785	12,532	9,607	8,309	6,400	5,800	5,800	5,900	5,800	0	0	0	0	-
Tax Provision	385,300	520,400	1,250,500	297,200	313,300	109,100	880,000	434,293	589,041	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Operating Expenses	7,070,300	5,618,500	4,687,400	3,800,600	4,871,400	3,742,300	3,395,575	3,229,992	2,459,103	1,776,108	1,189,362	836,309	646,767	554,453	451,685	327,364	239,478	162,956	-67,785	153,157	150,809	137,458	101,147	68,986	54,700	45,800	38,000	40,300	35,000	52,400	49,400	29,800	4,100	2,000
Total Other Income Expense Net	152,200	119,900	379,000	233,800	219,300	19,100	-1,080	-926	-12,578	-25,312	-231	2,012	3,549	2,122	4,488	17,223	20,897	16,548	41,021	48,228	4,462	9,435	12,160	-4,575	1,000	4,400	-3,400	-14,300	-14,700	0	0	0	5,200	-
Total Revenue	13,117,200	12,172,900	16,071,700	8,497,100	7,863,400	6,710,800	5,872,227	4,860,427	4,103,728	2,819,557	2,104,745	1,378,477	445,824	459,074	379,268	238,457	125,024	63,447	66,193	174,017	57,497	21,988	21,973	59,276	34,500	38,200	33,100	24,100	27,400	23,200	10,600	11,500	7,300	5,000

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31	1993-12-31	1993-09-30	1993-06-30	1993-03-31	1992-12-31	1992-09-30	1992-06-30	1992-03-31	1991-12-31	1991-09-30	1991-06-30	1991-03-31	1990-12-31	1990-09-30	1990-06-30	1990-03-31
Cost Of Revenue	517,000	211,900	404,900	457,500	540,600	317,800	297,100	404,900	982,600	453,200	693,700	308,000	353,100	274,000	275,500	217,300	223,900	226,600	152,500	179,200	117,200	110,369	91,661	114,898	105,740	104,232	102,921	84,168	74,681	44,228	69,033	111,752	110,831	109,083	88,840	83,955	59,474	55,593	46,379	43,572	48,114	38,573	39,613	29,055	30,169	20,145	21,843	12,298	2,989	450	395	382	599	372	405	717	387	472	435	392	631	292	7	69,577	73,365	58,119	49,925	430	430	3,054	2,810	1,852	2,145	3,246	1,675	2,491	3,474	8,986	529	2,225	907	4,844	259	666	1,726	1,637	1,861	1,259	1,162	1,274	1,885	2,188	8,738	2,512	1,265	3,051	100	1,000	1,200	1,300	1,600	1,300	1,200	900	900	800	500	500	0	0	0	0	0	0	0	0	0	0	0	0	0	10,600	0	0	0	0	0	0	5,000	2,400	2,900	-	-	-	-	-
Depreciation And Amortization	113,000	105,400	103,100	84,900	225,300	394,000	63,400	-81,400	74,500	73,200	71,100	67,400	61,700	59,300	58,800	56,100	54,300	52,900	52,100	51,000	42,759	35,441	33,642	36,358	34,507	37,719	35,126	38,115	28,900	27,839	25,029	22,977	22,910	20,674	15,298	16,027	14,135	14,005	13,016	11,530	11,292	10,803	9,702	9,407	9,778	9,329	9,417	8,416	7,926	8,276	7,902	6,978	6,086	4,894	4,524	4,183	4,935	3,590	2,998	2,724	2,626	2,774	2,941	2,946	2,899	2,859	2,874	2,855	3,396	3,708	3,690	3,798	3,880	3,935	3,831	3,858	3,916	3,876	3,797	3,773	4,314	3,656	2,679	2,288	2,049	2,169	2,228	2,008	1,810	1,519	1,419	1,329	1,296	1,154	1,045	926	900	900	900	700	700	700	700	900	1,100	900	1,200	1,200	1,600	1,500	1,500	1,500	1,300	1,600	1,400	1,600	1,200	1,100	1,000	900	900	800	700	700	600	500	500	400	300	200	200	-	-	-	-	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Ebit	1,150,700	1,005,600	1,101,800	946,700	1,146,800	1,223,700	1,109,900	1,258,500	2,443,000	1,830,800	3,767,200	1,267,600	1,177,700	1,024,600	928,600	674,700	621,400	776,300	232,700	553,800	675,341	643,355	588,546	591,837	504,304	571,787	531,251	439,790	318,103	362,802	291,628	329,308	208,172	392,422	344,859	283,553	233,232	182,719	222,406	185,939	200,781	236,802	158,103	153,050	135,892	202,364	87,478	22,201	-45,402	-58,457	-60,319	-47,959	-18,863	-32,547	-24,316	-32,842	-39,408	-4,881	-20,592	-20,981	-20,024	-23,598	-22,993	-23,215	-13,007	-44,507	-37,445	-40,392	-33,486	-28,257	-24,249	-21,663	216,449	-37,133	-40,346	-55,570	2,142	-10,896	-13,748	-20,080	-18,007	-26,988	-28,033	-29,587	-36,368	-34,553	-32,504	-27,963	-32,279	-26,456	-21,379	-13,660	-2,418	-6,013	-5,106	-9,706	-200	-5,300	-9,100	-9,800	-6,900	-3,500	2,100	-6,000	1,800	-300	-3,200	-2,400	-900	-100	-100	-1,900	2,200	2,100	1,600	-400	-5,100	-3,700	-10,000	-10,400	-11,200	-9,300	-10,500	-9,200	-6,100	-5,600	-3,500	-3,200	-5,300	-4,300	-3,500	-	-	-	-	-
Ebitda	1,263,700	1,111,000	1,204,900	1,031,600	1,372,100	1,617,700	1,173,300	1,177,100	2,517,500	1,904,000	3,838,300	1,335,000	1,239,400	1,083,900	987,400	730,800	675,700	829,200	284,800	604,800	718,100	678,796	622,188	628,195	538,811	609,506	566,377	477,905	347,003	390,641	316,657	352,285	231,082	413,096	360,157	299,580	247,367	196,724	235,422	197,469	212,073	247,605	167,805	162,457	145,670	211,693	96,895	30,617	-37,476	-50,181	-52,417	-40,981	-12,777	-27,653	-19,792	-28,659	-34,473	-1,291	-17,594	-18,257	-17,398	-20,824	-20,052	-20,269	-10,108	-41,648	-34,571	-37,537	-30,090	-24,549	-20,559	-17,865	220,329	-33,198	-36,515	-51,712	6,058	-7,020	-9,951	-16,307	-13,693	-23,332	-25,354	-27,299	-34,319	-32,384	-30,276	-25,955	-30,469	-24,937	-19,960	-12,331	-1,122	-4,859	-4,061	-8,780	700	-4,400	-8,200	-9,100	-6,200	-2,800	2,800	-5,100	2,900	600	-2,000	-1,200	700	1,400	1,400	-400	3,500	3,700	3,000	1,200	-3,900	-2,600	-9,000	-9,500	-10,300	-8,500	-9,800	-8,500	-5,500	-5,100	-3,000	-2,800	-5,000	-4,100	-3,300	2,000	-7,000	1,300	1,200	1,200
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	56,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	813	0	-813	813	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Gross Profit	2,917,300	3,150,800	2,753,200	2,704,600	2,873,800	2,618,400	2,560,100	2,560,200	3,969,100	2,999,600	4,444,800	2,220,700	2,069,800	2,020,000	1,676,500	1,610,900	1,945,600	1,821,800	1,781,200	1,532,600	1,810,600	1,553,127	1,516,361	1,396,587	1,476,707	1,396,441	1,367,195	1,234,823	1,152,146	1,175,894	1,143,596	1,089,097	987,246	1,028,339	909,777	785,657	742,855	670,195	619,321	582,168	562,298	558,454	418,029	410,609	384,433	407,542	282,556	219,491	119,988	102,383	107,415	111,822	133,076	105,607	115,481	102,817	96,413	116,983	89,597	74,589	55,206	65,292	60,646	56,383	64,730	22,311	22,195	15,788	9,916	12,570	16,448	16,367	15,279	12,948	14,691	13,718	43,616	27,533	27,889	59,765	20,365	12,548	10,273	9,470	3,186	4,929	3,708	3,682	3,239	4,206	3,894	6,897	10,678	12,394	13,191	7,447	11,800	10,300	4,700	4,200	5,800	9,500	12,300	5,600	10,500	8,100	6,100	5,700	6,500	6,200	6,200	5,200	5,800	6,200	7,600	6,900	7,700	8,900	3,600	3,000	2,900	-7,000	1,300	2,100	2,300	2,400	3,200	3,500	-3,000	-500	-1,200	2,000	1,300	1,300	1,200	1,200
Income Before Tax	1,147,600	1,110,800	1,082,900	858,000	1,324,700	1,509,800	963,200	1,061,100	2,503,400	1,816,600	3,752,800	1,253,000	1,224,600	998,300	918,900	668,600	889,800	768,500	224,700	546,100	676,200	635,861	656,074	585,398	554,767	565,605	525,850	432,289	341,527	365,881	292,256	330,151	227,289	393,289	327,996	276,523	221,287	176,078	203,119	175,263	198,153	225,684	147,692	141,831	134,559	191,468	76,743	11,651	-54,058	-61,803	-63,368	-43,663	-14,597	-31,641	-23,132	-30,304	-40,611	-1,015	-14,938	-17,481	-32,246	-18,036	-15,785	-8,607	-10,061	-32,827	-23,763	-26,906	-103,150	-27,410	-25,706	0	222,181	-31,641	-23,988	-1,110	3,974	-8,062	-11,538	67,668	-16,271	-24,418	-25,831	-27,171	-32,900	-29,799	-27,396	-22,423	-25,851	-19,891	-14,791	-10,218	-16,602	-3,151	-2,844	-7,254	-700	-4,900	-7,700	-8,800	-5,500	-1,300	2,200	-3,800	1,200	-1,000	-4,200	-5,800	-4,500	-4,400	-3,700	-7,500	-2,700	-2,400	-1,200	-2,100	0	0	0	0	0	0	-9,100	0	0	0	0	0	-2,100	-700	-500	-	-	-	-	-
Income Tax Expense	-12,000	103,000	114,500	40,200	127,600	194,100	111,100	87,600	274,400	184,400	653,900	137,800	75,400	156,200	21,600	44,000	97,800	98,900	31,600	85,000	-144,200	41,206	104,662	107,418	381,248	177,288	138,106	183,358	88,412	101,077	96,038	164,415	72,295	182,891	133,353	200,502	111,111	96,358	110,384	109,820	101,347	84,378	60,316	42,957	-335,848	-517	-501	-610	-615	562	-863	-216	846	-906	-1,184	218	-4,122	-857	-2,656	-3,500	-728	3,079	-4,534	-11,597	64	-8,669	-10,671	-10,475	-2,515	-847	-673	-1,283	246,121	-2,481	-13,347	-51,447	-650	180	801	-84,612	1,370	412	703	523	-675	-1,737	-2,081	-2,518	-3,901	-6,525	-6,545	-623	7,321	-2,802	-2,159	-2,388	1,200	-400	-1,300	-900	-1,400	-2,100	-1,400	-2,200	1,300	1,600	1,100	3,500	7,200	8,800	7,500	5,900	10,000	9,200	6,000	3,800	700	300	200	300	300	300	-1,100	100	300	200	200	100	-3,200	-3,400	-3,200	-	-	-	-	-
Interest Expense	18,300	17,800	18,900	18,000	17,400	15,300	13,100	13,600	14,100	14,200	14,400	14,600	14,800	26,300	9,700	6,100	6,700	7,800	8,000	7,700	7,349	7,494	6,918	6,439	6,035	6,182	5,401	7,501	3,394	222	2,173	1,406	3,609	1,715	2,748	6,169	6,350	9,232	10,177	11,613	11,661	11,736	11,365	11,675	11,495	11,413	11,236	11,160	9,455	4,061	4,047	3,719	2,458	2,234	2,342	2,084	1,756	581	1,328	1,750	12,222	5,562	3,604	7,304	1,473	5,840	6,841	6,743	12,043	3,011	3,011	3,011	2,866	2,746	8,179	27,230	1,832	1,417	1,105	43,874	868	1,285	1,101	1,208	1,734	2,377	2,554	2,770	3,742	3,403	3,294	1,721	7,092	1,431	1,131	1,226	500	200	700	500	1,400	1,100	1,500	1,100	600	700	500	1,700	3,600	4,300	3,600	2,800	4,900	4,500	2,800	1,700	0	0	0	0	0	0	1,400	0	0	0	0	0	1,600	1,800	1,500	-	-	-	-	-
Interest Income	148,700	133,700	118,300	95,200	70,500	0	0	0	0	0	0	0	0	0	0	62,900	53,200	7,900	124,900	35,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Income	1,159,600	1,007,800	968,400	817,800	1,197,100	1,315,700	852,100	973,500	2,229,000	1,632,200	3,098,900	1,115,200	1,149,200	842,100	897,300	624,600	792,000	669,600	193,100	461,100	820,400	594,655	551,412	477,980	173,519	388,317	387,744	248,931	253,115	264,804	196,218	165,736	154,994	210,398	194,643	76,021	110,176	79,720	92,735	65,443	96,806	141,306	87,376	98,874	470,407	191,468	76,743	11,651	-53,443	-62,365	-62,505	-43,447	-14,597	-33,875	-25,474	-30,522	-36,489	-1,015	-14,938	-17,481	-31,518	-21,115	-18,459	-11,618	-13,071	-35,838	-26,774	-29,917	-30,971	-27,410	-23,576	-20,380	-29,672	-34,652	-26,999	-4,123	2,792	-11,076	-14,549	64,532	-19,377	-27,400	-28,736	-30,110	-35,693	-32,816	-30,423	-25,445	-28,378	-19,931	-14,834	-13,037	-9,739	-3,211	-2,947	-7,318	-1,400	-4,900	-7,800	-8,900	-5,500	-1,400	2,100	-3,800	500	-1,900	-4,300	-5,900	-8,100	-8,900	-7,600	-7,800	-7,800	-7,100	-4,400	-4,200	-5,800	-4,000	-10,200	-10,700	-11,500	-9,600	-9,400	-9,300	-6,400	-5,800	-3,700	-3,300	-2,100	-900	-300	-	-	-	-	-
Net Income Applicable To Common Shares	0	0	968,400	817,800	1,197,100	1,315,700	852,100	973,500	2,229,000	1,632,200	3,098,900	1,115,200	1,149,200	842,100	897,300	624,600	792,000	669,600	193,100	461,100	820,353	594,655	551,412	477,980	173,519	388,317	387,744	248,931	268,764	264,804	196,218	165,736	154,994	210,398	194,643	76,021	110,176	83,375	92,735	68,305	96,806	141,306	87,376	98,874	470,407	191,468	76,743	11,651	-53,443	-62,365	-62,505	-43,447	0	-33,875	-25,474	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,792	0	-64,532	64,532	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Income From Continuing Ops	1,159,600	1,007,800	968,400	817,800	1,197,100	1,315,700	852,100	973,500	2,229,000	1,632,200	3,098,900	1,115,200	1,149,200	842,100	897,300	624,600	792,000	669,600	193,100	461,100	820,353	594,655	551,412	477,980	173,519	388,317	387,744	248,931	268,764	264,804	196,218	165,736	154,994	210,398	194,643	76,021	110,176	79,720	92,735	65,443	96,806	141,306	87,376	98,874	470,407	191,468	76,743	11,651	-53,443	-62,365	-62,505	-43,447	0	-33,875	-25,474	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Interest Income	130,400	115,900	-18,900	-18,000	-17,400	-15,300	-13,100	-13,600	-14,100	-14,200	-14,400	-14,600	-14,800	-26,300	-9,700	-6,100	-6,700	-7,800	-8,000	-7,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Non Operating Income Net Other	0	0	85,300	-70,700	195,300	301,400	-133,600	-183,800	-122,200	-16,400	420,000	154,900	72,400	-28,500	272,200	-25,400	220,800	37,800	-82,900	73,800	-34,542	16,432	40,804	24,606	21,991	11,861	-19,061	9,248	1,719	3,079	628	843	-184	2,582	-14,115	-861	-19,730	2,591	-9,110	937	-2,259	618	954	456	384	517	501	610	799	715	998	1,037	0	453	592	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Non Recurring	0	0	0	56,100	30,000	0	197,000	28,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Operating Income	972,900	1,111,000	1,016,500	946,700	1,146,800	1,223,700	1,109,900	1,258,500	2,639,700	1,847,200	3,347,200	1,112,700	1,167,000	1,053,100	656,400	700,100	675,700	738,500	315,600	480,000	718,100	626,923	622,188	567,231	538,811	559,926	550,312	430,542	347,003	362,802	291,628	329,308	231,082	392,422	344,859	283,553	247,367	182,719	222,406	185,939	212,073	236,802	158,103	153,050	145,670	202,364	87,478	22,201	-45,402	-58,457	-60,319	-40,981	-12,777	-32,094	-23,724	-28,659	-39,408	-1,291	-16,266	-19,231	-34,599	-19,931	-19,389	-15,911	-11,534	-38,667	-30,604	-33,649	-33,486	-28,257	-24,249	-21,663	219,315	-34,387	-32,167	-28,340	3,974	-9,479	-12,643	23,794	-17,139	-25,703	-26,932	-28,379	-34,634	-32,176	-29,950	-25,193	-29,593	-23,294	-18,085	-11,939	-9,510	-4,582	-3,975	-8,480	-700	-5,100	-8,400	-9,300	-6,200	-2,400	700	-4,900	1,200	-1,100	-3,700	-4,100	-4,500	-4,400	-3,700	-4,700	-2,700	-2,400	-1,300	-2,100	-5,100	-3,700	-10,000	-10,400	-11,200	-9,300	-9,800	-9,200	-6,100	-5,600	-3,500	-3,200	-3,700	-2,500	-2,000	2,000	-7,000	1,300	1,200	1,200
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Operating Expenses	2,431,400	1,927,700	2,141,600	2,159,300	2,237,600	1,712,500	1,550,300	1,678,500	2,312,000	1,605,600	1,791,300	1,416,000	1,255,900	1,240,900	1,295,600	1,128,100	1,493,800	1,309,900	1,618,100	1,231,800	1,209,700	1,036,573	985,834	944,254	1,043,636	940,747	919,804	888,449	879,824	857,320	921,001	871,541	866,995	745,000	653,758	586,059	554,962	543,069	443,294	439,801	398,339	360,225	299,539	286,614	268,932	225,323	216,921	209,588	168,379	161,290	168,129	153,185	146,452	138,073	139,610	132,193	136,208	118,746	106,298	94,212	90,436	85,515	80,042	72,294	76,264	60,978	52,799	49,437	43,832	43,881	43,507	39,882	201,891	50,581	48,533	44,549	43,116	45,998	41,061	38,196	38,411	43,095	37,464	38,515	39,546	38,742	35,519	30,134	33,994	28,774	23,864	21,024	28,926	19,488	18,431	18,978	12,600	16,400	14,300	14,800	13,600	13,200	12,800	11,400	10,200	10,000	10,300	10,300	11,000	10,600	9,900	9,900	8,500	8,600	8,900	9,000	12,800	12,600	13,600	13,400	14,100	12,900	11,100	11,300	8,400	8,000	6,700	6,700	5,700	4,400	3,700	-	8,300	-	-	-
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Reconciled Depreciation	113,000	105,400	103,100	99,500	100,100	92,600	74,400	74,300	74,500	73,200	71,100	67,400	61,700	59,300	58,800	56,100	54,300	52,900	52,100	51,000	42,759	35,441	33,642	36,358	34,507	37,719	35,126	38,115	28,900	27,839	25,029	22,977	22,910	20,674	15,298	16,027	14,135	14,005	13,016	11,530	11,292	10,803	9,702	9,407	9,778	9,329	9,417	8,416	7,926	8,276	7,902	6,978	6,086	4,894	4,524	4,183	4,935	3,590	2,998	2,724	2,626	2,774	2,941	2,946	2,899	2,859	2,874	2,855	3,396	3,708	3,690	3,798	3,880	3,935	3,831	3,858	3,916	3,876	3,797	3,773	4,314	3,656	2,679	2,288	2,049	2,169	2,228	2,008	1,810	1,519	1,419	1,329	1,296	1,154	1,045	926	900	900	900	700	700	700	700	900	1,100	900	1,200	1,200	1,600	1,500	1,500	1,500	1,300	1,600	1,400	1,600	1,200	1,100	1,000	900	900	800	700	700	600	500	500	400	300	200	200	-	-	-	-	-
Research Development	1,177,200	1,075,300	1,085,300	1,101,200	1,043,100	911,300	794,300	843,800	785,600	665,400	714,200	742,900	744,500	684,600	722,000	583,900	683,100	663,400	1,048,300	641,800	601,200	556,972	529,289	498,586	527,983	529,749	509,975	507,435	479,206	543,047	559,930	470,112	461,210	425,924	390,330	343,113	351,745	337,728	294,501	287,379	268,140	224,045	187,463	180,299	181,024	158,295	147,373	138,862	129,041	127,924	143,149	129,392	125,212	122,043	124,526	117,471	118,790	105,434	94,231	82,146	76,314	73,855	66,577	61,270	64,825	51,689	43,864	41,235	35,774	34,808	34,398	32,084	37,911	41,116	40,642	35,912	34,789	32,828	36,297	32,181	33,267	34,650	33,717	34,390	34,455	34,294	30,702	25,475	30,100	25,039	19,596	16,805	15,786	14,085	14,410	11,975	9,900	12,900	10,800	11,200	9,900	9,900	9,100	8,200	7,000	6,800	6,900	7,100	6,900	7,700	6,800	6,900	6,000	5,700	5,800	5,800	9,100	9,500	10,300	10,800	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	63,800	0	0	0	0	0	0	0	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Selling General Administrative	737,700	640,500	652,000	601,100	660,500	529,100	476,300	450,000	559,600	445,000	414,700	405,600	367,300	326,900	348,300	367,300	586,800	419,900	417,300	410,800	491,314	369,232	364,884	330,770	409,913	306,766	306,908	296,846	325,937	270,045	292,038	289,677	294,954	209,993	174,588	158,991	143,743	149,748	102,414	108,850	82,085	97,607	72,463	77,260	57,739	46,883	47,705	58,428	36,349	32,916	24,585	23,411	20,641	15,658	14,679	14,005	17,031	12,840	11,632	11,674	13,491	11,368	13,465	11,024	11,439	9,289	8,935	8,202	7,628	6,019	6,299	5,946	6,895	6,219	6,216	6,146	4,853	4,184	4,235	3,790	4,237	3,601	3,488	3,459	3,365	2,811	2,956	3,400	2,732	2,461	2,383	2,031	3,106	1,737	1,711	3,026	1,700	1,600	1,500	1,600	1,400	1,300	1,700	1,400	1,200	1,400	1,700	1,500	1,400	1,400	1,600	1,500	1,200	1,400	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Tax Provision	-12,000	103,000	114,500	40,200	127,600	194,100	111,100	87,600	274,400	184,400	653,900	137,800	75,400	156,200	21,600	44,000	97,800	98,900	31,600	85,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Operating Expenses	1,914,400	1,715,800	1,736,700	1,701,800	1,697,000	1,394,700	1,253,200	1,273,600	1,329,400	1,152,400	1,097,600	1,108,000	902,800	966,900	1,020,100	910,800	1,269,900	1,083,300	1,465,600	1,052,600	1,092,500	926,204	894,173	829,356	937,896	836,515	816,883	804,281	805,143	813,092	851,968	759,789	756,164	635,917	564,918	502,104	495,488	487,476	396,915	396,229	350,225	321,652	259,926	257,559	238,763	205,178	195,078	197,290	165,390	160,840	167,734	152,803	145,853	137,701	139,205	131,476	135,821	118,274	105,863	93,820	89,805	85,223	80,042	72,294	76,264	60,978	52,799	49,437	43,402	40,827	40,697	38,030	-204,036	47,335	46,858	42,058	39,642	37,012	40,532	35,971	37,504	38,251	37,205	37,849	37,820	37,105	33,658	28,875	32,832	27,500	21,979	18,836	20,188	16,976	17,166	15,927	12,500	15,400	13,100	13,500	12,000	11,900	11,600	10,500	9,300	9,200	9,800	9,800	9,900	10,600	9,900	9,900	8,500	8,600	8,900	9,000	12,800	12,600	13,600	13,400	42,600	2,300	11,100	11,300	8,400	8,000	6,700	6,700	700	2,000	800	-	-8,300	-	-	-
Total Other Income Expense Net	14,300	-200	85,300	-88,700	177,900	286,100	-146,700	-197,400	-122,200	-16,400	420,000	154,900	72,400	-28,500	272,200	-25,400	214,100	37,800	-82,900	73,800	-41,900	16,432	33,886	24,606	15,956	11,861	-19,061	9,248	-5,476	3,301	2,801	2,249	-184	2,582	-14,115	-861	-19,730	2,591	-9,110	937	-2,259	618	954	456	384	517	501	610	799	715	998	1,037	638	453	592	439	553	857	1,328	1,750	2,648	3,667	3,604	7,304	1,473	5,840	6,841	6,743	-69,664	847	-1,457	0	2,866	2,746	8,179	27,230	1,832	1,417	1,105	43,874	868	1,285	1,101	1,208	1,734	2,377	2,554	2,770	3,742	3,403	3,294	1,721	-7,092	1,431	1,131	1,226	-500	200	700	500	700	1,100	1,500	1,100	-600	-700	-500	-1,700	-3,600	-4,300	-3,600	-2,800	-4,900	-4,500	-2,800	-1,700	0	0	0	0	0	0	700	0	0	0	0	0	1,600	1,800	1,500	-	-	-	-	-
Total Revenue	3,434,300	3,362,700	3,158,100	3,162,100	3,414,400	2,936,200	2,857,200	2,965,100	4,951,700	3,452,800	5,138,500	2,528,700	2,422,900	2,294,000	1,952,000	1,828,200	2,169,500	2,048,400	1,933,700	1,711,800	1,927,800	1,663,496	1,608,022	1,511,485	1,582,447	1,500,673	1,470,116	1,318,991	1,226,827	1,220,122	1,212,629	1,200,849	1,098,077	1,137,422	998,617	869,612	802,329	725,788	665,700	625,740	610,412	597,027	457,642	439,664	414,602	427,687	304,399	231,789	122,977	102,833	107,810	112,204	133,675	105,979	115,886	103,534	96,800	117,455	90,032	74,981	55,837	65,584	60,653	56,383	64,730	22,311	22,195	15,788	10,346	15,624	19,258	18,219	17,424	16,194	16,366	16,209	47,090	36,519	28,418	61,990	21,272	17,392	10,532	10,136	4,912	6,566	5,569	4,941	4,401	5,480	5,779	9,085	19,416	14,906	14,456	10,498	11,900	11,300	5,900	5,500	7,400	10,800	13,500	6,500	11,400	8,900	6,600	6,200	6,500	6,200	6,200	5,200	5,800	6,200	7,600	6,900	7,700	8,900	3,600	3,000	2,900	3,600	1,300	2,100	2,300	2,400	3,200	3,500	2,000	1,900	1,700	2,000	1,300	1,300	1,200	1,200

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	13,117,200
Cost of Revenue	-883,700
Gross Profit	12,233,500	12,233,500

Operating Income (+$)
Gross Profit	12,233,500
Operating Expense	-7,070,300
Operating Income	4,047,100	5,163,200

Operating Expense (+$)
Research Development	4,439,000
Selling General Administrative	2,554,100
Selling And Marketing Expenses	0
Operating Expense	7,070,300	6,993,100

Net Interest Income (+$)
Interest Income	417,700
Interest Expense	-73,000
Other Finance Cost	-900
Net Interest Income	345,600

Pretax Income (+$)
Operating Income	4,047,100
Net Interest Income	345,600
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	4,199,300	3,894,900 EBIT - interestExpense = 3,974,100 4,199,300 4,026,600
Interest Expense	73,000
Earnings Before Interest and Taxes (EBIT)	4,047,100	4,272,300
Earnings Before Interest and Taxes (EBITDA)	4,047,100

After tax Income (+$)
Income Before Tax	4,199,300
Tax Provision	-385,300
Net Income From Continuing Ops	3,991,100	3,814,000
Net Income	3,953,600
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	7,954,000
Total Other Income/Expenses Net	152,200	-345,600

Technical Analysis of Regeneron
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Regeneron. The general trend of Regeneron is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Regeneron's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (0.0%)		Bearish trend (0.0%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Regeneron Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 923.03 < 947.37 < 953.29.

The bearish price targets are: 890.43 > 887.94 > 840.25.

Tweet this

Regeneron Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Regeneron Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Regeneron Pharmaceuticals Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Regeneron Pharmaceuticals Inc. The current macd is -15.97821644.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Regeneron price going down in the near term. -2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Regeneron. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Regeneron price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1

Regeneron Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Regeneron Pharmaceuticals Inc. The current adx is 22.72.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Regeneron shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1

Regeneron Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Regeneron Pharmaceuticals Inc. The current sar is 920.73.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Regeneron Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Regeneron Pharmaceuticals Inc. The current rsi is 31.27. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Regeneron Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Regeneron Pharmaceuticals Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH < 20: The STOCH %K is below 20 and oversold. -2
STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Regeneron price going down in the near term. -2
Trending down: The STOCH %K is trending down. -1

Regeneron Pharmaceuticals Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Regeneron Pharmaceuticals Inc. The current cci is -89.46128477.

Regeneron Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Regeneron Pharmaceuticals Inc. The current cmo is -42.18040167.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Regeneron Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Regeneron Pharmaceuticals Inc. The current willr is -81.19883447.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1

Regeneron Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Regeneron Pharmaceuticals Inc. The current atr is 18.15.

Regeneron Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Regeneron Pharmaceuticals Inc. The current obv is 8,043,023.

Regeneron Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Regeneron Pharmaceuticals Inc. The current mfi is 30.17.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

MFI < 50: -1

Regeneron Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Regeneron Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-04	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-06	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-12	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-15	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2023-12-21	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2023-12-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-27	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-29	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-08	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-10	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-11	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-12	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-17	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-23	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-01-24	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-26	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-31	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-02	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-05	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-06	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-13	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-22	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-02-23	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-02-28	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-29	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-04	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-05	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-06	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-07	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-11	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-14	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-20	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-25	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-03	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-09	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-11	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-16	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-04-17	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-19	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
2024-04-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-23	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-04-25	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside

6.3. Candlestick Patterns

Regeneron Pharmaceuticals Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Regeneron Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	31.268
Ma 20	Greater than	Ma 50	922.507
Ma 50	Greater than	Ma 100	949.141
Ma 100	Greater than	Ma 200	925.127
Open	Greater than	Close	912.680
Total			3/5 (60.0%)

Create your own Symbol Scanner

Get notifications about Regeneron Pharmaceuticals Inc

I send you an email if I find something interesting about Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc Buy, Hold or Sell?

Let's analyse Regeneron together

Get notifications about Regeneron Pharmaceuticals Inc

Quick analysis of Regeneron (30 sec.)

What can you expect buying and holding a share of Regeneron? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Regeneron (5 min.)

$890.68

$228.23

$29.71 - $458.15

$257.95 - $686.39

2. Growth of Regeneron (5 min.)

Is Regeneron growing?

How much money is Regeneron making?

How much money comes from the company's main activities?

3. Financial Health of Regeneron (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Regeneron? (5 min.)

What can you expect buying and holding a share of Regeneron?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Regeneron

About Regeneron Pharmaceuticals Inc

Financial Health

Valuation

1.1. Profitability of Regeneron Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Regeneron Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Regeneron Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Regeneron Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Regeneron Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Regeneron Pharmaceuticals Inc
Buy, Hold or Sell?